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Abstract 
 
In this project, we have designed, constructed, and validated a human tissue-engineered blood 
vessel construct (TEBV) to assess whether it could be used as a new model system in which to study 
thrombus formation under physiologically relevant conditions.  
A layer-by-layer fabrication technique was adopted to fabricate the TEBV. This allowed for the 
biological properties of both the medial and intimal layers of the construct to be assessed 
individually, as well as in combination as the full TEBV. The TEBV model was shown to mimic the 
anatomical structure and cellular phenotype of the native human artery. In addition, a novel 
technique for quantitatively assessing the pro- and anti-aggregatory properties of these constructs 
was developed, utilising real-time measurements of cytosolic Ca2+ signalling to assess real-time 
human platelet activation when exposed to the tissue-engineered blood vessels constructs. The 
real-time measurement of cytosolic Ca2+ signalling of human platelets when exposed to the TEBV 
models was shown to be a sensitive technique to assess the haemostatic properties of the 3-
dimensional (3D) TEBV to validate the physiological relevance of the construct. Experiments 
conducted with this novel methodology, alongside other traditional platelet function assays, 
demonstrated that our TEBV had an anti-aggregatory intimal layer and a pro-aggregatory medial 
layer, consistent with the haemostatic functions of this blood vessel layers in vivo.  
We have also established an ex vivo ferric chloride (FeCl3) arterial injury model to be used as an 
alternative to intravital microscopy study of in vivo thrombus formation in mice models. Treatment 
of the TEBV with FeCl3 elicited a significant increase in platelet aggregation upon the surface of the 
construct when these cells were perfused over the construct at arterial shear stresses. By using this 
perfusion system, experiments also provided initial evidence that the use of the general anaesthetic 
ketamine, in intravital microscopy experiments may interfere with thrombus formation, and 
therefore could affect the validity of results seen in previous in vivo studies. In conclusion, we have 
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successfully created a TEBV that is able to replicate the functional properties of the native vessel 
and which may be useful as a novel model to study human thrombus formation. 
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1. Introduction  
1.1. Haemostasis 
Haemostasis is the physiological response to reduce the extent of haemorrhage at sites of vascular 
injury, while maintaining normal blood flow elsewhere in the circulation (Gale, 2011). This process 
is tightly regulated as it must be rapidly activated within seconds of an injury to the blood vessel, 
but the response must also remain localized here to ensure unwanted blood clotting does not occur 
elsewhere in the undamaged circulation. Haemostasis comprise of two main phases - primary and 
secondary haemostasis. These two phases of haemostasis are mechanistically intertwined and 
happen simultaneously (Gale, 2011). Primary haemostasis involves platelet aggregation upon the 
subendothelial lining exposed by vascular damage to produce a plug which patches up the damaged 
blood vessel wall, whereas secondary haemostasis involves the activation of the blood coagulation 
system and deposition of insoluble fibrin to help scaffold together and strengthen the developing 
blood clot (Palta et al., 2014). Blood vessel damage or endothelial cells (ECs) exposure to particular 
proinflammatory cytokines causes the balance to shift towards procoagulant or pro-thrombotic 
phenotype (Van Kruchten et al., 2012). The next section will discuss the multi-stage process that 
underlies the formation and regulation of thrombus formation. 
1.2. The multi-stage process of thrombus formation 
1.2.1. Endothelium inhibition of platelets 
In a healthy blood vessel exposed to normal blood flow conditions, platelets circulate in an inactive 
state and do not adhere to the vessel wall or other platelets. ECs normally provide an anti-
thrombotic and anti-coagulant surface by secreting several inhibitors of platelet function, as well 
as inhibitors of the coagulation cascade. Prostacyclin (PGI2) and nitric oxide (NO) are the main anti-
platelet agents secreted by ECs (Bunting et al., 1983). Both molecules trigger a signalling cascade 
leading to an increase in cytosolic cAMP in platelets, that works to block their aggregation (Mitchell 
et al., 2008). PGI2 and NO are continuously released from ECs but their production increases in 
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response to certain molecules involved in coagulation processes such as bradykinin and thrombin. 
Aggregating platelets also release adenosine triphosphate (ATP) which increases PGI2 and NO 
production from surviving ECs around the edge of the site of puncture, limiting thrombus formation 
to the site of vascular damage. These give-and-take responses between ECs and platelets are key 
to regulating the localised activation of the haemostasis system.  
PGI2 is produced by vascular endothelium and acts as a vasodilator and an inhibitor of platelet 
aggregation (Bunting et al., 1983). PGI2 is a product of arachidonic acid metabolism by 
cyclooxygenase (COX) followed by metabolism of the COX product, prostaglandin H2, by 
prostacyclin synthase. The importance of endogenous PGI2 in preventing arterial thrombosis has 
been convincingly demonstrated by use of the prostacyclin receptor knockout mice (Murata et al., 
1997). After endothelial damage to the carotid arteries, prostacyclin receptor (IP)−/− mice had 
extensive carotid thrombi that were occlusive and led to death in a proportion of the mice, whereas 
wild-type mice had smaller, non-occlusive thrombi and there were no deaths (Murata et al., 1997). 
It follows that the regulation of vascular PGI2 production is an important process for normal 
regulation of haemostasis.  
NO is a soluble gas with a half-life of 6 – 30 s, continuously synthesized from the amino acid L-
arginine in endothelial cells by the constitutive calcium calmodulin-dependent enzyme nitric oxide 
synthase (NOS; Palmer et al., 1988). There are two forms of NOS expressed in the endothelium: 
endothelial NOS (eNOS; type III) and inducible NOS (iNOS, type II). In the intact blood vessel wall, 
most of the NO is presumed to arise from the activity of endothelial eNOS (Förstermann et al., 
1991). There is a continuous, basal release of NO dependent upon eNOS activity which represents 
a sizeable portion of the total nitric oxide-releasing capacity of native endothelial cells. Once the 
endothelium has been damaged, exposure of smooth muscle cells (SMCs) to cytokines and other 
stimulators of NOS induction may have important physiological consequences for the blood 
vessel. eNOS has been shown to play a minor role in inhibiting arterial thrombus formation using 
 4 
 
eNOS knockout mice (Ozüyaman et al., 2005). A minimal effect on platelet aggregation was 
observed and this was found not to be linked with accelerated arterial thrombosis in vivo. This was 
tested using aggregometry studies of platelets from WT and eNOS-/- mice which showed no 
significant difference between the two. Also, no marked increase in cGMP formation and 
vasodilator-stimulated phosphoprotein (VASP) phosphorylation was observed. In addition, 
thrombin-induced P-selectin surface expression remained unchanged in eNOS-/- platelets. Another 
study has shown eNOS-/- knockout mice had significantly decreased bleeding times even after 
endothelial NO production was controlled (Freedman et al., 1999). This suggests that platelet-
derived NO appears to play an important counterregulatory role after platelet activation by 
inhibiting the recruitment of platelets to the growing thrombus (Freedman et al., 1997). Others 
have shown that eNOS deficiency is associated with increased platelet recruitment and enhanced 
fibrinolysis due to the lack of NO-dependent inhibition of Weibel-Palade body release (Iafrati et al., 
2005). These anti-aggregatory mechanisms are crucial for maintaining a physiological laminar blood 
flow without disruption to the closed vascular system. It is only when these barriers are overcome 
that platelets can become activated. That can happen after local injury or in response to the rupture 
of an atherosclerotic plaque.  
1.2.2. Platelet adhesion to subendothelial matrix 
Upon vascular injury, the endothelial lining is damaged removing its inhibitory effect and the 
flowing blood becomes exposed to the subendothelial matrix. This allows platelets to become 
activated by binding to adhesive ligands in the subendothelial matrix such as collagen, laminin, 
fibronectin and thrombospondin (Watson et al., 2010). Type I and III collagens, are the most potent 
activators of platelets providing much of the thrombogenic potential of the subendothelial matrix 
(Clemetson and Clemetson, 2001). In addition these collagens can also bind to von Willebrand 
Factor (vWF) with high affinity (Lecut et al., 2004). VWF also binds to exposed collagen to further 
increase the adhesive potential of the subendothelial matrix. At high shear rate, vWF acts by 
slowing down the platelets to allow adhesion and binding to other components of the 
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subendothelial matrix. This occurs by reversibly joining its A1 domain with GPIbα found on platelets. 
This rolling and tethering stage facilitate the formation of subsequent interactions between platelet 
receptors (integrin α2β1 and glycoprotein VI; GPVI) to collagen, leading to firm adhesion and 
platelet arrest. Synergistic actions between the platelet receptors cause platelets to adhere 
optimally. For instance, binding of integrin α2β1 and to collagen strengthen each other’s action 
(Auger et al., 2005). These interactions are further strengthened by activation of GPVI (Lecut et al., 
2004; Pugh et al., 2010; Siljander et al., 2004). In addition to these adhesive ligands, platelets are 
also activated by thrombin produced by tissue factor (TF) released from the vessel wall. Thrombin 
cleaves and activates the Protease-activated receptors (PARs), PAR1 and PAR4, and may also bind 
to GPIb activating distinct signalling pathways through each of these receptors that lead to different 
degrees of platelet activation (Nieman, 2016).  
Upon activation, platelets undergo a number of changes mediated by an agonist-evoked rise in 
cytosolic Ca2+ concentration ([Ca2+]cyt). This is elicited by platelet cell-surface receptors binding to 
both the adhesive and soluble ligands listed above to their respective receptors. The activation of 
these receptors generally leads to either phospholipase C (PLC) β or γ activation, which catalyses 
the production of Inositol 1,4,5-trisphosphate (IP3). IP3 in turn triggers Ca2+ release from the dense 
tubular system (the platelet equivalent of the endoplasmic reticulum) through its ability to activate 
IP3 receptors. An increase in [Ca2+]cyt plays a vital role in platelet activation where all stages of 
platelet plug formation requires a rise in the cytosolic Ca2+ concentration as well as, shape change 
and alternation of αIIbβ3 integrins to high affinity ligand binding (Tadokoro et al., 2011). The earliest 
observable events in response to these Ca2+ rises are changes of platelet shape from quiescent 
discoid shaped platelet and starting to spread over the subendothelial matrix extended thin 
filopodia to create spiny spheres. 
1.2.3. Secretion and Thromboxane formation 
After the initial adhesion and activation of platelets to the subendothelial matrix, platelets start to 
produce thromboxane A2 from arachidonic acid, as well as release stored autocrine activators of 
 6 
 
platelets from their dense granules to try to recruit more circulating platelets to the surface of the 
thrombus. Dense granules release adenosine di-phosphate (ADP), ATP and serotonin which 
facilitates the second wave of platelet aggregation following integrin activation (Johnston-Cox et 
al., 2011). ADP binds to the P2Y1 and P2Y12 receptor on platelets which acts to enhance and extend 
platelet activation allowing the platelet by both enhancing cytosolic Ca2+ rises as well as mediating 
Gi-mediated activation of integrin αIIbβ3  (Stefanini and Bergmeier, 2010).  
1.2.4. Platelet aggregation and plug stabilisation 
In quiescent platelet, the fibrinogen receptor, integrin αIIbβ3 a is normally kept in a resting or low-
affinity state in circulating platelets, but transforms into a high-affinity “activated” state after 
platelet activation. Upon platelet activation, activated integrin αIIbβ3 a, binds to its ligands 
(fibrinogen) mediating a stable platelet aggregation, and thrombus formation. The integrin–
proximal intracellular signalling mechanism that induces changes in the extracellular ligand binding 
domain of integrins from a “low-affinity” state to the activated state is referred to as “inside-out” 
signalling (Figure 1.1; Li et al., 2010). This process activates the ligand binding function of integrins 
via the binding of talin and kindlin proteins to the cytoplasmic domains of integrin αIIbβ3 (Shen et 
al., 2012).  
 
 
 
 
 
 
 
 
 
 
Figure 1.1 – “Inside-out” signalling. The “Inside-out” signalling strengthens adhesive contacts and the 
appropriate force necessary for integrin-mediated cell migration, invasion, ECM remodelling, and 
matrix assembly (Shen et al., 2012). 
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1.2.5. Secondary haemostasis - Activation and regulation of the blood coagulation 
cascade 
The blood coagulation system is a cascade of events involving proteolytic activation of plasma-
based zymogenic forms of clotting factors to generate thrombin and fibrin to support haemostasis. 
Briefly, this cascade is composed of intrinsic and extrinsic pathways which are triggered by either 
negatively-charged surfaces such as inorganic polyphosphates secreted from the platelet dense 
granules, as well as TF in the subendothelium which becomes exposed to plasma in response to 
vessel damage (Adams and Bird, 2009). Both pathways converge on a final common pathway to 
activate factor X, causing the conversion of prothrombin (factor II) to thrombin and finishing with 
the conversion of fibrinogen to fibrin. This section will cover a brief discussion about the link 
between platelet activation and localised regulation of the coagulation system at the site of vessel 
damage as part of fibrin clot formation as well as its resolution through the fibrinolysis pathway.  
The coagulation cascade can be categorised into three phases: (a) initiation phase, (b) amplification 
phase and (c) propagation phase. The initiation phase simply involves TF exposure to coagulation 
factors by forming a catalytic complex with factor VIIa (TF:FVIIa). This forms what is known as the 
‘extrinsic factor tenase complex’ thus activating the extrinsic pathway leading to small amount of 
thrombin generation (Adams and Bird, 2009; Bates and Weitz, 2005). The next phase follows 
(amplification phase) involves the thrombin triggering the activation of factor VIII to factor VIIIa, as 
well as the formation of factor IXa by the extrinsic tenase complex to form the ‘intrinsic factor 
tenase’ complex (FIXa:FVIIIa) on platelets’ surfaces but also on microparticles (Figure 1.2). This 
pathway is significant as it results in an increased thrombin production and also 50 - 100-fold 
increase in factor Xa production (Adams and Bird, 2009).   
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The propagation phase of coagulation helps ensure sufficient fibrin deposition in the thrombus. 
This phase involves platelet recruitment at the site of injury as well as the activation of the clotting 
cascade on their surface. This stage is dependent upon the number of platelets involved and results 
in a ‘thrombin burst’ causing fibrin formation from fibrinogen to generate a stabilised clot. The 
binding of these clotting factor to the platelet surface is dependent on the availability of 
extracellular Ca2+ to act as a cofactor, alongside surface expression of negatively charged 
phospholipids such as phosphatidylserine (PS) on the platelet surface. The expression of PS on the 
platelet surface is dependent on strong platelet activation, leading to large, prolonged Ca2+ signals 
triggering the activation of the platelet phospholipid scramblase, anoctamin 6 to move 
phosphatidylserine from the inner to the outer leaflet of the platelet membrane (Heemskerk et al., 
2013). This requirement for the platelets to provide a catalytic surface coagulation, helps localise 
the amplification stage of coagulation in the vicinity of the thrombus. The action of locally-formed 
thrombin on PAR1 and PAR4 platelet receptors ultimately helps in this process by reinforcing 
Figure 1.2 – Factor VIIa binds to tissue factor to form the extrinsic tenase, initiating the coagulation 
cascade. This in turns activates factors IX and X into factors IXa and Xa, respectively. Factor IXa binds 
to negatively charged phospholipid surfaces where it interacts with factor VIIIa to form intrinsic tenase. 
This complex activates factor X into factor Xa. Factor Xa then binds to factor Va to form 
prothrombinase, thereby increasing the rate of factor Xa–mediated conversion of prothrombin to 
thrombin. Thrombin then converts fibrinogen to fibrin (Bates and Weitz, 2005). 
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platelet activation triggering the prolonged platelet activation required for PS exposure. Thrombin 
also helps trigger other locally circulating platelets lead to the activation of integrin αIIbβ3 – 
therefore providing a basis for the concomitant development of the thrombus as well as the fibrin 
deposition that will structurally support it (Mehrbod et al., 2013).  
Fibrin monomers join together to form polymers and the action of factor XIIIa (activated by 
thrombin) leads to cross-linkage of fibrin strands. This forms a stable fibrin interaction. Thrombin-
activatable fibrinolysis inhibitor (TAFI) is also activated by thrombin which acts to protect the clot 
from plasma-mediated fibrinolysis (Adams and Bird, 2009). Hence, we summarise that the 
coagulation cascade is essential for homeostasis, acting to seal localised vascular injuries and that 
platelet activation and coagulation are complementary processes. 
The fibrinolysis pathway also plays an important role in haemostasis (Kolev and Longstaff, 2016). 
Fibrinolysis typically results in clot dissolution and is initiated endogenously as plasminogen is 
converted to plasmin by either of two primary serine proteases, proteases tissue-type plasminogen 
activator (tPA) and urokinase-type plasminogen activator (uPA; Chapin and Hajjar, 2015). The 
formed plasmin cleaves and breaks down fibrin leading to clot breakdown and dissociation. 
Dysregulation of this pathway may lead to vascular occlusion due to thrombosis, and so these serine 
proteases are down-regulated by plasma-localised protease inhibitors, such as antithrombin and 
tissue factor pathways inhibitor, or the activity of protein C on the surface of endothelial cells (Gale, 
2011; Palta et al., 2014). These regulatory systems help localise the activity of the blood coagulation 
system and prevent aberrant activation of this cascade in undamaged areas of the vasculature. 
Therefore, haemostasis should be maintained by simultaneously avoiding thrombosis via 
maintaining a balance between pro-thrombotic and anti-thrombotic systems. However, if the 
primary or secondary haemostatic system is impaired or activated unnecessarily this can lead to a 
number of haemostatic pathologies. 
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1.3. Diseases linked to haemostasis  
There are a number of congenital disorders that affect the normal activation of primary and 
secondary haemostasis that cause excessive bleeding in patients.  These include haemophilia types 
A and B which are both caused by a recessive expression of the defective gene by the X 
chromosome. Hemophilia A is due to deficiency of the coagulation factor VIII, and hemophilia B is 
due to deficiency of factor IX. Other bleeding disorders include von Willebrand disease which is a 
congenital deficiency in vWF. This disease causes defects in platelet aggregation but also causes a 
deficiency of factor VIII (Ruggeri, 2007). In addition, defects in other coagulation factors exists such 
as factors XI, factor VII and prothrombin, however these are low in frequency. Moreover, bleeding 
disorders can arise from deficiencies in α2 antiplasmin, a plasminogen inhibitor, or plasminogen 
activator inhibitor-1. The former resulting in an increased fibrinolysis and the latter resulting in a 
lack of control of fibrinolysis by not breaking the activity of plasminogen activation factor 
(Carpenter and Mathew, 2008). There are also bleeding disorders caused by platelet function 
defects which include storage pool disorders. This heterogeneous group of congenital disorders 
have a common deficiency in granules or their constituents such as defects in ADP release from 
activated platelets. In addition to storage pool disorders, Glanzmann thrombasthenia and Bernard–
Soulier Syndrome are other defects that are known to cause excessive bleeding in patients affected 
by these diseases. Glanzmann thrombasthenia is a genetic disorder that leads to qualitative or 
quantitative disturbance in the platelet membrane GPIIb-IIIa complex. Bernard–Soulier Syndrome 
also caused by a lack or qualitative defect in the platelet membrane receptor GPIb-IX-V complex, 
leading to inability of platelets to bind to vWF during the initial steps of platelet adhesion (Simon et 
al., 2008). 
In contrast to bleeding disorders, thrombosis is caused by overactivity of the primary or secondary 
haemostasis system and leads to the formation of unwanted blood clots within the intact 
circulatory system. These can be classified into three different forms, (i) arterial, (ii) venous 
 11 
 
thrombosis and (iii) mixed microvascular form. Venous and arterial thrombi are formed in their 
respective parts of the circulatory tree, where they are triggered by distinct pathological processes. 
Arterial thrombi are generally formed principally from platelets usually triggered by the rupture of 
an atherosclerotic plaque leading to abnormal release of collagen and tissue factor into the 
bloodstream. These form white clots which are distinct from the red clots found in venous 
thrombosis (Franchini and Mannucci, 2008). Virchow established the risk factors for venous 
thrombosis back in the 19th Century where he identified roles for venous stasis, injury to the vessel 
wall and a hypercoagulable state as key risk factors in the development of venous thrombosis. 
Nonetheless, it is only recently that the cellular mechanisms underlying venous thrombosis have 
been identified. However, Wagner et al (2012)., have shown that neutrophils become activated 
under conditions associated with changes associated with each part of Virchow’s triad (Wagner and 
Frenette, 2008). These activated leukocytes release their nuclei as neutrophil extracellular traps 
(NETs). The negatively charged histones provide a surface that appears to be able to activate both 
platelets and the intrinsic coagulation cascade, leading to the onset of thrombosis formation. These 
thrombi can do significant damage through their ability to occlude blood vessels blood vessels 
either directly or by breaking off from the initial clot (embolisation) and lodging in another distant 
circulation (Heit et al., 2016).  
Blocking blood supply to the downstream tissue can trigger a number of potentially life-threatening 
disorders such as heart attacks, strokes and pulmonary embolisms. These acute cardiovascular 
events are amongst the deadliest of range of cardiovascular diseases (CVDs) which including 
diseases of the cardiac muscle and of the vascular system supplying the heart, brain, and other vital 
organs.  CVDs remain the most common cause of death worldwide, with the 2013 Global Burden of 
Disease (GBD) study estimating that CVDs caused 17.3 million deaths globally (Townsend et al., 
2016). CVDs accounts for more than 4 million deaths each year across Europe, accounting for 45% 
of all deaths (Townsend et al., 2016).  
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1.4. Haemostasis models  
1.4.1. In vitro models 
Due to ethical issues involved in undertaking in vivo testing in humans, many studies of human 
platelet function and thrombus formation are conducted in vitro. A variety of methods are available 
to assess platelet function such as measuring platelet aggregation using light transmission 
aggregometry (LTA), expression of activation markers such as P-selectin or phosphatidylserine 
exposure using flow cytometry, or measurement of soluble markers of granule secretion such as 
ATP or 5-HT. Others include, solid-phase binding assays using coverslips, an enzyme-linked 
immunosorbent assay (ELISA)-based binding assay using specific antibodies or Immunodetection 
via colorimetry is an alternative for using radioactive iodine as the detector (Ledford-Kraemer, 
2010; Lopez and Zheng, 2013). These assays however fail to capture much of the physical flow 
conditions inside the human body. 
1.4.1.1. Parallel plate flow chambers (2-dimensional models) 
A more realistic in vitro model is the perfusion of platelets or whole blood through a parallel plate 
flow chamber in which physiological shear rates of blood flow can be generated (Chung et al., 2003; 
Dong et al., 2002; Sakariassen et al., 2001; Van Kruchten et al., 2012). These chambers are used to 
study platelet adhesion and aggregation upon a coverslide coated with an adhesive platelet ligand. 
In addition, blood coagulation can also be simultaneously studied when whole blood is used. Unlike 
most other platelet function tests, experiments with flow chambers take into account the physical 
parameter of blood flow and therefore the influence of haemodynamics on the participating cells 
and biomolecules. Therefore, these are useful tools to use in determining the signalling events 
underlying blood clotting at a molecular level.   
Currently used parallel plate flow chambers include custom-made and commercial flow devices, 
that are widely used in studying thrombus formation (Van Kruchten et al., 2012). Parallel plate flow 
chambers usually involve perfusion of platelets over a platelet-activating surface at physiological 
 13 
 
shear rates. Hence the device can provide a novel insight into the haemostatic function of platelet 
activation, particularly in combination with fluorescence microscopy. Microscopes are continuously 
being improved by the use of high-resolution cameras to improve the quality of digital images. 
Currently used flow chambers include parallel-plate flow chambers, newly developed biochips with 
microfluidic channels and rectangular microcapillaries, all of which have been used to study the 
thrombus-forming processes (Roest et al., 2011). This facilitates real-time monitoring of platelets 
aggregation under shear stress. However, these chambers are mainly used to assess platelets 
behaviour upon exposure to immobilised agonists in the absence of the cells of the blood vessel 
wall and cannot be used to study 3-dimensional vascular models. A previous study compared  the 
effect of currently used in vitro devices with regards to pre-coating the devices for flow experiments 
(Roest et al., 2011). Most studies used collagen coating (92%) for their assays, with less popular 
coatings including fibrinogen, vWF, synthetic peptides or the use of an endothelial cell monolayer 
(Roest et al., 2011; Shi et al., 2016; Van Kruchten et al., 2012). The study concluded that care should 
be taken to maintain laminar flow and recommended the use of Horm type I collagen for testing 
platelet aggregation. The use of collagen-coated surfaces are the closest resemblance to 
physiological conditions in vivo and are thus preferred for flow assays (Heemskerk et al., 2011).  
There are at least 20 different subtypes of collagen (Manon-Jensen et al., 2016). The presence of 
these differing collagen isoforms in the vasculature is dependent on the structure and function of 
the vessel in question. In an uninjured arterial wall, type I and III collagen are the predominant 
collagen isoforms found in the Tunica media and adventitia. Platelet assays mainly use fibrillar and 
monomeric forms of these arterial collagen isoforms d to study platelet aggregation to attempt to 
replicate in vivo conditions. In vitro assays mainly use fibrillar forms of type I collagen from equine 
tendons, calf skin, and human placenta, although types III, and IV have also been used (Li et al., 
2013; Wu et al., 2000). Monomeric collagen forms can also be used to allow the monitoring of 
platelet aggregation under physiological flow conditions in vitro. To do this they are typically 
solubilised in acetic acid and further coated onto perfusion chambers prior to perfusion with 
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platelet suspensions, plasma or whole blood (Li et al., 2013; Wu et al., 2000). These types of 
collagens differ from Horm collagen, a native form of type I and III collagens. These include 
differences in the (i) mix of collagen isoforms being used and (ii) their tertiary and quaternary 
structures of the collagen formed during re-construction. The commercially available Horm collagen 
is described as a solution of type I (95%) and type III (5%) fibrils isolated from equine tendon 
(Bianchini et al., 2015). Hence this suggests that the presence of both these types of collagen is 
essential and how they present themselves in the matrix to the platelets.    
Shi et al., (2016) perfused whole blood over collagen-coated microfluidic channels using different 
shear rates. This study showed that platelet thrombus formation varied under different shear rates 
(Shi et al., 2016). The thickness of the formed thrombi was shown to be proportional to shear rate 
used. Using a high shear rate (2500-5000 s-1) causes thick thrombus formation with tendency to 
embolise, which was regulated by an attachment-detachment balance. These data therefore 
highlight the importance of recreating the physical environment in which thrombus formation 
occurs. 
Lopez & Zheng designed a model consisting of in vitro tissue engineered synthetic capillary model 
using endothelial cell-coated microchannels, to study biological events occurring in microcirculation 
such as remodelling, angiogenesis and ECs function (Lopez and Zheng, 2013). This study aimed to 
overcome the limitation of previous challenges faced by microfluidic chambers that include: (i) 
difficulty with fabricating a chamber in which the vessel has cylindrical morphology and (ii) non-
distensible. Polydimethylsiloxane (PDMS) and collagen were used to create channels in which ECs 
were seeded. However, this system is only representative of capillaries and lacks other key cells 
found in larger veins and arteries. This simplified model involving a single layer of ECs is missing the 
more complex biological and chemical environment of arteries required to study vascular diseases 
such as atherosclerosis. Though much progress has been made in the fabrication of microfluidic 
chambers, they still have limitations in their ability to mimic the geometry of actual blood vessels. 
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One disadvantage is that conventional microfluidic chambers have square or rectangular cross 
sections resulting from the limitations of the fabrication procedures. These features result in 
inhomogeneous and unphysiological shear conditions on the vessel wall, as the shear stresses are 
very different at corners than at the centre of the walls (Zheng et al., 2014). This inhomogeneity 
creates artfactually-high shear stresses that hinder interpretation of studies of shear-dependent 
platelet-vessel wall interactions. Extensive studies have been studied to establish the foundations 
of adhesion, activation, aggregation and granule secretion concepts in platelets in vitro (Zheng et 
al., 2014).  
Though these in vitro studies are reasonable starting point for studying the basic mechanisms of 
thrombus formation, these studies lack the precise control of the properties of the blood vessel 
surface that plays a central role in regulating the formation of platelet thrombi. Thus, in vivo studies  
in animal models provides a system which can more faithfully recreate the physical and chemical 
environment found in native human blood vessels (Falati et al., 2002; Furie and Furie, 2008, 2007, 
2005).  
1.4.2. In vivo models 
In vitro studies fail to replicate the haemodynamic factors and/or the complexity of in vivo system 
with regards to direct and indirect platelet activation with other cells such as endothelium and 
leukocytes. To address these weaknesses and limitations, research has turned into animal models 
to study haemostasis (Bellido-Martín et al., 2011a; Falati et al., 2002; Furie and Furie, 2008), 
emphasising techniques such as intravital microscopy, a tool that allows imaging of several 
biological processes in live animals (Masedunskas et al., 2012). In these experiments thrombus 
formation is induced by using a variety of methods to artificially damage the endothelial lining 
during the course of experiment. The effects of this formation on blood flow through the injured 
vessel can be measured using doppler or temperature sensing probes. In addition, intravital 
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microscopy can be used to allow direct visualisation of thrombus formation using fluorescently 
labelled platelets. 
Several in vivo blood vessel injuries can be introduced in mice and these include: (i) mechanical 
disruption, (ii) photo-oxidation of ECs using Rose Bengal dye, (iii) vessel ligation, (iv) oxidation with 
FeCl3 and finally (v) the commonly used laser-induced vessel wall injury. Laser induced vessel wall 
injury is the second mostly used technique after FeCl3, due to its high level of resolution (Denis et 
al., 2011), nevertheless the rest of the techniques employed can create reliable clotting responses. 
Though there are known differences in the molecular mechanism underlying the formation of 
thrombi in these different models. Due to these differences, the next section will review each of 
these methods. 
1.4.2.1. Ferric chloride model  
The use of FeCl3 as a thrombogenic agent has become a common method for investigating the 
mechanisms of thrombosis in transgenic mice (Bonnard and Hagemeyer, 2015; W. Li et al., 2013). 
This agent is typically applied to the outer aspect of arteries inducing oxidative damage to vascular 
cells. However, it can also be applied on the luminal side of the vessel wall, since Tseng et al., (2006) 
have shown that ferric ion permeates the endothelial basal lamina before entering the arterial 
lumen via an endocytic-exocytic pathway, damaging not only endothelial cells but also SMCs (Tseng 
et al., 2006). A similar study was recently done in rats using ZsGreen1 green fluorescent protein-
labelled platelets where FeCl3 caused time-dependent increase in fluorescent thrombi (Mizuno et 
al., 2016). Studies of genetically-altered mouse models have showed two independent pathways 
involved in platelet activation (Dubois et al., 2006a; Furie and Furie, 2008). The ferric chloride 
model, which causes denudation of the endothelium and exposure of the subendothelial matrix, 
has shown to be dependent on collagen pathway. Using this method, a range of times measured 
between 5 and 30 minutes has been reported from injury to complete vessel occlusion (Bonnard 
and Hagemeyer, 2015), which suggests that FeCl3 concentrations, types of anaesthesia, surgical 
techniques, mouse age and genomic background, method of measuring blood flow, and other 
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environmental variables have substantial effects in this model. This wide variability may be 
acceptable for a single study, but it makes it very difficult to compare studies from different groups 
and may make detection of subtle differences difficult.  
1.4.2.2. Laser and mechanical injury models  
The laser-induced injury model uses a laser to create a defined area of damage to the blood vessel 
of interest to trigger a clotting response. Platelets aggregation in this model has been found to be 
dependent on tissue factor and thrombin production, since this type of injury causes an insignificant 
amount of collagen exposure. This therefore represents a difference of the FeCl3 model as the 
clotting observed in the laser injury model is independent of the collagen receptor GPVI and vWF 
(Dubois et al., 2006a). Together, both FeCl3 and laser induced injury models trigger two independent 
pathways of platelet activation suggesting that both of these pathways may mediate the response 
in the human circulation (Bellido-Martín et al., 2011a). Despite the difference in the initiating trigger 
for the onset of thrombus formation, the consequences of platelet activation are the same in these 
two types of injury models. However, it is still unclear how platelets are recruited to adhere to the 
laser injured vessel wall in the absence of collagen exposure, this may be caused by activation of 
surrounding endothelial cells caused by the laser, leading to the expression of adhesive molecules 
that are able to bind platelets to the damaged vessel wall.   
Tang et al., (2016) have standardised an in vivo mouse model to study thrombus formation induced 
by mechanical injury (Tang et al., 2016). The study defined two degrees of injury induced by 
pinching the abdominal aorta with haemostatic forceps. This technique is able to induce two 
different grades of vessel wall damage (moderate and severe). Thrombus formation was monitored 
in real-time using a fluorescent microscope coupled to a CCD camera. A moderate type of injury 
has shown a thrombus formation that peaks are 1 minute post injury and resolves within 3 minutes 
whereas a larger thrombus was observed in the severe type injury (Tang et al., 2016).  
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1.4.2.3. Benefits and limitations of mouse models 
In the past, in vivo animal studies of thrombus formation have benefited significantly from using 
genetically modified mice. These allow targeted manipulations of the expression of a range proteins 
involved in the signal transduction pathways underlying platelet activation to help us understand 
their role in thrombus formation and allowing us to study haemostasis at a molecular level under 
physiological conditions (Sachs and Nieswandt, 2007). Mice models are attractive for use in platelet 
research owing to their small size, high fertility and exceptional reproductive capacity as well as low 
costs involved in maintaining them. In addition, 99% of mice genes are equivalent to humans, 
making them an ideal mode for in vivo study of human diseases (Guénet, 2005).  
Besides all these advantages there are also limitations in studying haemostasis and clotting 
disorders in mouse models. Extrapolation of data from mouse to human platelets should be 
performed cautiously as there are known variations between the two species that may influence 
the interpretation of data. These differences include: (i) platelet count and volume; (ii) differences 
in expression of some platelet receptors such as PARs and FcγRIIa; (iii) variations in haemodynamic 
shear rates in mice and human and (iv) the use of general anaesthetics in mice for in vivo studies, 
which may interfere with normal thrombus formation (Atkinson et al., 1985; Rowley et al., 2011; 
Sachs and Nieswandt, 2007; Weinberg and Ross Ethier, 2007). Together, these limitations therefore 
suggest that a humanised model system in which to recreate the in vivo environment found with 
the human circulatory system may provide additional insight into human thrombus formation. 
1.5. Tissue engineering of blood vessel models 
1.5.1. Principles of tissue-engineering  
Tissue engineering is a multidisciplinary field that combines the principles of engineering and life 
sciences to develop biological replicas of native tissues for the replacement of damaged organs in 
human patients. This employs the notion of using the body’s natural healing responses in 
combination with engineering principles to grow a new tissue (Langer and Vacanti, 1993). Tissue 
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engineering approaches have been intensively used to develop a human blood vessel constructs to 
recreate the physiological features found in the human body to study the processes of haemostasis 
and the pathological processes of thrombosis or be used in grafting to replace damaged blood 
vessel tissues. An ideal tissue engineered blood vessel construct should closely replicate the 
structure and function of the native vascular tissue. It is pre-requisite to fully understand the 
anatomy and physiology of blood vessel layers to enable the fabrication of functional TEBVs.  
1.5.2. Anatomical structure and function of native blood vessel wall 
The native arterial and venous wall is composed of three layers - the tunica intima, tunica media 
and tunica adventitia, (Figure 1.3; Patel et al., 2006).  
1.5.2.1. Intimal layer 
The tunica intima forms the 
innermost layer composing of a 
continuous layer of ECs. This layer is 
separated from the subsequent 
(medial) layer by a dense elastic 
layer known as the internal 
elastic lamina (IEL). The IEL represents a flexible barrier between the endothelium and inner SMCs 
layer and may have a role in atherogenesis via its modulation of diffusion across the artery wall 
(Sandow et al., 2009). Fenestrations in the IEL are implicated in myoendothelial signalling, enabling 
the passage of endothelial and SMCs projections and subsequent contact between these cell layers 
in some vessels (de Wit et al., 2006). The endothelial cell layer is crucial in negatively regulating the 
activation of the haemostasis system by both creating a physical barrier between the blood and the 
subendothelial matrix, as well as through its ability to secrete inhibitors of platelet function. 
The endothelial cell layer’s impermeability is created by the formation of tight junctions between 
the endothelial cells. Three types of EC junction have been identified and these are: (i) tight 
Figure 1.3 Shows layers of the blood vessel wall (Patel 
et al., 2006) 
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junctions; (ii) adherens junctions and (iii) gap junctions (Figure 1.4; Wallez and Huber, 2008). The 
main constituent of 
tight junctions is a 
transmembrane protein 
known as ‘occludins’. 
This transmembrane is 
associated with other 
cytosolic proteins to seal 
the EC layer. Tight 
junctions connecting the ECs, limit the diffusion of even smaller molecules (< 1 kD) to go through 
the vessel (Yuan and Rigor, 2010). These junctions cause the ECs to appear to some extent fused 
together. Moreover, adherens junctions are Ca2+ channel dependent which are formed by several 
transmembrane proteins such as cadherins and VE-cadherin, which are cell junction whose 
cytoplasmic face is linked to actin cytoskeleton. These endothelial cell junctions are involved in 
regulating endothelial cell permeability to circulating blood cells according to the functional 
requirement of body organ (Yuan and Rigor, 2010). The permeability of ECs changes by the 
rearrangement of surface occludins and cadherins, leading to activation of matrix 
metalloproteinases or endopeptidases that degrade extracellular matrix (ECM) proteins (Alexander 
and Elrod, 2002). Impairment of function of these endothelial cell junctions may lead to edema (an 
increase in the interstitial volume). Some endothelial cell stimuli such as arterial natriuretic factor 
(ANF), thrombin or histamine provoke a fast but temporary rise of vascular permeability, whereas 
vascular endothelial growth factor (VEGF) and cytokines trigger a prolonged response. The majority 
of these agonists are released inflammatory mediators (Mitchell and Niklason, 2003). Thus, 
ensuring endothelial cell permeability when conducting in vitro assays, is key to ensure that any 
endothelial monolayer is behaving similarly to its native counterpart. In addition, ECs also 
synthesise and releases a number of paracrine substances acting on cells of the blood. By secreting 
Figure 1.4 - Shows endothelial cell-cell junctions that control 
permeability of blood cells (Yuan and Rigor, 2010). 
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specific molecules like NO and PGI2, endothelial cells inhibit platelet activation and prevent 
thrombus formation as detailed above.  
Following blood vessel injury, ECs are lost from the site of vascular injury and so expose the 
subendothelial matrix triggering the activation of the haemostatic system. In addition, ECs 
surrounding the damaged blood vessel wall exhibit local activation induced by inflammatory 
cytokines. This shifts the balance from its normal inhibitory towards favouring platelet aggregation 
and thrombus formation. This shift occurs as ECs start to increase the production and expression of 
pro-aggregatory or pro-coagulant molecules and suppressing the normal anticoagulant 
mechanisms, facilitating activation of platelets and the blood coagulation system (Gross and Aird, 
2000; Preissner et al., 2000). There are two main pro-aggregatory mediators released by activated 
ECs that support platelet aggregation - platelet-activating factor (PAF) and vWF. PAF is a strong 
platelet activator which is produced by ECs promoted by thrombin, histamine and cytokines. vWF 
is normally stored within Weibel–Palade bodies of ECs and constitutively released into the plasma 
(Denis et al., 2011). The action of thrombin causes the release of vWF from their stores. 
Additionally, vWF has a function in stabilising factor VIII, involved in coagulation. This coagulation 
factor is necessary for binding of platelets to TF during vessel wall injury (Ruggeri et al., 1999). 
Interference with the anti-aggregatory function of the endothelial lining evokes a regulatory 
mechanism that maintains a physiological blood flow.  
 
1.5.2.2. Medial layer and the associated extracellular matrix  
The middle layer of the blood vessel, the tunica media, is composed of SMCs that provide structural 
support, mechanical strength and contractility to the blood vessel wall. SMCs are arranged helically, 
surrounded by elastin and collagen fibres that form a strong, elastic extracellular matrix. A major 
function of the vascular SMCs in medium to large vessels is to synthesize and organize the unique 
ECM responsible for the mechanical properties of the wall, these include elastin and collagen. 
Hence the ability of SMCs in providing these key proteins is essential to maintain mechanical 
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properties of the wall. The production of a functional ECM requires the coordinated expression of 
complex sets of genes that encode ECM proteins as well as the enzymes responsible for their 
secretion and assembly (Wagenseil and Mecham, 2009). Elastin is an ECM protein that is at least 5 
fold more extensible compared to a conventional rubber (Alberts et al., 2002). This astonishing 
property of elastin enables large arteries to expand during each heartbeat, storing mechanical 
energy to help ensure a continuous pressure gradient driving blood flow through the circulation 
between each cardiac cycle. In addition, the mechanical properties of arteries are controlled by the 
activity of SMCs. Collagen is less extensible compared to elastin, but offers mechanical strength to 
the vessel to protect it from aneurysm (Guthold et al., 2007). Collagen is found in the arteries of 
which type I, III, and V collagens are fibril-forming, with types I and III being mainly responsible for 
imparting strength to the vessel wall (Stuart and Panitch, 2009).   
Under physiological conditions, SMCs possess a contractile phenotype and control the dilatation 
and constriction of blood vessels thus regulating blood flow. Under certain pathological conditions, 
SMCs convert to a synthetic and non-contractile phenotype (Patel et al., 2006). This synthetic 
phenotype results in proliferation and increased matrix production in the tunica media.  In contrast 
to the endothelial cell layer, the subendothelial matrix within the medial layer normally provides a 
pro-thrombotic surface to trigger the activation of circulating platelets. Blood vessel damage leads 
to the platelets exposure to collagen within this layers hence their adhesion and activation (Patel 
et al., 2006). Due to its central role in triggering activation of the haemostatic system, the molecular 
basis of platelet-collagen interaction has been a major focus of research, especially its structure and 
its influence on platelet activation (Shinohara et al., 2013; Stinson et al., 1979). The role of collagen 
in platelet activation will be explained later in detail. The medial layer is separated from the 
adventitia (outer layer) by a dense elastic membrane called the external elastic lamina. 
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1.5.2.3. Adventitial layer 
The adventitia consists of connective tissue sheath without a distinct external border. It has a 
function of anchoring the blood vessel to ECM. Thus, this layer has a role in tethering the blood 
vessel to surrounding tissues. Fibroblasts are the major cell component found in the adventitia, but 
in larger arteries this may also possess network of smaller vessels called the vasa vasorum which 
supply the blood vessel wall with oxygen and nutrients as the diffusion distance is too long from 
the arterial lumen. It may be possible that the ECs of the vasa vasorum secrete vasoactive 
substances such as NO to the surrounding adventitial compartment which can influence its function 
(Kleschyov et al., 1998; Lin et al., 2004). Others have shown that the vasa vasorum may be involved 
in several vascular diseases such as atherosclerosis (Plante, 2002; Scotland et al., 2000). Some have 
suggested that NO may be produced by mast cells and neurons present in the adventitia (Laine et 
al., 2000; Yoshida et al., 1993). Other cell types that are found within the adventitia include 
pericytes and perivascular adipocytes. Pericytes functions to stabilise blood vessels and 
angiogenesis but there are some evidence suggesting a role in calcification which is commonly 
associated with atherosclerosis (Shao et al., 2006). Although perivascular adipocytes have been 
mentioned, but these types of cells are not morphologically counted as part of the adventitia itself 
but rather presents anatomically close to blood vessels (Auger et al., 2007). The adventitia also 
contains sympathetic nerve terminals that control vessel diameter. Vasoconstriction is achieved by 
the action of noradrenaline released from these sympathetic nerve endings, hence regulating blood 
flow through the artery (Levick et al., 2010).  
1.5.3. Current vascular tissue engineering strategies  
In the past 40 years, there have been considerable efforts in producing tissue-engineered blood 
vessels as an alternative vascular graft which maintain a high patency rate. Scientists attempted to 
improve synthetic grafts in number of ways such as; (i) seeding with ECs, (ii) embedding cells with 
anti-thrombotic drugs and (iii) development of new biomaterials. Herring et al (1978)., first 
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reported the successful isolation and seeding of ECs onto synthetic grafts (Herring et al., 1978). This 
study demonstrated an improved patency rate of the blood vessels when using 6 mm diameter 
synthetic grafts than when compared with unseeded grafts. However, the graft failed to show 
retention of the ECs under flow conditions, highlighting the limitation of using such approach. 
Therefore, a significant focus of research has been on improving ECs adhesion to biomaterial 
surfaces. This includes investigating the use of natural ECM proteins such as collagen, fibrin, 
fibronectin and laminin (Cooper and Sefton, 2011; Pankajakshan and Agrawal, 2010). However, this 
approach has been limited by the potential for development of a chronic inflammatory response 
targeted at the synthetic support. 
Tissue engineered blood vessels have generally been designed to be utilised for vascular grafting as 
a substitute for autologous transplantation in those patients lacking a suitable graft tissue. There 
are certain requirements that have to be met to achieve a highly functional blood vessel model. 
These requirements include: biocompatibility, non-thrombogenicity, non-immunogenicity as well 
as confluent and quiescent EC layer (Hasan et al., 2014). Also, it should have appropriate mechanical 
properties such as withstand the high pressure and haemodynamic stress found within the arteries 
in long term. In addition, it should also fulfil all the physiological requirements such as being able 
to constrict and relax and should be indistinguishable from the native blood vessel. Thus, creating 
a construct that meets these requirements represents a significant challenge.  
There are three main components that are needed to allow realistic tissue formation using tissue 
engineering techniques. Firstly, the use of an appropriate cell source that can maintain the cellular 
phenotype found in vivo to sustain tissue function. Secondly, the use of bioreactive mediators and 
an appropriate culture environment to help maintain the normal cellular phenotype. Lastly, the use 
of a scaffold that acts as temporal extracellular matrix to hold cells together in the normal patterns 
found inside the body. Current tissue engineering techniques involve the use of layer-by-layer 
fabrication technique (Wilkens et al., 2016), scaffold free constructs (Jung et al., 2015), plastic 
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compression of collagen hydrogels (Braziulis et al., 2012; Levis HJ, 2010) and angiogenesis, the 
process where new blood vessels form from existing vasculature (LaValley and Reinhart-King, 
2014). A recent review have discussed in vivo generation of TEBVs using the host reaction to an 
implanted biomaterial (Geelhoed et al., 2017). To be exact, this approach intends to make use of 
the body’s foreign body response to biomaterials, and exploits the host environment as a bioreactor 
for the generation of new tissues, essentially allowing for the re-construction of the entire vascular 
graft within the patient’s body.  
1.5.3.1. Scaffolds 
Scaffolds may be biological or synthetic (Fernandez et al., 2014; Goonoo et al., 2013; L’Heureux et 
al., 1998). At present, there are 4 main strategies used to create scaffolds that allow the formation 
of tissue that meets the criteria highlighted in the previous section. This includes the use of (1) 
decellularised tissues (2) synthetic polymer scaffolds (3) tissue self-assembly approach to create 
cell sheets and (4) hydrogels or biopolymer scaffolds. Each of these approaches have their 
advantages and disadvantages and relevant methods will be described in the next section, except 
for the decellularised tissues approach as it is beyond the scope of this project. 
1.5.3.1.1. Synthetic polymer scaffolds  
Various vascular models using biodegradable polymer scaffolds have been studied. This simply 
implies seeding cells onto degradable polymer to aid cell growth and remodelling. Cellularisation is 
achieved by cell seeding techniques used to optimise their distribution (Kim et al., 1998). Preferably, 
the polymer will be gradually absorbed in culture, yielding the tissue produced by the cells. These 
polymers are beneficial as they have tailorable mechanical properties, degree of resorption and 
micro/nano-structure, which can be manipulated by changing the chemical makeup in an effort to 
improve cell growth and tissue remodelling. Another benefit of these polymer scaffolds is that they 
have early mechanical function supporting the scaffold, until the cells produce enough ECM.  
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1.5.3.1.2. Nanofiber scaffolds 
Nanofibers provide a high surface area to volume ratio with microporous structures that support 
cell adhesion, proliferation, migration, differentiation and alignment (Ma et al., 2005). Fabrication 
of nanofibers has been adopted for use in vascular tissue engineering for reasons that some of 
these being biocompatiple, biodegradable and provide mechanical strength to the vessel replica 
(Agarwal et al., 2008). At present, there are three different methods available for creating 
nanofibers which include: (i) electrospinning, (ii) self-assembly and (iii) phase separation. 
Electrospinning is the most commonly studied method and shown to be potential for tissue 
engineering. The resulted nanofiber can be used to make synthetic biodegradable scaffolds that 
provide a suitable structure for cell proliferation, adhesion and differentiation.  
There are two main limitations of using synthetic polymers for vascular tissue engineering. Firstly, 
degradation of these polymers causes the formation of by-products such as lactic acid and glycolic 
acid. Although these compounds are naturally produced by the human body, when high local 
concentrations of these by-products are produced they can become toxic to cells due to their ability 
to trigger a drop in pH of the microenvironment. The second problem lies in the imbalance in the 
relative rate of polymer degradation and tissue remodelling. Generally, the synthetic polymer 
degrades more rapidly than the time taken for a full ECM to be developed by the seeded cells.  
Hence, the construct can become weakened and incapable to sustain the high arterial pressure of 
the blood – potentially resulting in aneurysm. Therefore, these methods will need to be further 
optimised to be able to be used in creating a transplantable vessel graft.  
1.5.3.1.3. Scaffold-free culture-cell sheets 
This methodology was developed by Jung et al., (2015) which is based on using cultured human 
cells, without using additional synthetic or exogenous materials (Jung et al., 2015). Briefly, sheets 
of SMCs were cultured on culture plates with high levels of ascorbic acid (to generate high levels of 
collagen synthesis), this produced an organised cellular sheet. The cell sheet was then detached 
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and placed on a tubular support to produce the medial layer. In the same way, a sheet of fibroblasts 
was cultured and wrapped around the media to form the adventitial layer. After 14 days, the two 
sheets were fused together to produce a cohesive structure. Finally, ECs were seeded on the 
luminal surfaces from the 2 ends and distributed through the vessel by rotating the sheet overnight. 
This has shown a well-defined, multi-layer arrangement with an apparent ECM, though the ECM 
did not display a circumferential alignment as found in the native blood vessel. The SMCs re-
expressed desmin which is a marker that was lost during culture and is indicative of a contractile 
phenotype. In addition, the ECs could be seen to possess a physiological phenotype as shown by 
their expression of vWF, production of PGI2, uptake of acetylated LDL and inhibition of platelet 
adhesion to their surface. The construct produced using this methodology had a burst strength 
above 200 mmHg, after three weeks of sequential culture in a rotating wall bioreactor and 
perfusion at 6.8 dynes/cm2, which is comparable to human vessels. However, cell sheet grafts have 
shown to be stiffer than the vessel being bypassed, this could lead to intimal hyperplasia (Jung et 
al., 2015). The stiffness of this construct is perhaps due to inadequate elastin deposition by the 
SMCs. Nevertheless, results from transiently grafting this type of blood vessel in canines 
demonstrated that it was able to function in vivo (L’Heureux et al., 1998). 
1.5.3.1.4. Hydrogel and biopolymer scaffolds 
Tissue engineering using hydrogels was first developed by Weinberg and Bell in 1986. This involved 
seeding ECs on the luminal surface of a tubular structure composed of type I collagen hydrogels 
filled with SMCs (Serbo and Gerecht, 2013). Type I collagen is a major component of the 
subendothelail matrix, and is a highly-abundant protein found throughout the human body, 
including the blood vessel wall (Xu and Shi, 2014). Fibrin can also be used as a biopolymer instead 
of collagen to form the basis of the blood vessel structure. Collagen and fibrin cause cells to entrap 
during gelation (fibrillogenesis) of the hydrogel allowing direct cellularisation within the construct. 
The advantages of using hydrogels are: (1) high degree of circumferential SMC alignment and (2) 
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direct cellularisation of the construct. However, these characteristics were not enough in the study 
by Weinberg & Bell (1986) to produce the mechanical properties found in native arteries since it 
could not withstand perfusion with arterial blood pressures (Weinberg and Bell, 1986).  
1.5.3.1.5. Cell source  
Differentiated primary cells and cell lines have also been used as cell sources for fabricating tissue 
engineered constructs (Sankaran et al., 2014; Sundaram and Niklason, 2012; Wilkens et al., 2016). 
The cellular components required to build stable blood vessels include ECs which line the inner 
surface of blood vessels and SMCs and lie in the subendothelial matrix of the medial layer. A 
commonly used primary cell type, human umbilical vein endothelial cells (HUVECs), play a role in 
endothelial layer formation, preventing platelet adhesion (Kelm et al., 2010). In addition, HUVECs 
are routinely cultured from readily available tissues in a reproducible manner. Syedain et al., (2011) 
demonstrated capability to fabricate tissue engineered arteries like native arteries by entrapment 
of human neonatal dermal fibroblasts in a fibrin gel (Syedain et al., 2011). The construct was 
subjected to a bioreactor to convey both transmural flow and cyclic distension ultimately leading 
to the formation of circumferentially aligned collagen and other ECM using a burst pressure of 
1,400–1,600 mmHg. A period of 7-9 weeks of culture is required for this method with notable 
mechanical properties of the grafts generated using this method make this approach extremely 
interesting for grafting (Syedain et al., 2011). Creating a tissue engineered vascular construct 
requires integration of SMCs and ECs to be able to form a tubular structure that mimics the native 
blood vessel (Nerem and Ensley, 2004). 
Various stem cell sources have been used to generate a viable vascular tissue engineered constructs 
that includes adult stem cells (Krawiec and Vorp, 2012). The inherent ability of stem cells to self-
renew and proliferate rapidly makes them a viable cell source addressing limitations of other 
approaches. These cells have been widely used in vascular tissue engineering applications (Krawiec 
and Vorp, 2012; Samuel et al., 2015). After extraction using Ficolle-Paque density centrifugation 
method these cells are subjected to a differentiation culture period, of which a graft can be created 
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comprising of SMCs and ECs that mimics a native blood vessel. These rich populations of progenitor 
cells are heterogeneous including endothelial precursor cells (EPCs), early-outgrowth EPCs, mature 
ECs, mesenchymal stem cells (MSCs), hematopoietic stem cells, monocytes, CD4+ T-cells, CD8+ T-
cells, B cells, natural killer cells, among others (Roh et al., 2010).  In order to make a more feasible 
vascular engineered construct, researchers have used EPCs isolated from adult peripheral blood in 
place of HUVECs. These cells regressed in 3 weeks whereas it took HUVECs more than 4 months. 
Various factors such as soluble growth factors, mechanical stimulation, cell-cell contact, and 
extracellular matrix substrate proteins are recognised to have an effect on the differentiation of 
MSCs (Sundaram and Niklason, 2012). 
1.5.3.1.6. Mediators  
General mediators that are used to examine tissue engineered blood vessels (TEBVs) include 
bioreactors, mechanical stimulation and the application of growth factors. Various studies have 
reported the use of TEBVs in physiological pulsatile flow yielding an enhanced tissue formation, 
ECM production, cellular alignment and the retention of cellular morphology (Zhang et al., 2009). 
These also include computer-controlled bioreactors (Song et al., 2012), which allow precise 
adjustment of physiological pressure. Figure 1.5, shows a dual-loop bioreactor providing 
physiological pulsatile flow conditions for TEBVs culture. Niklason and colleagues have designed a 
bioreactor which uses a distensible silicone tube, carrying a pulsatile flow of culture medium 
(Niklason and Langer, 1997; Niklason et al., 2002, 1999). Interestingly, some of these pulsatile 
bioreactors are able to incorporate multiple seeded vascular constructs in parallel. This provides a 
physiologically relevant strain to the synthetic polymer scaffold seeded with vascular cells. An 
increase in ECM formation and vessel strength were observed compared with scaffolds cultured in 
static conditions. Additionally, administration of a cyclic strain has shown an improved tissue 
organization and significantly increase the strength of collagen gel-based TEBVs (Ye et al., 2000). 
Other scientists have reported that mechanical preconditioning benefited the generation of 3D 
 30 
 
TEBVs culture systems (Nerem and Seliktar, 2001; Niklason et al., 1999). The sporadic stretch 
mediated by bioreactors increases the contractile nature of SMCs, increases synthesis and secretion 
of ECM and facilitates cellular proliferation. For these reasons, studies have focused in using 
pulsatile fluid flow exposure to guide the development of TEBVs (Pandit, 2005). 
 
 
 
 
 
 
 
 
 
 
Numerous research have been conducted in applying dynamic mechanical conditioning to improve 
mechanical properties of TEBV constructs composed of living cells embedded in a collagen-gel 
scaffold (Seliktar et al., 2000). This approach attempts to provoke a unique response from the 
embedded cells so as to rearrange their surrounding matrix, thus improving the overall mechanical 
stability of the constructs. This technique uses a cyclic strain resulting in an increased contraction, 
Figure 1.5 - Dual-loop bioreactor for tissue-engineered blood vessel graft culture. (A) Image of 
vascular bioreactor with electrospun silk fibroin vascular graft in culture; (B) Schematic diagram 
of the vascular bioreactor with indication of dual flow directions (Zhang et al., 2009). 
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mechanical strength and circumferential orientation (Seliktar et al., 2000). Other mediators that 
are used in vascular constructs include the application of growth factors (Bertanha et al., 2014). 
This study has applied endothelial inductor growth factor obtained from human platelet lysate to 
differentiate mesenchymal stem cells into functional endothelial cells. These cells were shown to 
acquire morphologic characteristics of endothelial cells and secrete high levels of vWF compared 
with the untreated cells.  
By utilising some of the above techniques it is possible to produce a blood vessel model that mimics 
the native artery to study platelet activation status. An arterial construct for use in basic studies 
haemostasis will have different requirements to those intended for use in transplantation. In 
transplantable constructs where a lack of immunogenicity, stable cell integration and an ability to 
withstand arterial pressures over a long timeframe is important however, these are lesser 
considerations for a construct to be used for haemostasis as their intended lifespan is much shorter.   
1.5.4. Characterisation of 3-dimensional (3D) models 
 
There are various 3D models that have attempted to replicate the native structure of the vessel 
wall which were designed to be mainly utilised for grafting (Dorweiler et al., 2006; Hoenig et al., 
2005; Hoerstrup et al., 2001; Sankaran et al., 2014). There are certain requirements that have to be 
met to achieve a functional blood vessel model. These requirements include non-thrombogenicity 
and a quiescent EC layer (Hasan et al., 2014).   
1.5.4.1. Characterisation of endothelial cell function   
To create a 3D tissue-engineered blood vessel model, the endothelial cell lining should be fully 
confluent, anti-thrombotic and possess no signs of the pathological inflammatory phenotype 
observed in some conditions. The mean life span for HUVECs is 10 serial passages, subsequently 
the cells become giant, multi-nucleated and eventually dies (Bouis et al., 2001). Therefore, no long 
term in vitro studies can be established with HUVECs.  
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ECs are characterised by their phenotypic features which include the presence of Weibel-Palade 
bodies (Weibel and Palade, 1964). These are large rod-shaped organelles that are specific feature 
for ECs. These Weibel-Palade bodies store vWF and are worthwhile observing to confirm the cells 
being cultured are ECs. vWF is a widely used endothelial cell marker that can be used to confirm 
endothelial cells origin, as explained in earlier sections (Zanetta et al., 2000). This marker along with 
the cell-surface marker, CD31 (also known as Platelet endothelial cell adhesion molecule- 1;PECAM-
1), have been widely used to assess endothelial cell phenotype. In addition, a common method is 
to ensure that the endothelial cells possess the normal cobblestone cell morphology through using 
fluorescence and scanning electron microscopy (Thomas and Nair, 2013). 
It is also important that the endothelial cell layer does not express inflammatory markers in a 
resting state, as these are not normally seen in healthy blood vessels exposed to physiological flow 
conditions. These inflammatory markers, such as intercellular adhesion molecule-1 (ICAM-1) and 
vascular cell adhesion molecule-1 (VCAM-1) have been used in numerous studies (Kim et al., 2001). 
ICAM-1 and VCAM-1 are inflammation markers normally expressed at low levels on the endothelial 
cell and are able to be enhanced by TNF-α (tumour necrosis factor-α). This parameter is essential 
for examining the inflammatory condition of the generated TEBV. In addition, the endothelial cells 
should be able to enhance the expression of inflammatory markers in response to exposure of 
inflammatory cytokines, such as TNF-α (Kjaergaard et al., 2013).  
Another vital characteristic that must be investigated is the endothelial cell permeability. If the 
endothelial layer is not complete then this could allow platelets and the coagulation system to be 
inappropriately exposed to the subendothelial matrix triggering unwanted clotting responses. 
Disruptions of the endothelial cell barrier integrity can possibly occur from incorrect seeding ability 
or due to manipulations during handling of construct. This may have significant effect on platelets 
adhesion and activation and to avoid such problem, permeability of the TEBV must be tested. The 
use of fluorescently labelled-high molecular weight dextran to test the permeability of the inter-
endothelial cell junctions is a simple approach of which has previously been used in vitro using cell 
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culture inserts. FITC-dextran is added on top of the cells, allowing it to permeate through the cell 
monolayer. The extent of permeability can be determined by measuring the fluorescence of the 
plate-well solution. However, permeability testing of 3D TEBV constructs using dextran cannot be 
achieved using this technique, due to the requirement of seeding HUVECs in the insert. 
Alternatively, the trans-epithelial electrical resistance can also be used to quantify the permeability 
of the endothelial junctions, by assessing how easy it is for electrical charge to transfer 
paracellularly through the endothelial layer. However, like the fluorescent techniques this has 
principally been applied to cellular monolayer. Thus, there is a need to develop new methodologies 
to assess the permeability of the endothelial layer in a 3D TEBV construct.  
However, very few studies have used platelets as a tool for measuring the influence of the tissue-
engineered vessels on platelet activity. The method most commonly used in determining the 
thrombogenicity of TEBV models is to use scanning electron microscopy to examining platelet 
adhesion upon the surface of the construct after perfusion (Boccafoschi et al., 2005; L’Heureux et 
al., 2001). For instance, if the TEBV model is lacking an intact endothelial monolayer, then the 
subendothelial matrix would promote platelet adhesion or aggregation due to the gaps present 
between endothelial cells. In contrast, an intact and well cultured endothelial cell monolayer would 
not promote platelet adhesion, due to the lack of exposure of the subendothelial matrix to the 
bloodstream as well as endothelial secretion of inhibitory substances such as NO and PGI2, as 
mentioned previously.  
1.5.4.2. Characterisation of platelet activation  
Despite the requirement for TEBV to prevent the activation of the haemostatic system only few of 
these studies have fully investigated platelet responses to these models (Boccafoschi et al., 2005; 
L’Heureux et al., 2001). Therefore, there is a need for new methodologies to fully test platelets 
activation and inhibition upon exposure to TEBVs. The methods commonly used by platelet 
biologists to characterise platelet activation are discussed in following section.  
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1.5.4.2.1. Adhesion  
Platelet adhesion to the subendothelial matrix is the first step of the haemostatic mechanism. The 
simplest method is to label washed platelets with the fluorescent cell membrane dye DiOC6 – these 
can then be perfused over the surface of the construct (Navarro-Núñez et al., 2015; Van Kruchten 
et al., 2012). DiOC6 can be used to detect adhesion of these fluorescently-labelled platelets using 
fluorescence or confocal microscopes. In addition, fluorescently-labelled antibodies to platelet-
specific cell surface markers such as CD41 have also been used to visualise platelets in in vivo studies 
using intravital microscopy (Furie and Furie, 2008). However, platelet adhesion is not a very 
sensitive test as platelets can transiently bind to many surfaces, whereas the irreversible binding 
that underlies platelet aggregation is not distinguishable from these tests.  
1.5.4.2.2. Granule Secretion 
Platelets contain 3 classes of secretor granules which are rapidly released upon agonist-stimulation 
– the lysosome, and the α- and dense granules. These granules contain distinct cargos which may 
play a number of roles in haemostasis and inflammation. For instance, the dense granules contain 
autocrine signalling molecules such as ATP, ADP and serotonin which are responsible for the 
recruitment of other circulating platelets, whilst the α-granules contain haemostatic proteins (e.g 
fibrinogen and vWF) as well as mediators of angiogenesis (e.g. VEGF). Therefore, assessing platelet 
granule secretion is a useful method for sensitively assessing platelet activation status. However 
not all platelet agonists effectively trigger granule secretion – with only “strong” platelet agonists 
such as collagen and thrombin being able to effectively trigger secretion, whilst “weak” agonists 
such as ADP and 5-HT are not able to (Lages and Weiss, 1988). 
There are various tests that can be used to evaluate agonist-evoked platelet granule release, 
including quantitative or semi-quantitative assays to measure release of granule components into 
the extracellular medium or increase in surface expression of markers of the platelet granule 
membrane (Saboor et al., 2013). Secreted granule contents may be measured in the platelet 
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supernatant at a single time point after stimulation and then compared to the total platelet content 
to determine the secreted fraction of granule contents. Alternatively, granule contents can be 
measured over a time course to determine the kinetics of secretion. Platelet secretion may also be 
evaluated by measuring increases in the surface expression of markers of the platelet granule 
membrane, such as P-selectin to measure α-granule release (Saboor et al., 2013). Measurement of 
platelet surface P-selectin is usually performed as a semi-quantitative test, in which the proportions 
of P-selectin positive platelets are compared before and after agonist stimulation (Tschoepe et al., 
1990).  
Another commonly used method to test platelet granule secretion is to indirectly measure ATP 
secretion from dense granules via luminescence from a bioluminescent reaction catalysed by firefly 
luciferase (Harper et al., 2009; Mumford et al., 2015). This test measures ATP release into the 
extracellular medium from the dense granules. The released ATP is able to react with luciferin and 
luciferase (firefly extracts) added to the external medium resulting in light emission. Other tests 
include the detection of PF-4 which is secreted during platelet activation and can be measured using 
ELISA, to evaluate α-granule release from platelets after agonist stimulation.  
To date, these tests have not yet been performed in platelets that has been exposed to tissue-
engineered constructs but rather utilised in basic and clinical research  to assess experimental and 
clinical defects in vitro or in platelets perfused over immobilised agonists or drugs (Dovlatova, 2015; 
Merten et al., 2000; Mumford et al., 2015).   
1.5.4.2.3. Aggregation  
Platelet aggregation through platelet-platelet cohesion mediated via fibrinogen through the 
activated integrin αIIbβ3 is the key step in the development of a thrombus. LTA is a widely-used 
technique used by basic and clinical scientists to monitor agonist-evoked platelet aggregation in 
vitro in platelet rich plasma or washed platelet suspensions (Gibbins and Mahaut-Smith, 2004). LTA 
is considered the ‘gold standard’ for platelet function testing and so it is nearly universally used in 
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clinics as well as platelet research labs (Michelson, 2004). Readings are recorded using an 
aggregometer, indicating several features of platelet activation such as: (i) shape change, (ii) 
reversible primary aggregation and (iii) irreversible secondary aggregation. The basis of the test is 
to monitor the relative amount of light passing through the platelet suspension compared to a 
platelet free blank (e.g platelet-poor plasma or saline solution). At rest, discoid platelets are 
homogenously distributed through the platelet suspension and so can deflect lots of light. However, 
upon activation, platelets change into a larger, spherical form that is able to block more light 
transmission – this is known as the shape change phase. Finally, after a short lag period platelet 
aggregation starts to occur and platelets clump together allowing more light to pass through the 
sample. The latency and the extent to which aggregation occurs can be observed in real-time and 
can be quantified allowing effective comparison between multiple experimental conditions. 
However, such method can only measure up to 8 samples at one time restricting the throughput of 
the system. In addition, there is a need for reasonably large volumes of platelet suspension. An 
alternative microplate-based assay has recently been developed which can measure platelet 
responses to a broad range of agonists at any given time using a 96-well plate read through a 
standard plate reader (Armstrong et al., 2009; Chan and Warner, 2012).  
However, whilst aggregometry is a good test for studying platelet function, aggregation requires 
strong platelet activation to occur to be observed.  Therefore, studies examining platelet 
aggregation either in vitro or on the surface of a blood vessel construct may not observe the low-
level platelet activation that may be occurring in response to contact with these constructs.  
1.5.4.2.4. Phosphatidylserine exposure  
Prolonged, strong platelet activation causes the exposure of negatively charged phosphatidylserine 
(PS) at their outer surface (Heemskerk et al., 1997). PS is normally located on the cytoplasmic face 
of the resting platelet membrane but appears on the plasma-oriented surface of discrete 
membrane vesicles that derive from activated platelets. The transbilayer migration of PS to the 
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outer membrane leaflet binds to the activated coagulation factor V, hence promoting Ca2+-
dependent binding of activated factor X to the platelet surface, resulting in localised assembly of 
the prothrombinase complex that accelerates the generation of thrombin at the site of thrombus 
formation (Bevers et al., 1982). Platelet procoagulant activity is most commonly measured by flow 
cytometry using fluorescently-labelled annexin V which binds strongly to the  exposed PS groups  
(Furman et al., 2000). However other groups also perform similar experiments assessing the binding 
of fluorescently-labelled coagulation factors to the platelets (Dörmann et al., 1998).  
Whilst these assays are an effective method for assessing the ability of platelets to assist in the 
activation of the blood coagulation cascade, it is unlikely to be effective to assess platelet activation 
in response to a tissue-engineered construct as PS exposure requires strong, prolonged activation 
of platelets – which may therefore miss cells that are only marginally activated.  
1.6. Measurement of cytosolic calcium concentration ([Ca2+]cyt)  
An increase in cytosolic calcium concentration is a crucial step in all stages of thrombus formation 
– with Ca2+ rises being obligatory for platelet adhesion, secretion, aggregation and 
phosphatidylserine exposure. These range from small Ca2+ rises observed in adherent platelets to 
the large, prolonged Ca2+ signals observed in pro-coagulant, PS-exposing cells. Therefore an 
assessment of platelet [Ca2+]cyt represents a sensitive method for assessing platelet activation. In 
addition, agonist-evoked rises in [Ca2+]cyt are also strongly sensitive to endothelial derived inhibitors 
such as NO and PGI2 – therefore assessment of this parameter should allow us to sensitively assess 
both platelet activation and inhibition in response to exposure to the blood vessel construct.   
Measurements of agonist-evoked changes in [Ca2+]cyt can be determined in platelets loaded with 
the high-affinity fluorescent calcium-sensitive indicator, Fura-2 (Harper et al., 2009). The loading of 
this fluorescent indicator is performed using the acetoxymethyl (AM) ester derivative of the Fura-
2. The AM esters shield the negative charges of the indicator allowing it to be cell-permeable. 
However once inside the AM esters are hydrolysed by non-specific esterases to yield anionic Fura-
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2 which becomes trapped inside the cytosol where it can be used to measure the Ca2+ concentration 
inside the cytosol. Fura-2 is a ratiometric calcium indicator, meaning that the Ca2+ concentration is 
assessed through changes in the emission from two different excitation wavelengths (340 and 380 
nm). The use of ratiometric dyes is advantageous as this help to eliminates many of the artefacts 
that can affect fluorescence readings. This include artificial changes in fluorescence intensity caused 
by factors such as variations in cell loading, photobleaching, differences in dye leakage from the 
cell, changes in cell thickness and volume, and difference in optical path length. In addition, the use 
of ratiometric dye will also have the advantage of preventing artefactual signals caused by loss of 
platelets from the suspension as they adhere to the blood vessel construct.    
1.7. Aims and objectives of the current research project 
In a construct to be used for studies of haemostasis, the prime considerations must be for the 
construct to be able to prevent platelet activation prior to vessel injury, adequately replicate the 
normal in vivo clotting response upon injury and be simple enough to make repeatable, to be able 
to elicit a reproducible platelet response across batches of the construct. The overall aim of this 
project is to: 
• Fabricate and characterise a tri-layered 3D TEBV generated using a layer-by-layer 
fabrication approach. By using human primary cell source in both the intimal and medial 
layers, these two layers will be separated with high density aligned nanofibers to align the 
endothelial cells and aid in the production of an aligned, low permeable ECs layer. Thus, 
preventing cross-migration of both cell types between the layers at the same time, 
allowing cell-cell communication between the ECs and the SMCs. In contrast to the 
approaches used to produce artificial blood vessels for grafting and transplantation, where 
lack of immunogenicity, high mechanical strength and appropriate cell integration is 
important, the key design parameters in this construct will be to achieve a functional EC 
layer that prevents platelet adhesion prior to injury, and a functional media layer that can 
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trigger platelet activation once the vessel wall is damaged. Fully recapitulating the well-
organized vessel wall structure is important for proper functioning of tissue engineered 
blood vessels and so it is vital to define regional cellular localisation within TEBVs post its 
culture period.  
• This thesis evaluates pro- and anti-thrombotic properties of the created blood vessel 
model that has the correct vessel wall layered structure found in vivo. Hence, the first aim 
of this thesis is to fabricate functional tissue engineering blood vessels which possess 
required the pro- and anti-thrombotic properties.  
• Design a unique ex vivo method in which it is possible to assess platelet activation 
sensitively and in real-time, in response to exposure to the produced blood vessel 
constructs. This method tests the activation level of platelets in response to the 3D human 
blood vessel constructs via quantifying changes in the platelets’ [Ca2+]cyt in real-time using 
a fluorescence spectrophotometer. Through exposing the constructs to washed human 
platelet suspension labelled with Fura-2, we will be able to assess in real-time the 
activation status of the platelet suspension, or modulation of platelet responsiveness to 
soluble agonists. 
• Investigate the functionality of the 3-dimensional tissue-engineered blood vessel using the 
newly developed methodology. In particular, we aim to develop a TEBV construct which 
inhibit platelet activation and resist platelet adhesion due to the presence of endothelial 
cell lining, whereas the TEML construct show a pro-aggregatory feature that promote 
platelet activation consistent with the known properties of the subendothelial matrix. 
Other conventional methods will also be used to validate the pro- and anti-aggregatory 
properties of the constructs. These include platelet aggregometry, aggregation on the 
surface of the constructs using DiOC6-labelled platelets visualised under fluorescence 
microscopy and dense granular secretion using luciferin-luciferase assay which detects the 
amount of ATP secreted from platelets’ dense granules post exposure to the fabricated 
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constructs. The endothelial cell function will be assessed by inhibiting its anti-thrombotic 
nature using specific inhibitors that inhibit NO and PGI2 production. The endothelial cell 
layer will be subjected to the inflammatory cytokine, TNF-α, to produce a diseased model. 
The surface platelet aggregation and monitoring of [Ca2+]cyt of platelets incubated with the 
diseased model will be investigated. Establish a lesioned blood vessel model under fluid 
dynamic condition in order to study the effect of anaesthetics on platelet responses to the 
construct. This will be done to establish an alternative to intravital microscopy. We intend 
to do this by using the tissue-engineered human blood vessel construct developed in this 
project to create an ex vivo ferric chloride arterial injury model by recreating physiological 
blood flow conditions inside a commercially-available parallel flow chamber. Given the 
potential impact of general anaesthetics on platelet function, experiments were also 
performed to assess if preincubation with ketamine into the developed arterial injury 
model could alter the response observed in this system. 
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Fabrication and 
characterisation of human 
3D blood vessel constructs 
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1. Introduction  
Cardiovascular disease is one of the primary causes of morbidity and mortality worldwide. Each 
year, thousands of people die from acute cardiovascular events caused by abnormal blood clotting 
responses. This includes disorders such as myocardial infarction, ischaemic stroke and pulmonary 
embolism.  Due to the prevalence of these vascular diseases, there is a need for us to better 
understand the cellular and molecular mechanisms underlying blood clotting so that we can try and 
design better techniques to prevent unwanted clotting that occurs in these disorders.  
In vivo study of haemostasis in mice has provided a number of valuable results on mechanisms 
underlying thrombus formation (Bellido-Martín et al., 2011b; Falati et al., 2002; Sachs and 
Nieswandt, 2007). However, there are potential limitations of the animal models used which may 
limit the insight that the models may reveal about these disorders in humans (Janssen et al., 2004; 
Rowley et al., 2011; Weinberg and Ross Ethier, 2007). Therefore, these factors should be considered 
before attempting to apply results obtained from in vivo mouse models to human clotting 
pathways.  
Tissue engineering of human blood vessel replicas has emerged as a promising alternative approach 
to the use of autologous grafts in coronary artery bypass grafts. The existing diverse and advanced 
techniques used in current tissue engineering field enable us to mimic the anatomic, biological and 
physical features of a native blood vessel into tissue engineered counterpart. The central target of 
this thesis is to establish a highly reliable human blood vessel model in which we can better study 
the processes underlying haemostasis. This model should be able to overcome the technical 
limitations faced with current in vivo animal models and in vitro models. However, there are 
limitations in current tissue engineered blood vessel models which involve cellular, anatomical or 
functional limitations. Some of the current vascular models lack the multi-layered structure which 
lack the physiologically relevant 3D structures and the interactions of the different cell types 
normally present (Lopez and Zheng, 2013). Other scientists have created TEBV models that do not 
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show the anatomical similarities that are found in vivo human blood vessels such as the use of rolled 
cell sheets (Ren et al., 2014). Further existing limitations include the use of synthetic hydrogel which 
do not fully replicate the in vivo ECM environment (Geckil et al., 2010; Liu et al., 2009). Also, the 
use of a tubular structure vascular models which do not fully enable the visualisation of platelet-
endothelial cell interactions (Peck et al., 2012). Although these models may provide useful 
information, these do not fully address the current challenges that are faced in tissue engineered 
blood vessel models. Hence, it is crucial to address these limitations, through the introduction of 
multiple optimisation steps using currently available tissue engineering techniques.    
Current methods that are widely used to create  scaffolds to produce these tissue engineered blood 
vessels include hydrogels and nanofiber scaffolds (Hu et al., 2010; Subramanian et al., 2012; Yang 
et al., 2011). Aligned nanofibers can promote effective cell adhesion and proliferation, and provide 
a construct with mechanical properties  of the native coronary artery (Mo et al., 2004). Nanofiber 
scaffolds can be fabricated using an electrospinning technique to generate highly dense and aligned 
nanofibers on which cells can be seeded. Synthetic biodegradable polymers such as PLA, 
polycaprolactone (PCL) or polylactic-co-glycolic acid (PLGA) are now commonly used in tissue 
engineering of scaffolds (Subramanian et al., 2012; Yang et al., 2011). PLA is widely used in the 
biomedical field due to its biodegradability, biocompatibility, thermal plasticity and suitable 
mechanical properties. Previous studies have shown that endothelial cells respond to their 
topographical microenvironment, aligning and elongating themselves along the direction of the 
nanofibers (Sankaran et al., 2014). This adhesion and spreading of cells can also be further 
enhanced by coating nanofibers with endogenous extracellular matrix molecules such as 
fibronectin, which have been shown to increase endothelial cell survival (Cooper and Sefton, 2011). 
Aligned nanofibers could therefore be used to provide mechanical support for HUVECs growth and 
adhesion, to produce an endothelial cell lining that can extend in the direction of blood flow, to 
mimic the cellular arrangement found in the tunica intima in vivo. 
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HUVECs have been previously grown atop of PLA nanofibers however, these studies lack underlying 
layers that support platelets’ thrombogenicity. In addition, the SMCs function has been shown to 
be modulated by the composition of the ECM (Chan-Park et al., 2009). A suitably timed SMC 
phenotype modulation is thought to be the key to success: a synthetic phenotype is required 
initially for vessel remodelling, whereas a contractile phenotype is required ultimately for 
vasoactivity (Reidinger and Rolle, 2014). The surrounding ECM has been shown to influence the 
mechanical properties of SMCs, in particular, collagen. Current tissue engineered constructs 
identified issues relating to low densities of SMCs and collagen, limiting construct performance 
(Chan-Park et al., 2009). Thus, existing research is focusing in mimicking this environment by 
seeding SMCs into collagen hydrogels using various tissue engineering techniques. To the best of 
our knowledge, currently used artificial tissues cannot replicate all the functions of the real tissues 
and do not have the essential layered structure that are effectively characterised for platelet 
studies. The structural integrity of the TEBV model is essential as cells should not migrate through 
the layers during culture. Thus, the main objective for this chapter is to fabricate and characterise 
a tri-layered TEBV generated using a layer-by-layer fabrication approach. 
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2. Methods 
2.1. Electrospinning of PLA nanofibers   
For the fabrication of Poly-L,D-lactic acid (PLA) nanofibers, a 2% solution was prepared for 
electrospinning. Initially, PLA granules (96%L/4%D; Purac biochem BV, Gorinchem, Netherlands) 
were dissolved in chloroform, followed by addition of dimethylformamide (7:3 ratio). The solution 
was left to mix overnight at room temperature with continuous magnetic stirring. Once the solution 
is fully blended, it was loaded into a 5 mL glass syringe (KR Analytical, Sandbach, UK) with 18-gauge 
blunt tip needle (11.7 mm, KR Analytical, Sandbach, UK) and connected to a syringe pump (KR 
Analytical, UK) in a horizontal mount. The solution was pushed through the syringe into a capillary 
blunt steel needle at a constant speed of 0.025 mL/min and a total volume of 0.2 mL. The steel 
needle was connected to an electrode of a high-voltage power supply (SpellmanHV, UK) feeding 
though the positive electrode +6 kV. The solution then formed aligned PLA nanofibers which 
deposited onto the negatively charged collector (30 ×10 cm) -6kV, with 2 sheets of thin steel 
‘blades’ arranged in parallel and 4 cm apart. The collector was electrically connected to a static 
copper plate. The distance between the tip of the needle and the collector was at all times kept at 
15-20 cm (Figure 2.1). The electrospinning parameters are shown in table 2.1.  
 
 
 
 
 
 
 
 
 
 
 
Figure - 2.1 Experimental set-up of the electrospinning system. 
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A densifier, constructed from metal steel, was used to carefully collect the deposited PLA 
nanofibers. Following the densification of the PLA nanofibers, these fibers were transferred 
carefully onto a portable cellulose acetate frames (16 cm2) to enable for cell culture usage. 
After collection, all samples were placed in a vacuum at room temperature for 20 minutes to 
ensure that residual solvents were removed. They were sterilised under ultraviolet light for 90 
seconds, three times before usage. To facilitate visualisation of the nanofibers, Rhodamine B has 
been added to the PLA solution at a final concentration of 0.1% (w/v) in 2% solution for 
fabrication of fluorescently-labelled nanofibers (Figure 2.2). 
 
Solution (w/v) % Voltage 
(kV) 
Flow rate 
(mL/min) 
Tip-Collector 
Distance 
(cm) 
Volume (mL) Time (min) 
PLA 2% 6  0.025 15 - 20 2 10 
Table 2.1 Electrospinning parameters. 
 
 
 
 
 
 
Figure - 2.2 Shows aligned nanofiber collection and imaging. A) Illustrates the manual densification 
process of nanofiber collection; B) Visualisation of transferred nanofibers under bright field and 
fluorescence microscopy. Arrows = direction of nanofibers. 
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2.2.  Culture of primary cells 
Human coronary artery smooth muscle cells (HCASMCs; Life Technologies, UK) and human 
umbilical vein endothelial cells (HUVECs; Life Technologies, UK) were cultured according to the 
supplier’s recommendations. HUVECs were cultured in medium 200 (Life Technologies, UK) 
supplemented with low serum growth supplement (LSGS; Life Technologies, UK) whereas 
HCASMCs were cultured in medium 231 (Life Technologies, UK) supplemented with smooth 
muscle growth supplement (SMGS; Life Technologies, UK). The cells were placed in a humidified 
incubator at 37°C and 5% CO2 with medium exchanged every other day, until confluent. In the 
present study, both HCASMCs and HUVECs were used until passage 5.  
2.3. Construction of a 3D tissue engineered medial layer (TEML) 
Type I collagen from rat tail was used to form the ECM for smooth muscle cells and construct a 
3D TEML construct. All reagents were kept pre-chilled on ice to prevent unnecessary gelation 
during preparation. These reagents include: 10x αMEM, 1M NaOH, dH2O and rat tail type I 
collagen (BD biosciences, California, USA). HCASMCs pellet were mixed at a density of 5 x 105/mL 
into a neutralised solution of 3 mg/mL type I collagen, according to the manufacturer’s protocol 
shown below, and using αMEM in place of phosphate-buffered saline: 
𝐹𝑖𝑛𝑎𝑙 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒
10
= 𝒗𝒐𝒍𝒖𝒎𝒆 𝒐𝒇 𝟏𝟎 𝒙 𝜶𝑴𝑬𝑴 
(𝑓𝑖𝑛𝑎𝑙 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒) 𝑥 (𝑓𝑖𝑛𝑎𝑙 𝑐𝑜𝑛𝑐. 𝑜𝑓 𝑐𝑜𝑙𝑙𝑎𝑔𝑒𝑛 𝑑𝑒𝑠𝑖𝑟𝑒𝑑)
𝑠𝑡𝑜𝑐𝑘 𝑐𝑜𝑛𝑐. 𝑜𝑓 𝑐𝑜𝑙𝑙𝑎𝑔𝑒𝑛 
= 𝒗𝒐𝒍𝒖𝒎𝒆 𝒐𝒇 𝒄𝒐𝒍𝒍𝒂𝒈𝒆𝒏 
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑐𝑜𝑙𝑙𝑎𝑔𝑒𝑛 𝑥 0.023 = 𝒗𝒐𝒍𝒖𝒎𝒆 𝒐𝒇 𝟏𝑴 𝑵𝒂𝑶𝑯 
𝑓𝑖𝑛𝑎𝑙 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒
− (𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 10𝑥 𝐷𝑀𝐸𝑀 + 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑐𝑜𝑙𝑙𝑎𝑔𝑒𝑛 + 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 1𝑀 𝑁𝑎𝑂𝐻)
= 𝒗𝒐𝒍𝒖𝒎𝒆 𝒐𝒇 𝒅𝑯𝟐𝑶 
 
Where final solution volume is 0.2 mL x (number of samples), final concentration of collagen 
desired is 3 mg/mL and the stock concentration of collagen (which is subject to batch variation). 
0.2 mL of the mixture was then loaded onto a 1 cm2 square shaped filter paper frame with 
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underlying non-adherent PTFE plates, and the collagen-cell mixture was left to set for 40 minutes 
at 37˚C, 5% CO2. The PTFE plates were removed and the gels were transferred into 24 well-
plates. The formed gel was then covered with supplemented medium and the medium was 
changed every 48 hours. HCASMCs were subsequently allowed to grow in the TEML. 
Another method was used to fabricate the TEML construct by fine-tuning of the above protocol. 
Instead of using HCASMCs pellet, the required number of cells were thoroughly suspended in a 
small volume of supernatant medium that was aspirated after centrifugation. This leads to a 
change in the final equation where the volume of media is subtracted from the final solution 
volume as shown below: 
 
𝐹𝑖𝑛𝑎𝑙 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒
10
= 𝒗𝒐𝒍𝒖𝒎𝒆 𝒐𝒇 𝟏𝟎 𝒙 𝜶𝑴𝑬𝑴 
(𝑓𝑖𝑛𝑎𝑙 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒) 𝑥 (𝑓𝑖𝑛𝑎𝑙 𝑐𝑜𝑛𝑐. 𝑜𝑓 𝑐𝑜𝑙𝑙𝑎𝑔𝑒𝑛 𝑑𝑒𝑠𝑖𝑟𝑒𝑑)
𝑠𝑡𝑜𝑐𝑘 𝑐𝑜𝑛𝑐. 𝑜𝑓 𝑐𝑜𝑙𝑙𝑎𝑔𝑒𝑛 
= 𝒗𝒐𝒍𝒖𝒎𝒆 𝒐𝒇 𝒄𝒐𝒍𝒍𝒂𝒈𝒆𝒏 
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑐𝑜𝑙𝑙𝑎𝑔𝑒𝑛 𝑥 0.023 = 𝒗𝒐𝒍𝒖𝒎𝒆 𝒐𝒇 𝟏𝑴 𝑵𝒂𝑶𝑯 
𝑓𝑖𝑛𝑎𝑙 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 
− (𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 10𝑥 𝐷𝑀𝐸𝑀 + 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑐𝑜𝑙𝑙𝑎𝑔𝑒𝑛 + 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 1𝑀 𝑁𝑎𝑂𝐻
+ 𝒗𝒐𝒍𝒖𝒎𝒆 𝒐𝒇 𝒎𝒆𝒅𝒊𝒂) = 𝒗𝒐𝒍𝒖𝒎𝒆 𝒐𝒇 𝒅𝑯𝟐𝑶 
 
Primarily, the collagen reagents were mixed together prior to adding the cell suspension. 0.2 mL 
of the mixture was then loaded onto a 1 cm2 square shaped filter paper frame with underlying 
non-adherent PTFE plates, and the collagen-cell mixture was left to set for 40 minutes at 37˚C, 
5% CO2. The PTFE plates were removed and the gels were transferred into 24 well-plates. The 
formed gel was then covered with supplemented medium with changing the medium every 48 
hours. HCASMCs were subsequently allowed to grow in the TEML until they were observed to 
possess an elongated spindle-shaped morphology.  
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2.4. Construction of a 3D tissue engineered intimal layer (TEIL) 
0.2 mL of a neutralised 3 mg/mL BD type I collagen solution was loaded upon a square frame 
made by filter paper with an area of 1 cm2 to form an acellular collagen gel base first. An aligned, 
portable PLA nanofiber mesh previously fabricated (section 2.1) was coated with fibronectin (10 
ng/mL). The coating was performed by placing the portable nanofiber mesh atop of a non-
adhesive PTFE plate. A 1 mL of the fibronectin solution with a concentration of 10 ng/mL was 
applied on these nanofibers and allowed to incubate for 1 hour at room temperature. Following 
incubation, the fibronectin solution was removed, and the nanofiber was dried and used for 
construct fabrication. The coated nanofiber was placed atop of the constructed collagen gel. The 
fibronectin coating is a standard step in all fabricated TEIL constructs, unless or otherwise stated. 
The corners were then carefully sealed using a freshly prepared rat tail type I collagen solution. 
The sample was then placed in the incubator programmed at 37˚C, 5% CO2 until the collagen 
was set. A sterile scalpel blade was used to cut the outer corner and remove the acetate frame. 
After successful attachment of the nanofibers to the collagen hydrogel, HUVECs (4 x 104 cells 
per sample) were carefully seeded in two separate occasions using small 10 μL volumes on top 
of the nanofibers. This is to prevent the cells from leaking over the confined area and eventually 
cell loss. The cells were allowed to attach at 37˚C, 5% CO2 for 1 hour. Samples were then topped 
up with supplemented 200 medium and subsequently allowed to be cultured for 4 days at 37˚C 
and 5% CO2, with a single media change on day 2.  
2.5. Construction of a 3D multi-layered tissue engineering blood vessel (TEBV) 
A 3D multiple layered TEBV construct was fabricated by using the methods explained above 
combining both TEIL and TEML constructs. A layer-by-layer methodology was used to fabricate 
the TEBV construct. Initially HCASMCs were seeded in type I collagen to make the primary base 
of the TEBV construct, creating TEML. Mainly, the collagen reagents were mixed together prior 
to adding the cell suspension. 0.2 mL of the mixture was initially loaded onto 1 cm2 square 
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shaped filter paper frame with underlying non-adherent PTFE plates for optimisation, and the 
collagen-cell mixture was left to set for 40 minutes at 37˚C, 5% CO2. The PTFE plates were 
removed and the gels were transferred into 24 well-plates. The formed gel was then covered 
with supplemented medium with changing the medium every 48 hours. HCASMCs were 
subsequently allowed to grow in the TEML until they were observed to possess an elongated 
spindle-shaped morphology.  
Once the HCASMCs acquired a spindle-shaped morphology within the TEML, the media was 
removed. The TEML sample was placed on PTFE plates and PLA nanofiber mesh coated with 
fibronectin (10 ng/mL) was placed to create the second layer, acting as an internal elastic lamina. 
The fibronectin coating is a standard step in all fabricated TEBV constructs, unless or otherwise 
stated. The corners were then carefully sealed using a freshly prepared rat tail type I collagen 
solution. The sample is then placed in the incubator programmed at 37˚C, 5% CO2 until the 
collagen is set. A sterile scalpel blade was used to cut the outer corners, removing excess 
nanofibers and the outlining acetate frame. After successful attachment of the nanofibers to the 
collagen hydrogel, HUVECs (4 x 104 cells per sample) were carefully seeded in two separate 
occasions using small 10 μL volumes on top of the nanofibers. Once HUVECs were attached, 
samples were topped up with the mixture supplemented medium 200 and 231 at the ratio of 
7:3, and subsequently allowed to be cultured for 4 days at 37˚C and 5% CO2, with a single media 
change on day 2. In such way, a tri-layered construct was fabricated composed of medial and 
intimal layers separated by PLA nanofibers. 
2.6. Nanofiber coating 
An experiment was designed to examine the effect of nanofiber coating on HUVECs attachment 
and growth over the course of 10 days (Table 2.2). The fabricated nanofiber scaffolds were 
coated with various materials such as soluble form of Horm-collagen (HC; 1 µg/mL) or dual 
coating of fibronectin (10 ng/mL) and Horm-collagen (1 µg/mL), previously discussed in section 
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1.4.1.1. The coating was performed by placing the portable nanofiber mesh atop of a non-
adhesive PTFE plate. A 1 mL of the various solutions were applied on these nanofibers and 
allowed to incubate for 1 hour at room temperature. Following incubation, the solutions were 
removed, and the nanofibers were dried and used for TEIL fabrication. All samples including an 
uncoated control sample were imaged 4 and 10 days of culture using brightfield inverted 
microscope (Olympus, Japan).  
 
 
 
Table 2.2 shows the various nanofiber coating combinations used to attain a greater HUVECs 
coverage.  
 
2.7. HUVECs seeding density 
Various HUVECs densities on fibronectin coated nanofibers were investigated to observe the 
optimum cell seeding density. TEIL constructs were fabricated as stated in section 2.4 with two 
different HUVECs densities of 2.5x104/cm2 and 6.25x104/cm2. The cells were seeded on 
fibronectin (10 ng/mL) coated PLA nanofibers. A control sample was also prepared without 
underlying nanofibers to observe HUVECs coverage without alignment using a cell density of 
2.5x104/cm2. The samples were cultured up to 14 days and images of the constructs were taken 
at 10 and 14 days of culture. 
2.8. TEBV characterisation 
2.8.1. Fluorescent visualisation of TEBVs 
To observe the overall multi-layered structure of TEBV, the cells in each layer was stained with 
a cell tracker. HCASMCs were labelled with 5(6)-CFDA, SE; CFSE (5-(and-6)-Carboxyfluorescein 
Diacetate, Succinimidyl Ester), mixed isomers (CFDA, SE; 80 μM; Life Technologies UK) for 15 
minutes at 37˚C and 5% CO2 prior to seeding into the hydrogel (Boucher et al., 2015). The cells 
Nanofiber coating Sample 1 Sample 2 
Horm collagen ✓  ✓  
Fibronectin - ✓  
Foetal calf serum - - 
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were washed and re-suspended with a fresh medium to remove the excess dye after the end of 
incubation. This dye is a fixable-cell-permeant, green fluorescein-based cell tracker used for 
labelling cultured cells. HUVECs were labelled with 7-amino-4-chloromethylcoumarin (CMAC) 
cell tracker blue (20 μM; Life Technologies, UK) for 30 minutes and incubated at 37˚C and 5% 
CO2 before seeding atop of the nanofiber. The cells were washed and re-suspended with a fresh 
medium to remove the excess dye after the end of incubation and prior to seeding. The 
fibronectin-coated nanofiber separating both of the layers was labelled with rhodamine b as 
stated in section 2.1. The TEBV was cultured as previously stated above. At the end of the culture 
period, the sample was imaged using a confocal microscopy and z-stacked with 15 μm steps. 
CFDA, SE was imaged at an excitation of 492nm and an emission of 517nm. Whilst, CMAC was 
imaged at an excitation of 353nm and an emission of 466nm. Rhodamine b was recorded at an 
excitation of 554nm and an emission of 627nm. The 3 layers were reconstructed in a 3-
dimensional image to define the locations of the cells post-culture.  
2.8.2. Endothelial cell permeability assay 
Two different methods were used in determining permeability of the endothelial lining the TEIL 
construct. In the first method, 150 kDa Fluorescein isothiocyanate-dextran (Sigma Aldrich, USA) 
solution (1 mg/ mL in PBS) was applied on top of the cultured 3D TEBV samples and incubated 
for 60 minutes at 37˚C and 5% CO2 (Chetprayoon et al., 2015). The fluorescently-labelled dextran 
was then removed and the samples were washed three times with PBS. The TEIL construct was 
examined in two different regions where HUVECs were confluent or non-confluent. This was 
determined by examining the construct by light microscopy for the underlying nanofibers. A z-
stack (XYZ) scan from the luminal HUVECs surface through the TEBV was performed using 
confocal microscopy (Olympus, Japan). The slice step was set to 10 μm and 30 steps were 
recorded through the depth of the sample. Confluent and non-confluent regions of the TEIL 
sample were separately recorded on the same sample. The fluorescence intensity at the 
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different depths of the samples were measured using ImageJ software (National Institute of 
Health).  
The second method uses the same principle by seeding a small volume of 5 µl 150 kDa FITC-
labelled dextran solution on the centre of an inverted 3D TEBV construct. Prior to this, a 1.5 mL 
of PBS solution was added into a cuvette spectrophotometer. An aluminium foil with small 
openings was used to create a gasket to hold the construct above the PBS solution. The TEBV 
sample was overturned, in which the endothelial layer is facing downwards, and placed atop of 
the aluminium gasket. After the addition of dextran, the sample was immediately placed into 
the spectrophotometer holder to record the fluorescence. The permeability of the construct 
could then be measured via tracking the fluorescence in the PBS.   
2.8.3. Immunostaining  
2.8.3.1. Phenotyping HUVECs using CD31 
To phenotypically assess whether HUVECs sustained its phenotype once applied on nanofibers, 
a CD31 (Dako, Glostrup, Denmark) immunostaining was performed (Cârţână et al., 2012; Fiedler 
et al., 2006). Initially, the TEIL (cultured for 4 days) was fixed with cold acetone for 5 minutes 
prior to staining. The acetone was discarded and the samples were washed with PBS. Following 
fixation, the TEIL samples were incubated with 10% FBS (Lonza, UK) diluted in PBS for 1 hour at 
room temperature, to block non-specific binding. The FBS solution was discarded and all the 
solution was removed without letting the samples to dry. Mouse anti-human CD31 monoclonal 
antibodies (1:20) was applied on the TEIL sample for 1 hour at room temperature. To avoid the 
evaporation of liquid during the incubation period, samples were stored in a closed box with 
placing wet paper inside the box to provide moisture. The samples were washed 3-times with 
PBS for 5 minutes, to remove any unbound primary antibodies. Subsequently, Alexa-Fluor 594 
goat anti-mouse IgG1 (H+L) secondary antibody (1:200, Life Technologies, UK) was incubated 
with the samples for 1 hour at room temperature, to detect the specific binding to CD31. The 
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samples were washed 3-times with PBS for 5 minutes, to remove any excess secondary 
antibodies. Samples were stained with DAPI-containing mounting medium. Non-aligned HUVECs 
monolayer was also prepared for comparison. These cells were cultured in an 8µ-well slide (Ibidi; 
Martinsried, Germany) with matching HUVECs density and stained for CD31 protein. 
Fluorescence images were obtained using a fluorescence inverted microscope (Nikon Eclipse Ti, 
Japan).  
2.8.3.2. Intercellular adhesion molecule-1 (ICAM-1) expression of HUVECs  
Immunofluorescence staining of ICAM-1 (Santa Cruz Biotech; Middlesex, UK) was performed on 
cultured TEBVs for 4, 10 and 14 days cultures. Initially, TNF-α (500 U/mL) was used as a positive 
control to stimulate ICAM-1 expression on the surface of HUVECs 24 hours prior to fixing, to 
mimic inflammation (Sawa et al., 2007; van Buul et al., 2010). Specifically, TNF-α was added at 
3, 9 and 13 days to specific wells containing culturing TEBV samples. Unstimulated TEBV samples 
were prepared for controls. At the end of culture, samples were fixed overnight with 4% formalin 
solution. The samples were washed with PBS. Samples were blocked with 10 % goat serum 
(Santa Cruz Biotech; Middlesex, UK) for 20 minutes followed by incubation with mouse 
monocloncal anti-human ICAM-1 primary antibody (1:200) for 1 hour at room temperature. The 
samples were washed 3-times with PBS for 5 minutes, to remove any excess primary antibodies. 
This was followed by the incubation with Alexa-Fluor 594 goat anti-mouse IgG (H+L) secondary 
antibody (1:200, Life Technologies, UK). The samples were washed 3-times with PBS for 5 
minutes, to remove any unbound secondary antibodies. These were then stained with DAPI-
containing mounting medium. The samples were then visualised using fluorescence inverted 
microscope (Nikon Eclipse Ti, Japan) to obtain fluorescent images. 
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2.8.3.3. Cell viability assessment using live-dead cell staining assay 
Cell viability was assessed using a live-dead cell double staining kit (Life Technologies, UK). 
Initially, the culture media was removed from the TEBV construct. The construct was washed 
once with PBS and a solution mixture containing calcein-AM (green) and ethidium homodimer-
1 (red) was added. The kit contained Calcein-AM and Propidium iodide which fluorescently 
stained live and dead cells, respectively. The mixed dye solution was incubated with the TEBV 
construct for 30 minutes at 37°C and 5% CO2 in the dark. After the incubation period, the 
solution was discarded to remove the unbound excess dye. PBS was added to the sample to 
keep the sample moist and avoid drying. The cells were immediately examined using a FV300 
confocal microscope (Olympus, Japan). For 3D samples such as TEBV, confocal laser scanning 
microscopy has widely been applied (Gantenbein-Ritter et al., 2011). The primary advantage of 
this approach is its ability to produce optical sections through TEBV construct, by moving the 
focal plane of the instrument stepwise through the depth of the construct. A series of optical 
sections (stacks) were collected which was combined to produce a volume rendered 3D 
reconstructions of the TEBV construct. 
2.8.3.4. Phalloidin staining of TEML constructs 
TEML constructs cultured for 10 days were fixed with 4% paraformaldehyde in PBS for 20 
minutes at room temperature. The samples were then washed with PBS and permeabilised with 
500 µL of 0.1% TritonX-100 in PBS for 5 minutes at room temperature. Yet again, the samples 
were rinsed with PBS. 500 µL of tetramethylrhodamine-conjugated Phalloidin (10 µg/mL; Sigma-
Aldrich, UK) was incubated with the TEML samples for 60 minutes at room temperature in the 
dark, to fluorescently stain actin filaments. Cell morphology was examined using confocal 
microscopy (Olympus, Japan).  
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3. Results 
3.1 Optimising the intimal layer 
In the initial part of the project, HUVECs were cultured on aligned nanofibers to generate an 
aligned endothelial cell layer, and experiments were performed to assess whether the cells 
change their phenotype with these culture conditions. Figure 2.3 shows a diagrammatic 
representation of parameters and variables that were tested to optimise and characterise the 
intimal layer.  
3.1.1 HUVECs alignment 
Since aligned electrospun PLA nanofibers have previously been shown to have beneficial effects 
on the attachment and alignment of other cell types (Sankaran et al., 2014; Yang et al., 2011), 
experiments were performed to examine the effect on the extent of orientation of HUVECs 
growth when cultured on PLA nanofibers. PLA nanofibers were fabricated and used to support 
HUVECs layer during cell culture to facilitate the production of a highly-aligned HUVECs layer. 
HUVECs were initially cultured in tissue culture flasks. HUVECs were not used after passage 5 
as these cells are known to alter their phenotype with HUVECs spreading and migration 
decreasing at later passages (Liao et al., 2014). A TEIL was constructed by culturing HUVECs 
atop of an aligned PLA nanofiber mesh.  These nanofibers were then transferred on top of 
collagen type I hydrogels and their ability to align HUVECs growth was tested against HUVECs 
seeded without nanofibers. The 2-dimensional endothelial cells are initially round when 
unattached to the tissue culture flask after attachment, and ultimately acquiring a cobblestone 
morphology a few hours after seeding (Figure 2.4A).  
Once HUVECs became confluent, the cells were harvested and 2.5 x 104 HUVECs were seeded 
on top of a collagen hydrogel in the presence or absence of an uncoated PLA nanofiber scaffold 
(area = 1 cm2). The underlying collagen gel provides sufficient mechanical strength to allow easy 
handling of the constructs. The samples were cultured for 2 days and optical image were taken 
(Figure 2.4B and C). HUVECs showed random orientation and similar morphology to the 2D 
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HUVECs monolayers as described above, however seemingly tightly packed due to the 
underlying collagen type I hydrogel (Figure 2.4B). In comparison, seeding the cells on top of the 
aligned nanofiber mesh supported with an underlying collagen type I hydrogel showed a high 
degree of cellular alignment, with an average angle of 6.3° orientation against the direction of 
the nanofibers. HUVECs were observed to be highly-aligned within an hour post-seeding (Figure 
3.2C). Aligned nanofibers orient the HUVECs growth in one direction facilitating their growth in 
the desired direction. However, gaps between the HUVECs could be seen in places even when 
the constructs were cultured for over 14 days. HUVECs appeared to be unable to fully cover the 
surface of a construct with uncoated PLA nanofibers due to large spaces being visible between 
the cells. The diameter range of the nanofibers was determined by analysis of the 
representative images shown in Figure 2.2B, with an average diameter of 631 nm. 
 
 
 
 
 
 
 
HUVECs layer
Alignment
Aligned Random
Coating
Coated Non-coated
Inflammation
ICAM-1
Stimulated
Non-
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Phenotype
CD31
Aligned Random
Live-dead
Permeability
Figure 2.3 - Shows a simplified diagrammatic representation of the features that have been tested to optimise and characterise the HUVEC layer. 
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3.1.2 The effect of nanofiber coating on HUVECs attachment and coverage 
The effect on HUVEC cell attachment and growth of coating the PLA nanofibers with Horm collagen, 
and fibronectin was assessed. Firstly, nanofibers were coated with either Horm collagen alone 
(1μg/mL) or in combination with fibronectin (10 ng/mL). Horm collagen was used to coat the 
nanofibers as this is a key adhesive ligand for platelet binding to the subendothelial matrix after 
vascular damage. These coated nanofibers were then transferred on top of collagen hydrogels and 
their ability to facilitate HUVECs attachment and coverage were tested against HUVECs seeding on 
uncoated nanofibers. Preliminary experiments demonstrated that the optimal seeding density for 
Figure 2.4 - Shows morphology and orientation of cultured HUVECs in 2-dimensions and 3-
dimensions.  Confluent HUVECs monolayer culture in cell culture flask (P2); tissue-engineered 
intimal layer showing HUVECs morphology cultured without (A) and with (B) highly aligned PLA 
nanofibers. Results are representative of 6 experiments (n=6). Scale bar A) = 200 µm and B,C) 80 
µm. 
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cell culture was 2.5 x 104 /cm2, and this was initially used. Table 2.2 shows the different nanofiber 
coatings tested. These samples were cultured for 10 days to observe their growth over the culture 
period.  
Figure 2.5, shows HUVECs seeded atop of the differentially-coated nanofibers. At day 4 of culture, 
none of the samples show a complete coverage by HUVECs, although this was observed to improve 
over the culture period in some samples. At day 10 of culture, Horm-collagen coated samples 
showed an increased HUVECs coverage compared to the uncoated sample, although some gaps 
between the HUVECs layer could still be seen. Dually-coated (fibronectin+Horm collagen) nanofiber 
sample showed a significantly enhanced surface coverage of HUVECs compared to the uncoated 
sample. At day 10, HUVECs had entirely covered the dually-coated nanofibers without visible gaps 
under light microscopy. Due to the enormous cost involved in using Horm-collagen for construct 
fabrication, fibronectin-coated nanofibers were used for subsequent samples to achieve a 
complete layer of HUVECs.  
3.1.3 The effect of HUVECs density on fibronectin coated-nanofibers 
The next experiment investigated the effect of varying HUVECs seeding densities and culture time 
to optimise the development of a complete HUVECs layer. Therefore, HUVECs were seeded atop of 
fibronectin-coated nanofibers attached on the surface of a collagen hydrogel to provide mechanical 
support. Two different seeding densities were used 2.5 x 104 cells/cm2 and 6.25 x 104 cells/cm2. 
Figure 2.6 shows that using a higher HUVECs density occupied a bigger surface area on the 
nanofibers and HUVECs eventually detached and left gaps that expose the underlying nanofibers. 
This is clearly shown at day 14 of culture with arrows pointing at the gaps between HUVECs (Figure 
2.6B). However, using a lower HUVECs seeding density appears to be better as the HUVECs sustain 
a perfect coverage over 14 days of culture (Figure 2.6D).  In contrast, HUVECs seeded directly onto 
a collagen gel do not appear elongated (Figure 2.6E-F). In these regards, we can conclude that a 
seeding density of 2.5 x 104/cm2 is an ideal density to be used for construct generation. However, 
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14 days of cell culture would significantly limit the experimental throughput. Further assessment 
found that increasing the seeding density to 4 x 104/cm2 and culturing for 4 days gives the same 
result with regards to an increased HUVECs coverage (Figure 2.7). For this reason, this seeding 
density and timeframe was used for subsequent experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 - Shows optical images of HUVECs growth atop of various coatings of nanofibers, at 
days 5 and 10 post seeding. A, B) Horm-collagen coated nanofibers; C,D) dual (Fn+HC)-coated 
nanofibers; E,F) Uncoated nanofibers. HC = Horm-collagen; Fn = Fibronectin; Scale bar A, C and E 
= 1500 μm; B, D and F = 400 μm. Results are representative of 3 experiments. 
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Figure 2.6 - Shows light microscopy images of different HUVECs densities seeded with and without 
nanofibers at 10 and 14 days of culture. A, B) with underlying fibronectin-coated nanofibers; C,D) 
with underlying fibronectin-coated nanofibers; E,F) without underlying nanofibers. Scale bar = 400 
μm (except for D = 200 μm). Arrows show gaps between HUVECs. Results are representative of 3 
experiments. 
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3.1.4 CD31 immunostaining of HUVECs  
Due to previous reports of changes in HUVECs phenotype when grown using different culture 
environment, experiments were performed to examine if HUVEC phenotype was stable in our 
culture system. ECs exhibit a number of unique cell specific markers, of which the expression of the 
platelet endothelial cell adhesion molecule (PECAM-1, CD31) is a widely accepted marker of normal 
HUVEC phenotype (Unger et al., 2002). Therefore, we examined whether the cell morphological 
changes observed upon culturing of HUVECs elicited any alteration in their basic endothelial 
phenotype by examining the expression of this endothelial cell marker.  
Figure 2.8 shows the CD31 staining images of HUVECs grown on aligned PLA nanofibers or those 
allowed to grow randomly on an 8 μ-well culture plate. It can be observed that both HUVECs 
Figure 2.7 - Shows light microscopy images of TEIL construct cultured for 4 days. A cell density 
of 4 x104 was used to generate HUVECs monolayer with a high coverage. The cells were cultured 
on an underlying fibronectin-coated (10 ng/mL) nanofibers. Scale bar = 150 μm. Results are 
representative of 4 experiments. 
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populations strongly expressed CD31. Qualitative examination confirmed that the basic HUVECs 
phenotype does not change with changes in the cell alignment. This is in agreement with our 
findings that nanofibers-cultured HUVECs also maintain the normal elongated cobblestone 
morphology expected of ECs. There was no obvious difference observed between the aligned and 
non-aligned HUVECs in their CD31 expression with regards to phenotype. 
 
 
 
 
 
 
Figure 2.8 - Fluorescence images showing HUVECs CD31 expression. HUVECs were grown without (A-
C) and with PLA nanofibers (D-F). Mesenchymal stem cells used as a negative control (G-I). A, D, G ) DAPI 
channel, B, E, H) TRITC channel, C, F, I) Merged images of DAPI and TRITC channels. CD31 (HUVECs 
marker, Red); DAPI (nucleus marker, Blue), Scale bar = 200 μm. 
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3.1.5 ICAM-1 expression of HUVECs  
Immunofluorescent labelling was performed to characterise HUVECs present on the surface of the 
TEBV construct. In healthy endothelial cells, these cells express limited amount of the ICAM-1 cell 
surface marker, however under pathological conditions HUVECs can be seen to express large 
amounts of ICAM-1 indicating a transition of these cells into an inflammatory phenotype which is 
linked to leukocyte adhesion and transmigration towards the trigger of inflammation. Therefore, a 
high expression of ICAM-1 protein on HUVECs would indicate their adoption of this pro-
inflammatory phenotype. ICAM-1 is present at low levels on the surface of healthy HUVECs, but its 
expression can be increased by treatment with pro-inflammatory cytokines. Therefore, TNF-α was 
used to stimulate expression on the surface of HUVECs to determine whether our samples showed 
a pro-inflammatory phenotype. To define stimulatory conditions in which endothelial cells express 
elevated levels of ICAM-1, we treated TEBVs with the prototypic inflammatory cytokine TNF-α for 
24 hours. ICAM-1 expression was increased for samples stimulated with TNF-α as assessed by 
confocal microscopy imaging (Figure 2.9). Subsequent confocal microscopy analysis showed that 
the surface of the endothelial cell membrane forms small filopodia-like protrusions on TNF-α 
stimulated samples. The untreated samples show a minimal expression of ICAM-1 surface markers, 
suggesting that our TEBV cells possess a physiological, non-inflammatory phenotype.  
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3.2 Optimising the medial layer 
3.2.1. Morphology of smooth muscle cell monolayers 
HCASMCs seeded onto cell culture plates possess round shape morphology with a bright centre 
under the light microscope, until they become attached. Once the cells are fully attached to the 
bottom of the cell culture plate, the cells stretch and acquire a spindle-shaped morphology (Figure 
2.10). Confluency of the plate can be achieved within 4 days of culture when seeded at a density of 
0.5 x 106 cells in T75 flasks.  
 
 
 
A B C 
D E F 
Figure 2.9 - Fluorescence images showing ICAM-1 protein expression of TEBVs. ICAM-1 
expression of unstimulated tissue-engineered blood vessel (A-C) compared with 24-hour TNF-
α-activated tissue-engineered blood vessel (D-F) cultured for 4 days. Results are 
representative of 4 experiments (n=6). ICAM-1 (HUVECs inflammatory marker, Red); DAPI 
(nucleus marker, Blue), Scale bar = 50 μm. 
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3.2.2. HCASMCs morphology within the collagen hydrogel  
To accurately replicate the medial layer of the blood vessel, we seeded HCASMCs within type I 
collagen hydrogels to mimic the composition of the native medial layer. Experiments were 
performed to optimise the culture and processing conditions for the HCASMCs grown within the 
TEML construct. Initial work optimised the mixing order of the HCASMCs pellet with collagen gel 
components. The cells were harvested from cell culture plates and seeded into type I collagen 
hydrogels using two different forms involving the addition of collagen mixture onto (i) cell pellet or 
(ii) cell suspension. Using the former method, the majority of the HCASMCs are round and do not 
seem to be spreading within the hydrogel after 2 days of culture (Figure 2.11A). After 6 days of 
culture the HCASMC morphology had not significantly changed (Figure 2.11B). In contrast, when 
collagen mixture was added to a cell suspension, the seeded HCASMCs show successful spreading 
within the hydrogel. HCASMCs initially show a rounded morphology that change over time. 
Subsequently the cells started to acquire an elongated, spindle-shaped morphology with elongated 
cell body. The cells rapidly regained their original spindle-shaped morphology within 24 hours of 
  
Figure 2.10 - Shows optical images of the morphology of human coronary artery smooth muscle 
cells 24 hours post seeding on cell culture flask. A) low magnification; B) high magnification. 
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seeding within the collagen hydrogels (Figure 2.12). The TEML was then cultured and cell 
morphology was monitored for up to 10 days. Therefore, the mixing of HCASMCs with a cell 
suspension was used for culturing the TEML in all subsequent experiments. 
 
 
 
 
 
 Figure 2.11 - Shows light microscopy images of the morphology of human coronary artery 
smooth muscle cells seeded within type I collagen hydrogel using the pellet method. A) 
HCASMCs morphology 2 days post collagen type I seeding; B) 6 days post type I collagen 
seeding. Scale bar = 150 µm  
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3.3 Assembly of TEBVs 
Once majority of the HCASMCs were elongated (at around day 10 of culturing), the TEML 
construct could be seeded with HUVECs. To accurately replicate the physiological vessel wall 
layers, HUVECs were seeded atop of aligned PLA nanofibers supported with the previously 
Figure 2.12 - Shows the morphology of Human Coronary Artery Smooth Muscle Cells 24 hours 
post seeding in type I collagen. A,B) An illustration of HCASMCs morphology 0 and 24 hours post 
collagen type I seeding; C) A low magnification of bright field image of HCASMCs morphology 24 
hours post type I collagen seeding. D) A high magnification of bright field image of HCASMCs 
morphology 24 hours post type I collagen seeding Scale bar = C) 400 μm; D) 150 μm. 
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constructed TEML to create a 3D TEBV model (as shown in Figure 2.13). The HUVECs were 
observed to show alignment on top of this construct within an hour of seeding.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13 - Diagrammatic representation of a (A) top view of a multi-layered TEBV 
construct and its assembly; (B) Side view sketch of the TEBV construct showing the 
locations of the cells within the construct. 
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3.3.1. Defining regional cellular localisation within TEBVs 
To observe whether the cells stably stayed within their seeding region or migrate between layers 
of the co-culture, HUVECs and HCASMCs were tracked using cell tracker dyes. TEBVs were cultured 
for 4 days and imaged using confocal microscopy to show cellular locations. As shown in Figure 
2.14, HUVECs remained in the upper region where they were initially seeded, and no cells migrated 
to the below layer. Alternatively, HCASMCs also remained within the TEML and no cells migrated 
into the other regions too. This layer made up majority of the construct due to the thickness of the 
collagen hydrogel. From these tracking experiments of the TEBV in co-culture, it was demonstrated 
that this technique has allowed us to reproducibly generate a tri-layered vessel model which stably 
maintained defined intimal and medial layers throughout the culture period. 
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3.3.2. Cell viability staining of TEBV using live-dead assay 
Cell viability is an important parameter in tissue engineering to evaluate the effect of environmental 
conditions on cell viability. To assess cell viability within TEBV layers, live-dead staining was used. 
Using this technique viable cells show predominantly green fluorescence whereas dead cells appear 
to mainly emit red fluorescent light. HCASMCs within the TEBV can be observed to be viable as 
shown by the strong green fluorescence from these cells displaying spindle-like morphology as 
observed previously in section 3.2.2 (Figure 2.15). No dead HCASMCs were detected for the first 10 
HCASMCs 
 Layer 
HUVECs 
Layer 
PLA nanofibers 
Layer 
 
B C 
HUVECs layer 
PLA nanofibers 
Layer 
HCASMCs layer 
Figure 2.14 - Fluorescent 3D image of z-stack TEBV highlighting the integrated tri-layered 
construct. A) Side view of a multi-layered TEBV construct; B) Angle view of the TEBV construct 
showing the locations of the cells within the construct. C) Top view of the TEBV construct. Blue 
= HUVECs; Red = nanofibers; Green = HCASMCs. Scale bar = C) 30 μm. 
A 
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minutes of imaging. Similarly, for HUVECs, the number of dead cells was zero at the start of imaging. 
In addition, HUVECs show a strong green fluorescence showing almost complete coverage across 
the surface of the TEBV construct, indicating the creation of a viable, confluent intimal layer in 
agreement with our previous findings, these cells are also found to be highly-aligned indicating the 
underlying nanofibers are serving to provide contact guidance to the HUVECs (Figure 2.15H). 
Although the endothelial layer appears to be complete, the potential for paracellular transport at 
a molecular level remains, therefore the permeability of the endothelial cell layer required 
investigation. 
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Figure 2.15 - Shows fluorescence live-dead staining fluorescent images of TEBV layers cultured for 4 
days using calcein-AM and ethidium homodimer-1. Live-dead staining of HCASMCs within TEBV (A-C); 
High magnification image of a live smooth muscle cell (D-F); 3-dimensional z-stack image of combined 
TEML section planes (G); Live-dead staining of the top upper layer of TEBV construct (H). A, D) FITC 
channel; B, E) TRITC channel and C, F) Overlay of FTIC and TRITC channels. Scale bar = 200 µm for A-C, H 
and 100 µm for D-F. Results are representative of 4 experiments (n=6). Calcein-AM (live cell marker, 
Green); ethidium homodimer-1 (dead cell marker, Red). 
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3.3.3. Permeability of the TEBV  
Initial permeability experiments were performed to test whether confluent sections of the HUVECs 
layer of TEBV was able to create effective intercellular junctions to resist the transfer of plasma 
proteins across the endothelial lining. The permeability of the intimal model was tested by 
examining the ability of a fluorescently-labelled high molecular weight dextran molecule to 
permeate across the endothelial lining. To do this the constructs were exposed to a solution 
containing high molecular weight FITC-dextran (1mg/mL) on the luminal surface of the construct, 
for 1 hour at 37˚C and 5% CO2 (n = 3). Using confocal microscopy, 30 z-stack sectioned images (slice 
thickness = 10 µm) were recorded for each sample, to observe the extent of FITC-dextran infiltration 
across the luminal surface of complete and non-complete regions of the HUVECs layer. The start of 
the z-stack was determined by focusing on the HUVECs layer and starting to set the Z-stack settings 
to slice from this focal plane (0) to 300 µm depth. By using the ImageJ software package, it was 
possible to analyse the amount of FITC dextran fluorescence found in each of the individual images 
from the Z-stack collection.  
These data were then used to plot a graph of FITC dextran intensity against the sample thickness 
(depth) for the different regions of the construct. These data are shown in Figure 2.16, and showed 
that at the same depth of the sample, FITC-dextran intensity was higher in non-complete regions 
of the construct than in regions where HUVEC growth has reached high coverage. Thus, complete 
regions of HUVECs seeded on nanofibers showed a better ability to reduce the penetrance of the 
fluorescent dextran into the underlying collagen hydrogel than in non-confluent regions of the 
same construct. However, the confluent HUVECs layer does not completely block translocation of 
the fluorescent dextran. Further experiments were required to consider whether this is due to an 
inability of the HUVECs to form tight intercellular junctions or whether this is due to FITC dextran 
diffusing laterally through the gel from areas underlying non-confluent regions of the sample to the 
areas of the gel underneath areas of confluent HUVEC growth. It could also be the selected slice 
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thickness for the z-scan is too large, and so the observed fluorescence is actually collected from the 
applied dextran solution above the cell layer. Also, HUVECs layer in covered and non-covered 
regions do not start from the same fluorescent point. Namely, non-complete regions start from a 
higher fluorescent point compared to a complete region. Therefore, the experimental set-up was 
not a valid method to test for permeability. Hence, another technique was pursued to test for a 3-
dimensional permeability test to accurately measure dextran movement across the endothelial cell 
layer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Due to concerns that dextran could be artefactually permeating into the construct via leaking down 
the sides, another method was devised to measure permeability using fluorescently labelled-high 
molecular weight FITC-dextran permeation through TEBV constructs (Figure 2.17). For this 1.5 mL 
of PBS was added into a spectrophotometer cuvette and aluminium foil was placed atop of the 
solution with small openings to create a mask to allow a 5 μl sample of the dextran solution to only 
come into contact in central regions of the construct. After addition of the dextran, the sample was 
Figure 2.16 - A line graph of FITC-dextran intensity against the sample depth in 
different HUVECs complete regions.  
 
 
 
 
 
 
 
 
  
 
Non-complete region 
Complete region 
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immediately placed into the spectrophotometer holder to record the fluorescence. The 
permeability of the construct could then be measured via tracking the fluorescence in PBS. The 
more dextran solution flowing into the PBS solution, the higher the fluorescence reading detected 
by the spectrophotometer, indicating a greater permeability of the TEBV construct. All samples 
were compared against the permeability of a collagen hydrogel without any cellular elements 
included (maximum fluorescence). TEBV and collagen hydrogel (control) samples were both 
cultured for a total of 14 days and placed in a cuvette as shown in Figure 2.17. A percentage of 
maximum fluorescence was plotted as shown in the equation below: 
Percentage of maximum fluorescence (%) =
𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑎𝑚𝑝𝑙𝑒
𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 
𝑥 100   
 
 
 
 
 
 
 
 
Figure 2.17 - A permeability design used to measure the dextran permeation through the 
construct. A porous aluminium foil was used to hold the construct in place followed by 
placing the gel on the aluminium foil. The dextran was then placed atop of the construct and 
recorded for 10 minutes.   
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The fluorescence of the sample was determined in real-time via fluorescence spectrophotometer. 
The signal was triggered by the migration of dextran into the PBS solution and through the construct 
(if permeable). The maximum fluorescence is measured by freely adding the dextran solution into 
the PBS wherethe signal is detected by the fluorescence spectrophotometer. Figure 2.18 shows the 
dextran solution permeation through the collagen hydrogel and TEBV constructs. At the beginning, 
there is no dextran permeated through both of the constructs. With time, more and more dextran 
is flowing through the collagen hydrogel compared to TEBV. At 10 minutes of recording the dextran 
is still flowing through the collagen hydrogel without levelling off. Dextran permeation is reduced 
in TEBV constructs by almost 20% at the end of the run compared to the collagen hydrogel sample. 
In general, dextran permeation through the TEBV construct show no change in fluorescence 
compared to the collagen hydrogel – thus suggesting that the TEBV is largely impermeable to the 
dextran. However, there are few limitations associated with the design of the methodology which 
will be discussed in detail in the discussion. 
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3.3.4. HCASMCs within the medial layer express F-actin 
Phalloidin staining has been most frequently used to study cytoskeletal structures within cells. 
HCASMCs are characterised by the presence of actin fibres, including "α-smooth muscle actin (α-
SMA), which help to convey contractile properties of the cell. The use of fluorescently labelled 
toxins which bind to F-actin such as phalloidin have been widely used in the research field to image 
cytoskeletal structure. In this experiment, HCASMCs within our TEML have been stained for F-actin 
filaments using Phalloidin-TRITC dye (Figure 2.18). The cells show a strong expression of F-actin 
filaments especially concentrated in the periphery of the cell surface and also in cellular protrusions 
to regulate cellular structure and movement of these highly contractile cells. However, this is not 
specific to SMCs but also ubiquitously expressed in other types of cells and therefore further work 
will be required to fully phenotype the HCASMCs. 
Figure 2.18 - High-molecular weight dextran permeation through TEBV and collagen hydrogel 
cultured for up to 14 days. 
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3.4. Permeability 
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A B 
50  μm 
Figure 2.19 - HCASCMs within the TEML express F-actin. TEML was cultured for 10 days and stained 
with TRITC-Phalloidin. A) Low magnification of HCASMCs expressing F-actin. B) High magnification 
of HCASMCs expressing F-actin. C) F-actin stained collagen gel without HCASMCs. Results are 
representative of 3 experiments.  
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4. Discussion:  
In this study, the methods for fabricating a tissue-engineered blood vessel construct were 
optimised.  The aim of these studies was to produce a tissue-engineered blood vessel construct 
with structural properties of the native artery, which could be stably maintained during co-culture. 
The work shown in this chapter has established the feasibility of producing a biological TEBV 
exclusively from primary human cells using appropriate nanofiber and hydrogel scaffolds.  
Experiments were performed to optimise the culture conditions for the production of TEML. Initial 
attempts of seeding HCASMCs within collagen hydrogels were unsuccessful as these cells failed to 
regain their normal cellular morphology. The cells were observed to be rounded even after a week 
of culture. This is most likely due to the order of adding components of the collagen hydrogel to the 
cells. In fact, mixing all the collagen reagents first and then adding the cell suspension is the most 
reliable and reproducible method as this ensured neutralisation of the pH of the solutions before 
its addition to the cells (Figures 2.11 and 2.12).  
Subsequent experiments assessed and optimised HUVECs attachment and growth upon PLA 
nanofibers in attempt to create a confluent, low-permeability endothelial layer that was able to 
maintain a normal cellular phenotype (Figures 2.4 and 2.5).  Initial experiments found that HUEVCs 
attached poorly to the uncoated nanofibers, however upon coating the nanofibers with fibronectin, 
HUVECs attachment and coverage on the surface of nanofibers was markedly improved. These 
observations are consistent with previous findings which have shown that fibronectin is able to 
increase HUVECs survival (Cooper & Sefton, 2011). In addition, they are also  supported by a recent 
study that examined human aortic endothelial cells (HAECs) growth on a fibronectin-modiﬁed 
hydrogel surface (Shinohara et al., 2013). These studies revealed that HAECs adhered to and grew 
better on the ﬁbronectin-modiﬁed hydrogel surface compared to other modified hydrogel surfaces.  
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In the native artery, ECs are found to orient themselves in response to the shear stresses exerted 
by blood flow.  A number of previous studies have shown that aligned nanofiber scaffolds can be 
used to orient the growth of endothelial cells, neurite and mesenchymal stem cells (Chew et al., 
2008; Laco et al., 2013; McCullen et al., 2007). In this report, we have shown that HUVECs alignment 
can be artificially achieved by growing them upon aligned PLA nanofiber scaffolds (Figure 2.4). The 
response of human endothelial cells to the topographical features of nanofibers has been 
previously described in a comprehensive review of the topic by Nisbet et al (Nisbet et al., 2009). 
This includes cellular responses such as endothelial cells growth in the direction of an arranged 
surface pattern and significant elongation along the nanofibers. Cellular orientation and migration 
is subject to surface pattern and geometry (Liliensiek et al., 2010). This enables the production of 
an intimal construct that is highly-aligned and provides a near-complete layer that could act as an 
effective barrier between the blood and subendothelial matrix. To assess whether the endothelial 
lining was as impermeable as its native counterpart it was necessary to devise a new methodology 
to test this in our 3D TEBV, as current techniques are based around assessment of the permeability 
of 2D monolayers using electrical resistance or permeability of fluorescent compounds. In this 
chapter, experiments assessed fluorescent dextran permeation through the construct. Although 
dextran transmigration assay has been used on endothelial cell monolayer using filter transwells or 
cell culture inserts there are limited studies addressing its use in 3D constructs (Chetprayoon, 
Matsusaki, & Akashi, 2015; Grainger & Putnam, 2011; Hordijk et al., 1999; Varma et al., 2002). Our 
initial strategy appeared to suggest that the dye may be able to permeate through the TEBV when 
it was placed atop the whole of the construct – however there were concerns about whether this 
was due to the dye leaking down the sides of the construct. Here we have stablished a new method 
that uses a spectrophotometer to measure dextran permeation through tissue-engineered vascular 
constructs, as shown schematically in Figure 2.17. By comparing the permeability of dextran 
through the TEBV with that of an acellular collagen hydrogel, it was possible to observe that more 
dextran permeated through the collagen hydrogel compared with the TEBV indicating that the cells 
 83 
 
within the TEBV construct are preventing dextran permeation. Although this methodology has 
produced some encouraging results, there are some potential limitations to this technique that will 
require further refinement. These include difficulties in placing the construct inside the cuvette, 
and due to the uneven surface of the aluminium foil this may accidentally damage the construct.  
Dye leakage can still occur since the sides of the construct are not sealed, if not carefully placed on 
top of the construct, the dye can escape through the sides and travel into the PBS solution being 
measured. Further work will be required to refine this methodology to provide better 
reproducibility. 
In addition to these features immunofluorescent analysis of the cellular phenotype of the TEIL has 
also shown that the HUVECs stably retain their healthy endothelial cell phenotype throughout the 
culture period. This was demonstrated by the maintained expression of the CD31 marker on the 
surface of HUVECs and low ICAM-1 inflammatory marker expression (Figures 2.9 and 2.18). These 
data therefore suggest that the HUVECs phenotype is not significantly altered by the culturing 
conditions used to create the TEBV. 
Confocal imaging of the TEBV have shown distinct zonal organisation in 3D TEBV constructs after 
being maintained in co-culture (Figure 2.14). These cells are localised where they had been seeded 
originally after 4 days of culture, confirming that the cells do not shift across between layers within 
the construct. During the experiments presented here, it was possible to see that the fluorescent 
nanofibers sustained their fluorescence intensity for the entire experimental period, suggesting 
that they are not subject to significant photobleaching and thus can be used to facilitate the 
visualisation of the adherent HUVECs layer. Additionally, a live-dead staining of the TEBV have 
shown that the cells are finding the culturing conditions favourable with all the cells being alive 
within the first 10 minutes of confocal imaging.  
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4.1. Conclusion  
In summary, a layer-by-layer fabrication technique has been successfully developed to fabricate a 
tri-layered human 3D tissue engineered blood vessel model composed of primary cell sources. 
Using a highly dense PLA nanofiber scaffold, we were able to generate a unidirectional, 
impermeable endothelial cell layer. The TEBV model can be observed to mimic the structure and 
cellular phenotype of native human counterpart. Using this 3D tissue engineered blood vessel 
model, it may be possible to create a model system in which to study the molecular and cellular 
events of haemostasis. 
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Chapter 3 
 
Establishment and optimisation of 
a real-time monitoring system to 
assess human platelet activation 
upon exposure to tissue-
engineered blood vessel constructs 
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1. Introduction 
This central role for platelet activation in thrombus formation has led to scientists using a variety 
of ex vivo platelet function assays to try to understand how these cells are normally regulated inside 
the body. However thrombus formation is further regulated by chemical and physical interactions 
between platelets, endothelium and leukocytes, as well as the blood flow conditions in the vicinity 
of the developing thrombus (Kim et al., 2013). Thus, whilst ex vivo study of isolated human platelet 
suspensions stimulated with soluble agonists or monolayers of extracellular matrix proteins or cells 
isolated from the blood vessel wall, creates a simple experimental system in which to assay platelet 
activation mechanisms, they are unlikely to adequately replicate responses observed in vivo.  
This has led to a growing interest in studying platelet activation in vivo. The most commonly used 
methodology is the use intravital microscopy to examine thrombus formation induced by artificial 
damage to the blood vessel during the course of the experiment. A number of mouse models of 
thrombosis have been studied including studies using ferric chloride-induced oxidative damage, 
Rose Bengal-induced photo-oxidative damage, laser injury and a variety of mechanical injuries 
(Bonnard and Hagemeyer, 2015; Furie and Furie, 2005, 2005; Rosen et al., 2001). However, each of 
these models has limitations that may affect the direct translation of these data into obtaining 
information regarding the human in vivo environment (Janssen et al., 2004; Rowley et al., 2011; 
Weinberg and Ross Ethier, 2007). Hence due to the inability to perform in vivo experiments on 
humans due to ethical concerns, there is a need to develop an in vitro system which can better 
assess human platelets’ reaction to intact, damaged or diseased human blood vessels. Developing 
such a system will greatly enhance our understanding physiological haemostatic processes and 
pathological responses occurring in vivo in humans.  
An intact blood vessel could be acquired through unwanted surgical tissue collected during vascular 
graft – however underlying cardiovascular pathologies in these patients may not make these tissues 
reliable indicators of normal haemostasis. In addition, the complexities of obtaining sufficient 
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quantity of such tissues to facilitate wide-spread use of this technique is a significant limiting factor 
of this approach. Therefore, tissue engineering has emerged as a promising approach to address 
these shortcomings. The construction of such a human tissue-engineered blood vessel construct 
that could be used to improve the physiological relevance of current in vitro studies has been 
described in chapter 2.  However, we require methodologies to allow us to assess the physiological 
relevance of our constructs. Previous studies examining artificial tissue-engineered blood vessel 
models examine the ability of constructs to withstand or facilitate platelet aggregation upon their 
surface, however as aggregation requires strong activation of platelets, low-level activation of 
platelets may be missed. Similarly, examination of the production of anti-aggregatory properties of 
the grafts usually assays the production of endothelial-derived inhibitors without directly examining 
their effect on platelet activation. Hence, there is a need for a monitoring method that allows us to 
assess the pro- and anti-aggregatory properties of the blood vessel constructs. An ideal method 
should allow real-time monitoring of platelets activation, with a sensitive readout for platelet 
activation that can measure both pro- or anti-aggregatory properties of either intact or damaged 
blood vessel wall. Monitoring of platelet Ca2+ signalling is widely used as a sensitive method for 
monitoring platelet activation – this is because rises in cytosolic Ca2+ concentration play a key role 
in all stages of platelet activation, with higher Ca2+ signals tending to enhance the ability of platelets 
to form thrombi (Gresele et al., 2017). In addition, endothelial derived inhibitors such as NO and 
prostacyclin are known to significantly inhibit thrombin-evoked rises in [Ca2+]cyt. Therefore, 
designing a system that allows us to measure cytosolic Ca2+ concentration from platelets exposed 
to the blood vessel construct would allow us to assess how interaction with our blood vessel 
constructs developed in chapter 2 can influence the activation state of human platelets. Thus, the 
main aim for this chapter is to develop and optimise a novel methodology for assessing the effect 
of our constructs on platelet function by creating a system that allows us to make real-time 
fluorescence spectrophotometry measurements of [Ca2+]cyt from suspensions of washed human 
platelets. 
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2. Methods 
2.1. Fabrication of tissue-engineered blood vessel constructs 
2.1.1. Generation of TEML constructs 
To prepare TEML constructs, HCASMCs were mixed at a density of 5 x 105/mL into a neutralised 
solution of 3 mg/mL type I collagen obtained from BD biosciences, according to the manufacturer’s 
protocol. 0.2 mL of the mixture was then loaded onto a 1 cm2 square shaped filter paper frame, and 
the collagen-cell mixture was left to set for 40 minutes at 37˚C, 5% CO2. The formed gel was then 
covered with supplemented medium and with changing the media every 2 days. HCASMCs were 
subsequently allowed to grow in the TEML until they were observed to possess an elongated 
spindle-shaped morphology.  
2.1.2. Generation of TEBV constructs 
TEBV construct was fabricated by placing a PLA nanofiber mesh coated with a 10 μg/mL fibronectin 
solution on the 3D TEML, to create the initial layer of the luminal surface. After successful 
attachment of the nanofibers to the TEML hydrogel, HUVECs (at a density of 4 x104 cells/cm2) were 
then seeded on top of the nanofibers to create a full TEBV construct. The HUVECs density is a 
standard seeding process unless or otherwise stated.  
2.2.  Ethical approval 
This project was approved by the Keele University Research Ethics Committee and all work was 
performed in accordance with the Declaration of Helsinki. 
2.3.  Preparation of platelet-rich plasma (PRP) and washed Fura-2-loaded human platelet 
suspensions 
Human platelets were used to test platelets activation and aggregation. A standard method of 
extraction was used. Blood was obtained by venepuncture from healthy volunteers who had given 
informed written consent. 5 mL blood was mixed with 1 mL acid citrate dextrose (ACD) 
anticoagulant (85 mM sodium citrate, 78 mM citric acid and 111 mM d-glucose). Platelet-rich 
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plasma (PRP) was then obtained by centrifuging at 1500 g for 8 minutes, and was then treated by 
the addition of 100 μM aspirin (ASA) and 0.1 U/mL apyrase) unless otherwise stated. PRP was then 
incubated with 2.5 µM Fura-2/AM for 45 minutes at 37°C. Platelets were then collected by 
centrifugation at 350 g for 20 minutes. Washed platelets were re-suspended into supplemented 
HEPES –Buffered Saline (HBS) to a final cell density of to 2x108 cells/mL.  To make supplemented 
HBS, HBS (pH 7.4, 145 mM NaCl, 10 mM HEPES, 10 mM d-glucose, 5 mM KCl, 1 mM MgSO4), was 
supplemented on the day of the experiments with 1 mg/mL Bovine Serum Albumin (BSA), 10 mM 
glucose, 0.1 U/mL apyrase and 200 µM CaCl2 (supplemented HBS). CaCl2 concentration of the 
supplemented HBS was adjusted to 1 mM prior to individual sample analysis. 
2.3.1. Preparation of PRP using prostacyclin 
To examine whether preparation with aspirin significantly alters the platelet response to our blood 
vessel constructs, experiments were performed in which PRP was prepared using either ASA or PGI2 
to prevent platelet activation. To prepare prostacyclin-treated, Fura-2 labelled washed human 
platelet samples, the PRP was treated with 10 μM PGI2 and 0.1 U/mL apyrase.  PRP was incubated 
with 2.5 µM Fura-2/AM for 45 minutes at 37°C. Prior to centrifugation, the PRP was treated again 
with 10 μM PGI2 to further inhibit unwanted platelet activation. The platelet pellet was re-
suspended with supplemented HBS as described above for ASA-treated cells. 
2.4. Designing and constructing a real-time monitoring system to assess platelets’ 
response to blood vessel construct by measurement of platelets’ cytosolic Ca2+ 
concentration ([Ca2+]cyt) 
2.4.1. Sample holder design 
To position the construct in contact with the human platelet suspension within the cuvette, an 
acetate frame was designed to act as a sample holder. This comprised of two regions including a 
central region holding the blood vessel construct and permitting exposure to the platelets with two 
flanking sides enabling easy handling (Figure 3.1). The central part was designed to facilitate 
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construct interaction with platelet suspension cut to a 1 cm length and 1 cm width square, to enable 
correct fitting on to the spectrophotometer cuvette. Within this square, another 0.5 cm x 0.5 cm 
square was cut in the middle to create a window for construct interaction with the platelets. The 
second part consists of two flanking sides extended from the central region ‘hook’. These were 4 
cm in length, to allow lowering and uplifting of the central region containing the construct. The 
length of the ‘hook’ can be adjusted depending on the volume of platelets used to ensure this could 
facilitate optimal contact of construct with platelets. 
2.4.2. Sample assembly 
Once tissue engineered blood vessel constructs were fabricated, the upper side of the construct 
(region of interest), was overturned upside down on an acetate frame, with the centre part 
permitting direct exposure to the platelet suspension. By slowly combining the construct with the 
central part of the acetate frame, this composite (sample holder and construct) is slowly lowered 
down into the cuvette containing platelets and levelled just above the platelet suspension. The 
sides of the acetate frame was bent around the cuvette to secure the composite. A magnetic stir 
bar was also added at the bottom of the cuvette to mix the washed platelet suspension and 
facilitate dynamic interaction between of platelet suspension with the construct.  
2.4.3. Real-time monitoring of [Ca2+]cyt of washed human platelet suspension  
Fluorescence was recorded from stirred aliquots of Fura-2-loaded washed human platelet 
suspensions in contact with the blood vessel constructs at 37°C using Cairn Research 
Spectrophotometer with excitation of 340 and 380 nm and emission of 515 nm. Changes in [Ca2+]cyt 
were monitored using the 340/380 nm fluorescence ratio. Data were calibrated using the method 
of Grykiewicz et al., (1985) (Grynkiewicz et al., 1985). Agonist-evoked changes in [Ca2+]cyt were 
quantified by integration of the change in fluorescence records from basal with respect to time 
from 5 -15 minutes after agonist addition. 
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Figure 3.1 - A picture showing the novel testing platform to assess the pro-aggregatory capacity of 
acellular collagen hydrogel or tissue-engineered vessel constructs in ex vivo platelet Ca2+ signaling assay. 
(A and B) are showing the measurements drawn on a cellulose acetate prior to cutting the frame. (C) The 
3D sample to be tested was placed on a cellulose acetate frame with the centre part permitting direct 
exposure to Fura-2- and DiOC6-co-labelled washed human platelet suspension. (D) The sample was 
lowered down allowing contact with the platelet suspension. (E) The picture of the assembled test sample 
with the presence of constant stirring of platelet suspension using a magnetic stir bar shown at the bottom. 
Platelet Ca2+ signaling in the platelet suspension was measured in real-time through Fura-2 fluorescence 
intensity, whilst platelet adhesion and aggregation on the surface of the samples were assessed by the 
imaging of DiOC6-labeled platelets after removal of the sample from the cuvette. Dashed arrow = sample 
holder. 
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2.5.  Assessment of the new monitoring system 
2.5.1. The effect of sample holder on platelet activation 
The sample holder generated from cellulose acetate frame was placed in a cuvette containing 1.2 
mL of Fura-2-loaded human platelet suspensions. The sample was introduced onto the new 
monitoring system explained in section 2.3. The [Ca2+]cyt was measured with initial recording of a 
basal reading for 1 minute followed by 4 minutes following stimulation with 0.2 U/mL thrombin. 
2.5.2. The effect of different platelet preparations on platelet activation 
To investigate whether using two different PRP preparations would influence platelets response to 
TEML constructs, an experiment was conducted comparing the effect of TEML construct on 
potentiating [Ca2+]cyt increase in platelets compared with acellular hydrogel (n=6). 10 μM PGI2 or 
100 μM ASA treated PRP preparations were used from the same donor at any given time. 1.5 mL of 
washed platelet samples from these preparations were used incubated with TEML constructs. The 
sample incorporated with either cellular or acellular hydrogels were placed into the cuvette holder 
of the spectrophotometer machine. Fluorescence recording was commenced 1 minute prior to 
construct addition to the platelets, of which a basal reading was taken from stirred aliquots of 
platelet suspension at 37°C using Cairn Research Spectrophotometer. 
2.5.3. The effect of time dependent TEBV incubation on platelet activation 
TEBV construct was incubated with 1.2 mL of washed platelet suspension at different times 1, 5, 10 
and 15 minutes and introduced onto the new monitoring system explained in section 2.3 (n = 4). 
[Ca2+]cyt basal reading was measured for 1 minute followed by 4 minutes following stimulation with 
0.2 U/mL thrombin  
2.5.4. The effect of various HUVECs densities on [Ca2+]cyt 
TEBV constructs were fabricated at various HUVECs densities, 5 x103, 4 x104 and 8 x 104 cells/cm2. 
These 3 different samples were cultured for 4 days. These samples were then individually assessed 
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using a 1.2 mL of platelet suspension and the new method explained in section 2.3 (n = 3). [Ca2+]cyt 
basal reading was measured for 1 minute followed by 4 minutes reading post thrombin (0.2 U/mL) 
stimulation. 
2.6. Statistics 
Values stated are mean ±SEM of the number of observations (n) indicated. Analysis of statistical 
significance was performed using a paired student’s t-test.  P < 0.05 was considered significant. 
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3. Results 
3.1. Designing a real-time monitoring system to assess the effect of tissue-engineered 
blood vessels constructs on activation state of human platelets 
To detect the activation status of platelets upon exposure to tissue-engineered blood vessel 
constructs, we have constructed a system to allow real-time monitoring of platelets activation 
(Figure 3.1). [Ca2+]cyt was quantitatively measured using human platelets loaded with Fura-2, a high-
affinity fluorescent Ca2+ indicator. The fluorescence signal from these platelets can be measured in 
real time using a fluorescence spectrophotometer. The construct can be removed after sufficient 
time was allowed for interaction with platelets. By pulling the flanking side of the acetate frame of 
which the construct is resting on, the remaining platelet suspension is put inside the cuvette holder 
to resume the recording. 
3.1.1. Thrombin-evoked response of platelets [Ca2+]cyt incubated with the sample 
holder 
Prior to using the method for testing tissue engineered constructs, a typical experiment was set-up 
to assess if pre-incubation with the acetate sample holder could artificially alter Ca2+. To do this, the 
[Ca2+]cyt of platelets was monitored following incubation with the sample holder as well as  following 
thrombin stimulation. These initial experiments showed that there appeared to be no apparent 
activation of platelets following pre-incubation. In addition, a robust Ca2+ signal which was similar 
to those previously reported in the literature suggesting no inhibition of platelet function elicited 
by the sample holder. These data therefore suggest that the acetate sample holder does not 
significantly alter the responsiveness of platelets exposed to it.  
3.2. Testing variables 
To assess and optimise the effectiveness of methodology described above, experiments were 
undertaken to examine the effect of altering a number of variables which might alter the results 
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seen. This included investigating the effects of different methods for producing the tissue-
engineered blood vessel constructs, changing HUVECs densities and time of incubation of the vessel 
construct with platelet suspension. The testing parameters and variables tested in this chapter are 
summarised in Figure 3.2. 
 
 
 
3.2.1. TEML activates platelets in a manner that is independent of the platelet 
preparation method 
It was predicted that exposure of platelets to the subendothelial matrix of the TEML should elicit 
platelet activation, and thus a rise in [Ca2+]cyt. However, the response observed may also depend 
upon the method of platelet preparation. Both ASA and PGI2 have been widely used to prevent 
unwanted platelet activation during the preparation of washed platelet samples (Dorsam et al., 
2005; Heemskerk, Farndale, & Sage, 1997; S. Kim et al., 2013; McCloskey et al., 2010; Rosado, 
Brownlow, & Sage, 2002). PGI2 inhibits platelets aggregation by activating cell surface prostacyclin 
receptors (IP) linked to activation of adenylate cyclase (AC), leading to the conversion of ATP to 
cAMP. This rise in cAMP prevents platelet activation and aggregation by inhibiting agonist-evoked 
V
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Figure 3.2 - Testing variables for platelets’ calcium signalling using tissue engineered blood vessels 
to assess the sensitivity of the model.  
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rises in [Ca2+]cyt (Paul et al., 1990). In contrast, the use of aspirin is common in platelet signalling 
studies to remove autocrine activation of platelets by thromboxane A2 production and therefore 
remove any confounding influence of this autocrine signalling molecule in studying the primary 
activation mechanisms of platelets by soluble or adhesive agonists. Its inclusion here permits 
examining how various constructs alter primary platelet activation in the absence of secondary 
autocrine mediators of platelet activation. To assess this, we examined the effect of pre-incubating 
Fura-2-loaded washed human platelets prepared with either ASA or PGI2 as a platelet inhibitor 
during the washing process, with either the TEML construct or a control collagen hydrogel. As can 
be seen in Figure 3.3, the TEML constructs causes an increase in [Ca2+]cyt prior to thrombin 
stimulation which was not observed in platelets exposed to the collagen hydrogel. These data 
therefore suggest that the TEML is able to trigger platelet activation which is not supported by the 
collagen hydrogel alone. This result was observed in both platelet preparation methods, with the 
Ca2+ signal being potentiated to 180.3 ± 43.3% and 174.6 ± 51.3% of control, collagen hydrogel for 
PGI2- treated and ASA-treated- samples respectively (P < 0.05; n = 4). The construct-evoked rises in 
the two preparation methods were found not to be statistically significant (P > 0.05). Therefore, 
platelet preparation by either method produced similar results, hence all further experiments used 
washed platelets prepared using ASA. 
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Figure 3.3 - [Ca2+]cyt measurement of fluorescently-labelled human platelets exposed to the 
luminal surface of TEML or acellular hydrogel using two different methods for PRP 
preparation. The PRP preparation was split into half of which one was treated with prostacyclin 
(PGI2, 10 μM) and the other with aspirin (ASA, 100 μM). The PRP preparations were then 
treated with Fura-2/AM (2.5 µM) for 45 minutes. PGI2 treated PRP was treated yet once more 
with PGI2 prior to centrifugation. Washed platelets (1.5 mL) from both preparations were 
individually incubated with TEML constructs for 15 minutes at 37˚C, under continuous 
magnetic stirring. The constructs were removed and the [Ca2+]cyt in the remaining suspension 
was recorded and stimulated with 0.2 U/mL thrombin. Results are representative of 3 
experiments (n=4).  
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3.2.2. Increasing HUVECs seeding densities reduces thrombin-evoked rises in [Ca2+]cyt in 
washed human platelets 
As endothelial cells play a key role in preventing platelet activation through releasing paracrine 
inhibitors of platelet function, experiments were performed to assess whether changes in the 
seeding densities of HUVECs used in the TEBV constructs could alter its inhibitory effect on platelet 
activation. Figure 3.4 shows thrombin evoked [Ca2+]cyt rise in platelets pre-exposed to TEBVs with 
different HUVECs densities. TEBVs with various HUVECs densities showed to inhibit thrombin-
evoked rises in platelet [Ca2+]cyt in a manner that was dependent upon the HUVECs seeding density 
of the constructs. Seeding TEBVs with a high density of HUVECs (8 X 104 cells/cm2) causes a 
significant reduction of thrombin evoked [Ca2+]cyt rise in platelets upon pre-exposure compared 
with the collagen hydrogel (46.9 ±4.5 % of control; n = 3; P < 0.05). Moreover, using a lower density 
of HUVECs (4 X 104 cells/cm2) on TEBVs also seems to cause a significant reduction in thrombin 
evoked [Ca2+]cyt rise in pre-exposed platelets compared with collagen hydrogel (49.0 ± 3.7 % of 
control;  n = 3; P < 0.05). Seeding even a lower HUVECs density of 5 X 103 cells/cm2 likewise elicit a 
significant inhibitory effect on [Ca2+]cyt of platelets pre-exposed to such construct (51.8 ± 9.3 % of 
control; n = 3; P < 0.05). These data demonstrate that the presence of more HUVECs on the 
construct elicits a greater inhibition of platelets pre-exposed to it. This is likely due to an increase 
in the inhibitory paracrine signalling molecules produced by the endothelial cells which are known 
to inhibit platelet activation. The use of a cell number of 4 x 104 cells/cm2, for a culture period of 4 
days can be seen to be sufficient in mediating a consistent, effective and reproducible inhibition of 
thrombin-evoked rise in [Ca2+]cyt of platelets in this system. Therefore, this is the cell seeding density 
has been on the TEBV in all future experiments. 
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3.2.3. The effect of TEBV incubation period  
Using the newly developed monitoring system, the effect of incubation period of TEBV with 
platelets was measured. In this experiment, TEBVs were seeded with 4 x 104 HUVECs/cm2 and 
cultured for 72 hours. These constructs were subsequently placed atop of platelet suspension for 
1, 5, 10 and 15 minutes. Changes in platelet [Ca2+]cyt was measured for 1 minute at baseline and 
then for a further 4 minutes following stimulation with 0.2 U/mL thrombin. As shown in Figure 3.5, 
the addition of thrombin elicits an agonist-evoked increase in [Ca2+]cyt with the highest reading for 
those platelets exposed to the hydrogel control. the inhibitory effect of pre-incubation with the 
TEBV was found to be time-dependent. The longer the incubation of platelets with TEBV, the more 
Figure 3.4 – A real-time measurement of thrombin-evoked cytosolic Ca2+ concentration 
increase in platelets pre-exposed to tissue-engineered blood vessels (TEBV) with various 
HUVECs densities. The constructs were cultured for 4 days and pre-incubated with 1.2 mL of 
washed human platelet suspension for 15 minutes prior to thrombin stimulation (0.2 U/mL). 
Hydrogel was used as a control to show a maximum stimulation. Results are representative of 
3 experiments (n=3).   
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inhibition of thrombin-evoked increase in [Ca2+]cyt. There is no significant difference observed in 
thrombin-evoked increase of [Ca2+]cyt in platelet pre-incubated for 1 minute with TEBV compared 
with the collagen hydrogel (107.3 ±3.9 % of control; n = 4; p > 0.05). A similar result was found in 
platelets pre-incubated for 5 minutes as this shows insignificant difference compared with the 
collagen hydrogel (60.3 ±16.5 % of control, n=4; p > 0.05). However, a significant difference was 
detected with platelet samples pre-incubated with TEBV for 10 and 15 minutes compared with the 
collagen hydrogel (53.0 ±11.9 % of control and 39.0 ± 11.6% of control; n = 4; p < 0.05, respectively). 
This results show that pre-incubating platelet with the TEBV for 10 minutes or more is sufficient to 
produce a reproducible inhibitory signal that reduces the thrombin-evoked increase in platelet 
[Ca2+]cyt. 
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Figure 3.5 – Time dependent incubation of platelets pre-exposed to TEBVs. The constructs 
were cultured for 4 days and pre-incubated with 1.2 mL of washed human platelet suspension 
for 1, 5, 10 and 15 minutes prior to thrombin stimulation (0.2 U/mL). Hydrogel was used as a 
control to show a maximum stimulation. Results are representative of 3 experiments (n=4).   
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4. Discussion 
This chapter demonstrated the development and optimisation of a new in vitro testing system to 
assess the effect of exposure to TEBVs on platelet activation status. Using this method, we were 
able to adapt traditional fluorescence spectrophotometric methods to detect the [Ca2+]cyt of 
suspensions of Fura-2-loaded human platelets to allow a real-time assessment of changes in 
platelet activation. Methods previously used to assess human platelet function such as assessing 
aggregate formation of the surface of the construct  (Boccafoschi et al., 2005; L’Heureux et al., 
2001; Sankaran et al., 2014) are limited, as these assess platelet activation at specified time points 
and only detect the highly-activated platelets that form thrombi. It also cannot distinguish between 
a construct that is inert to platelets from those actively inhibiting platelet function. The 
methodology presented here is an improvement as it allows real-time assessment of platelet 
activation in response to the construct, as well as allowing an assessment of inhibitory signals 
produced by the construct through using post-construct stimulation with thrombin. Due to the 
known relationship between higher rises in [Ca2+]cyt and greater adhesive and aggregatory potential 
of platelets (Sargeant and Sage, 1994; Varga-Szabo et al., 2009), it provides a valid method for 
quantitatively comparing the pro- and anti-aggregatory potential of tissue-engineered blood vessel 
constructs. This can be seen in the data demonstrating that platelet responses are sensitive to both 
HUVECs-seeding density and TEBVs pre-incubation period – demonstrating that the methodology 
has sufficient sensitivity to allow differences in the properties of the construct to be reliably 
assessed quantitatively. 
Using this methodology, we can assess the ability of the construct to directly activate human 
platelets during the incubation period with the construct, as well as assessing the ability of layers 
of the construct to inhibit or sensitize platelets to other agonist through monitoring alterations in 
the thrombin-evoked signal. Through these tests, experiments in this chapter have demonstrated 
that the TEML construct is able to directly activate human platelets and the TEBV constructs can 
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inhibit this function – consistent with the physiological role of these constructs in vivo. These pro- 
and anti-aggregatory properties of the TEML and TEBV constructs will be examined in more detail 
in the next chapter.   
The described experiments have been principally used to assess the optimisation of key variables 
of this technique, such as the platelet preparation method, HUVECs seeding density and the pre-
incubation period with the constructs prior to stimulation with soluble agonists. From these studies, 
it has been possible to observe that platelet responsiveness to our construct is not dependent upon 
the formation of thromboxane A2 as ASA preincubation does not significantly alter the response of 
platelets. This finding is consistent with previous findings that the main autocrine signal that 
potentiates collagen signalling is ATP secreted from platelet dense granules (Fung et al., 2012).  
4.1. Conclusion  
In this study, we have demonstrated a novel testing platform enabling analysis of the effect of 
tissue-engineered blood vessel constructs on platelets activation. Through exposing the constructs 
to washed human platelet suspension labelled with Fura-2, we are able to assess in real-time the 
activation status of the platelet suspension, or modulation of platelet responsiveness to soluble 
agonists. Through this method, we were able to optimise suitable HUVECs seeding densities and 
duration of incubation with tissue engineered constructs. This broad analysis of a range of different 
effects provides the potential for a simple, standardised and quantifiable method to directly 
compare the effects of a range of different tissue-engineered vessel constructs or biomaterials on 
platelet function. In addition, this methodology would also be accessible to simple modification to 
also potentially make it as a suitable in vitro testing system for studying healthy or diseased blood 
vessel models. 
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1. Introduction 
Platelets are prevented from being activated through a complex series of physical and chemical 
interactions with flowing blood and vessel wall cells. The most significant of these is the role of the 
endothelial cell monolayer, which functions to create an anti-thrombotic layer of the native blood 
vessel (Vassalle et al., 2003). The endothelial layer does this via secretion of paracrine inhibitors of 
platelet function such as NO and PGI2. PGI2 and NO are main anti-platelet agents secreted by ECs 
(Bunting et al., 1983). In addition, cells possess proteins that interfere with the blood coagulation 
cascade such as tissue factor pathway inhibitor and thrombomodulin (Kurz et al., 1990). 
NO and PGI2 are continuously released from ECs, as previously discussed in chapter 1. However, 
their production by ECs can be increased in response to certain molecules involved in mediating 
inflammation or blood such as bradykinin and thrombin (Bartha et al., 1989). Aggregating platelets 
also release ATP which increases PGI2 and NO production from ECs, allowing undamaged 
endothelial cell to limit the extent of thrombus formation at the site of vascular damage (Carter et 
al., 1988).This bi-direction communication between ECs and platelets play a key role in regulating 
haemostasis.  
Upon damage to the vessel wall, the inhibitory effect of the endothelium is removed and the 
haemostatic system is activated. This removes endothelial-derived inhibitors of platelet function, 
and allows platelets to bind to pro-aggregatory ligands present within the subendothelial matrix, 
such as collagen, laminin, fibronectin and vitronectin, as well as recruited plasma components such 
as von Willebrand factor and thrombospondin-I (Ruggeri, 2007). Of these components, type I and 
III collagen are considered most able to support platelet adhesion and trigger strong platelet 
activation (Farndale, 2009; Kawamoto and Kaibara, 1990; Savage et al., 1999). In addition to the 
type of collagen present, studies have demonstrated that the structure of the collagen is also a key 
factor in influencing its thrombogenicity, as different collagen preparations vary widely in their 
ability to support their adhesion and trigger platelet aggregation. For example, fibrillar collagen is 
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much more potent in inducing platelet activation than the same type of acid-solubilised monomeric 
collagen (Savage et al., 1999). Other studies have demonstrated that cross-linking of collagen fibrils 
is also important in inducing platelet activation (Kawamoto and Kaibara, 1990). Platelet binds to 
collagen via glycoprotein VI and integrin α2β1 receptors. This triggers Ca2+ signals through activation 
of phospholipase Cγ2 and subsequent cleavage of phosphatidylinositol 4,5-bisphosphate into 
inositol 1,4,5-trisphosphate and 1,2-diacylglycerol (Paul et al., 1990). Inositol 1,4,5-trisphosphate 
induces the release of calcium from the dense tubular system, whereas 1,2-diacylglycerol activates 
protein kinase C (Authi and Crawford, 1985). The collagen-induced inositol 1,4,5-trisphosphate-
mediated increase in [Ca2+]cyt is also accompanied by an influx of calcium from the extracellular 
milieu through both store- and receptor-operated channels (Gresele et al., 2017). 1,2-Diacylglycerol 
and calcium mediate the characteristic platelet activation responses such as shape change, granule 
secretion, and aggregation. These Ca2+ signals trigger the activation of adherent platelets which will 
begin to recruit other circulating platelets to build a thrombus through secretion and production of 
autacoids such as ATP, ADP, serotonin and thromboxane A2 by the activated platelets. This 
recruitment of platelets to the surface of the damaged vessel wall, creates a thrombus which plugs 
the wound and prevents further blood loss. 
The integrity of the endothelial lining acts dynamically to maintain haemostasis by balancing anti-
aggregatory and pro-aggregatory factors of the blood vessel wall. Under normal conditions, an 
intact endothelial cell layer functions as a barrier between the blood vessel components and 
vascular wall, inhibiting platelets and clotting factors from interacting with the thrombogenic 
subendothelial matrix. However, upon damage to the endothelial lining the subendothelial matrix 
is exposed to the bloodstream triggering platelet activation. Therefore, a model of blood vessel 
must possess both these pro- and anti-aggregatory properties which can be differentially expressed 
depending on the confluency of the endothelial lining.  
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Tissue engineering offers the potential to create a human blood vessel replica that can be utilised 
for studying platelet activation and thrombus formation under in vitro condition. To be appropriate 
for this purpose, the produced tissue-engineered blood vessel should possess similar physiological 
properties of a native human blood vessel. Thus, the tissue-engineered blood vessel construct must 
possess an anti-aggregatory luminal surface to prevent thrombosis and a quiescent endothelial cell 
layer possessing an anti-platelet, anti-coagulant and pro-fibrinolytic surface (Torikai et al., 2008; Yu 
et al., 2008).  In addition, the endothelial lining must be healthy and not demonstrate the 
inflammatory phenotype seen to contribute to the development and progression of an 
atherosclerotic plaque (Daniel and Sedding, 2011). However, upon damage of the blood vessel, the 
construct must also be able to switch from this anti-aggregatory phenotype to a pro-aggregatory 
condition which is able to support efficient but self-limiting thrombus formation as seen in the 
native vessel. Therefore, the main aim for this chapter is to assess and optimise the anti- and pro-
aggregatory properties of the tissue-engineered blood vessel construct to match the known 
properties of the native vessel. 
 
 
 
 
 
 
 
 
 
 
 
 
 108 
 
2. Methods 
2.1 Tissue engineered blood vessel constructs fabrication 
2.1.1 Generation of TEML constructs 
To prepare TEML constructs, HCASMCs were mixed at a density of 5 x 105/mL into a neutralised 
solution of 3 mg/mL type I collagen obtained from BD biosciences, according to the manufacturer’s 
protocol. 0.2 mL of the mixture was then loaded onto a 1 cm2 square shaped filter paper frame, and 
the collagen-cell mixture was left to set for 40 minutes at 37˚C, 5% CO2. The formed gel was then 
covered with supplemented medium and with changing the media every 2 days. HCASMCs were 
subsequently allowed to grow in the TEML until they were observed to possess an elongated 
spindle-shaped morphology. The formed gel was then covered with supplemented medium with 
changing the medium every 48 hours. HCASMCs were subsequently allowed to grow in the TEML. 
2.1.2 Generation of TEIL constructs 
0.2 mL of a neutralised 3 mg/mL BD type I collagen solution was loaded upon a square frame made 
by filter paper with an area of 1 cm2 to form an acellular collagen gel base first. An aligned, portable 
PLA nanofiber mesh coated with fibronectin (10 ng/mL) was placed on the collagen hydrogel. 
HUVECs (4 x 104 cells per sample) were carefully seeded in two separate occasions using small 10 
μL volumes on top of the nanofibers. This is to prevent the cells from leaking over the confined area 
and eventually cell loss. The cells were allowed to attach at 37˚C, 5% CO2 for 1 hour. Samples were 
then topped up with supplemented 200 medium and subsequently allowed to be cultured for 4 
days at 37˚C and 5% CO2, with a single media change on day 2.  
2.1.3 Generation of TEBV constructs 
TEBV construct was fabricated by placing a PLA nanofiber mesh coated with a 10 μg/mL fibronectin 
solution on the 3D TEML, to create the initial layer of the luminal surface. After successful 
attachment of the nanofibers to the TEML hydrogel, HUVECs (at a density of 4 x104 cells/cm2) were 
then seeded on top of the nanofibers to create a full TEBV construct. Once HUVECs were attached, 
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samples were topped up with the mixture supplemented medium 200 and 231 at the ratio of 7:3, 
and subsequently allowed to be cultured for 4 days at 37˚C and 5% CO2, with a single media change 
on day 2. 
2.1.4 Fabrication of control scaffolds (Horm collagen coating) 
In some experiments, PLA nanofibers were coated with Horm collagen (1 μg/mL diluted in HBS; 
Chrono-log, USA) for 1 hour at room temperature. Unbound Horm collagen was washed away using 
HBS and nanofibers were left to dry. The coated nanofiber was carefully sealed onto collagen 
hydrogels using freshly prepared rat tail type I collagen solution. These were placed in the incubator 
programmed at 37˚C, 5% CO2 until the collagen was set. A sterile scalpel blade was used to cut the 
outer corner and remove excess nanofibers. 
2.2 Preparation of platelet-rich plasma and washed Fura-2-loaded human platelet 
suspensions 
Human platelets were used to test platelets activation and aggregation. A standard method of 
extraction was used. Blood was obtained by venepuncture from healthy volunteers who had given 
informed written consent. 5 mL of blood was mixed with 1 mL of acid citrate dextrose anticoagulant 
(85 mM sodium citrate, 78 mM citric acid and 111 mM d-glucose). Platelet-rich plasma was then 
obtained by centrifuging at 1500 g for 8 minutes, and was then treated by the addition of 100 μM 
aspirin and 0.1 U/mL apyrase unless otherwise stated. PRP was then incubated with 2.5 µM Fura-
2/AM for 45 minutes at 37°C. Platelets were then collected by centrifugation at 350 g for 20 
minutes. Washed platelets were re-suspended into supplemented HEPES –Buffered Saline to a final 
cell density of to 2x108 cells/mL. To make supplemented HBS, HBS (pH 7.4, 145 mM NaCl, 10 mM 
HEPES, 10 mM d-glucose, 5 mM KCl, 1 mM MgSO4), was supplemented on the day of the 
experiments with 1 mg/mL BSA, 10 mM glucose, 0.1 U/mL apyrase and 200 µM CaCl2 
(supplemented HBS). CaCl2 concentration of the supplemented HBS was adjusted to 1 mM prior to 
individual sample analysis. 
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2.3 Assessment of the pro- and anti-aggregatory potential of the tissue engineered 
constructs and conditioned media from the construct using real-time monitoring of platelet 
[Ca2+]cyt 
PRP was incubated with 2.5 µM Fura-2/AM for 45 minutes at 37°C. Platelets were then washed by 
centrifugation and re-suspended in supplemented HBS to a final cell density of 2x108 cells/mL. 
Fluorescence was recorded from stirred aliquots of Fura-2-loaded washed human platelet 
suspensions in contact with the blood vessel constructs at 37°C using Cairn Research 
Spectrophotometer, with excitation of 340 and 380 nm and emission of 515 nm. This methodology 
has been used to assess the impact of exposure of human washed platelet suspensions to a variety 
of components of our tissue-engineered blood vessel constructs. Changes in [Ca2+]cyt were 
monitored using the 340/380 nm fluorescence ratio. Data were calibrated using the method of 
Grykiewicz et al., (1986). Agonist-evoked changes in [Ca2+]cyt were  quantified by integration of the 
change in fluorescence records from basal with respect to time from 5 - 15 minutes after agonist 
addition. 
Conditioned media from cultured 3D TEML constructs and cultured 2D HCASMCs monolayer were 
collected, with matching of cell densities and culture duration. 1 mL of conditioned media was 
added to 1 mL of washed Fura-2-loaded human platelets obtaining a final platelet concentration of 
2 x 108 cells/mL HBS and freshly supplemented medium (not exposed to cells) were used as controls. 
Changes in [Ca2+]cyt of Fura-2-loaded human platelets was recorded using a Cairn Research 
spectrophotometer with excitation at 340 and 380 nm and emission at 515 nm for 10 minutes.  
2.4 Assessment of tissue engineered constructs using conventional assays 
2.4.1  Fluorescent imaging of Platelet adhesion and aggregation upon layers of the 
TEBV 
To study aggregate formation upon the surface of the constructs, platelets were labelled with 
DiOC6. In these experiments, 5 mL whole human blood was collected into 1 mL ACD anticoagulant 
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containing the fluorescent plasma membrane label, DiOC6, to provide a final concentration of 1 µM 
(Metcalfe et al., 2016). The blood was mixed with anticoagulant and dye, and left to incubate for 
10 minutes at room temperature prior to centrifugation to collect PRP. Washed human platelet 
suspensions were then prepared by centrifugation at 350 g for 20 minutes. Platelets were then 
resuspended into supplemented HBS to a final cell density of 2x108 cells/mL. The TEBV, or layers of 
the TEBV, samples were then incubated with 1 mL of washed DiOC6-labelled human platelet 
suspensions for 15 minutes at 37°C. Following the incubation period, the platelet suspension was 
discarded and the constructs were washed once with HBS. Images of adhered platelets were taken 
under fluorescence microscope using excitation wavelengths of 485 nm and emission of 501 nm 
(Nikon Eclipse Ti, Japan). 
2.4.2 Aggregation studies 
Platelet aggregation studies were conducted using two different techniques, a traditional light 
transmission aggregometer (Metcalfe et al., 2016) and a microplate-based absorbance assay 
(Lordkipanidzé et al., 2014). The TEML, TEBV and collagen hydrogel were individually pre-incubated 
with washed human platelet suspension for 15 min at 37˚C with continuous magnetic stirring using 
the sample holders developed in chapter 3. At the end of this incubation, the constructs were 
removed and the platelet suspension was transferred for use in these experiments as set out below. 
2.4.3 Microplate-based absorbance assay 
200 µL of the remaining washed platelet suspension were added to a 96-well plate. A baseline 
recording was taken following the incubation with the construct using a BioTek Synergy 2 
microplate reader assessing absorbance at 600 nm. Platelets aggregation was then stimulated by 
addition of 0.2 U/mL of thrombin into each well and subjected to rapid agitation between readings. 
Absorbance was measured every minute for 6 minutes after agonist addition. The mean absorbance 
was then calculated and compared between experimental conditions. 
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2.4.3.1 Light Transmission aggregometry 
Platelet aggregation was measured using a ChronoLog light transmission aggregometer according 
to the manufacturer’s instructions. Following incubation with the blood vessel constructs, 0.5 mL 
of the platelet suspension was transferred into glass aggregometry tubes containing magnetic stir 
bars. Stirring was set to 1200 rpm and temperature of the aggregometry tube holder was 
maintained at 37°C. Prior to each reading, the baseline for full aggregation was set by comparison 
to a tube filled with 0.5 mL supplemented HBS. A baseline reading was then taken for 2 
mins. Platelets were then stimulated by adding 0.2 U/mL thrombin. Changes in light transmission 
was recorded during constant stirring of the samples at 37°C. Aggregation responses were 
quantified and compared by measuring the maximum percentage aggregation for each sample, 
8 minutes after thrombin addition. 
2.4.3.2 Dense granule secretion 
Platelet secretion was assayed using a luciferin-luciferase assay to quantify ATP release from the 
dense granules. The TEML, TEBV and collagen hydrogel were individually pre-incubated with 
washed human platelet suspension for 15 min at 37˚C with continuous magnetic stirring using the 
sample holders developed in chapter 3. Following this incubation period, 0.2 mL of platelets pre-
exposed to tissue engineered constructs were transferred to a clean 96-well plate and incubated 
with 10% [v/v] luciferin-luciferase (Sigma Aldrich, USA). A basal reading was obtained at this stage 
by integrating light emission for 1-minute following luciferin-luciferase addition at 37°C using a 
BioTek Synergy 2 microplate reader. The samples were then stimulated with 0.2 U/mL thrombin for 
1 min. Data were normalised to a maximum light emittance by treating all samples following 
thrombin stimulation with 10 µM of ATP (Sigma Aldrich, USA) which was added to each sample to 
obtain a maximum increase of ATP. Luminescence was quantified using a luminescence setting on 
Synergy 2 microplate reader. 
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2.4.4 Collagen morphology assessment 
2.4.4.1 Reflectance microscopy 
Acellular collagen hydrogels made from rat tail type I collagen and cultured TEML construct were 
transferred onto petri dishes with centrally located coverslips to enable visualisation with a PLAPON 
60× oil immersion objective using FluoView FV1200 laser-scanning confocal microscope (Olympus, 
Japan). The collagen fibre morphology was imaged under reflection mode.   
2.4.4.2 Scanning electron microscopy 
For imaging using scanning electron microscopy (SEM), the same group samples were subjected to 
standard critical point drying first and mounted onto aluminium stubs with carbon tape for 
SEM/EDXA examination using a bench top Hitachi TM3000 system under 1.5-5 kV acceleration 
voltage.   
2.5 Immunostaining of human type I and III collagens 
The presence of type I and III collagens of the TEML constructs were examined using monoclonal 
antibodies specific to human type I and III collagen, respectively. TEML constructs cultured for 10 
days were fixed for 40 mins at room temperature with 4% paraformaldehyde. Subsequent to fixing, 
the TEML constructs were incubated with Sudan Black B for 30 mins at room temperature. This was 
followed by blocking with 5% goat serum for 30 mins at room temperature. The cells were then 
incubated with either a primary antibody to human type I or type III collagen for 60 mins at room 
temperature. Both antibodies were used at a concentration of 1:200 [v/v] diluted in PBS with 0.1% 
[v/v] Tween 20 (PBST). Subsequently, the samples were incubated for 60 mins at room temperature 
with a 1:500 dilution in PBST of AlexaFluor-labelled goat anti-mouse secondary antibody. 
Fluorescence images were obtained using the confocal microscope (Olympus, Japan). 
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2.6 Platelet adhesion assay to TNF- α-treated HUVEC monolayers and blood vessel 
constructs 
 The HUVECs monolayer was seeded on a glass slide coated with 2% BSA (sigma Aldrich, UK) solution 
to prevent platelet activation on the glass surface. Tissue-engineered blood vessel constructs and 
HUVECs monolayers were incubated with either 100 U/mL or 1000 U/mL TNF-α (or an equivalent 
volume of its vehicle, HBS for 24 hours under standard culturing conditions. At the end of the 
incubation period, the media was removed and 1 mL of DiOC6-labelled washed platelets were 
incubated with the constructs for 15 minutes at 37°C under continuous magnetic stirring. The 
platelet suspension was then removed and the constructs were washed once with HBS. The samples 
were imaged using a Nikon fluorescence microscopy. 
2.7 Statistics 
Values stated are mean ± SEM of the number of observations (n) indicated. Analysis of statistical 
significance was performed using a two-tailed Student's t-test. P < 0.05 was considered statistically 
significant. 
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3. Results 
3.1 Analysis of pro- and anti-aggregatory properties of the constructs  
In the previous chapter, we established a methodology for assessing pro- and anti-aggregatory 
properties of tissue-engineered blood vessel constructs through real-time monitoring of [Ca2+]cyt.  
Therefore, experiments were performed using this technique to simultaneously compare the pro- 
and anti-thrombotic properties of each of the produced blood vessel constructs (hydrogel, TEIL, 
TEBV and TEML). This was performed by measuring construct- and thrombin-evoked rises in [Ca2+]cyt 
of platelets. Constructs were individually placed atop of washed Fura-2-loaded human platelet 
suspensions for 15 minutes at 37˚C with continuous magnetic stirring to assess whether any of the 
constructs could demonstrate a direct pro-thrombotic effect on the underlying platelet suspension. 
This was followed by the removal of the construct and addition of thrombin to assess the impact of 
any soluble agonists and inhibitors released from the 3D models on sensitizing or inhibiting the 
platelet response to this soluble agonist. 
As shown in Figure 4.1, prior to thrombin stimulation, platelets exposure to the TEML were found 
to trigger a significant increase in platelet cytosolic Ca2+ concentration compared to collagen 
hydrogel prior to thrombin stimulation (179.3 ±42.7% of control; n=6). These data therefore 
indicate that exposure to the TEML alone could trigger activation of platelets, in line with our 
previous results shown in chapter 3.  In addition, thrombin-stimulation also evoked a larger increase 
in the [Ca2+]cyt of platelets exposed to the TEML when compared to the collagen hydrogel alone 
(169.2 ± 33.1% of control; n = 8; P <0.05). This is consistent with the platelets aggregating on the 
surface of the construct able to increase the activation status of the underlying platelets in the 
suspension. These data therefore suggest that the TEML may provide a suitable pro-aggregatory 
surface on which to from thrombin when the endothelial lining has been damaged. 
Thrombin-evoked rises in [Ca2+]cyt in TEBV-exposed platelets were found to be significantly reduced 
compared to those in contact with the collagen hydrogel (24.0 ± 11.3% of control; n = 8; P  < 0.05).  
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Similar to the TEBV, the exposure of washed platelets to the TEIL caused a significant reduction of 
thrombin-evoked [Ca2+]cyt when compared to samples exposed to the acellular collagen hydrogel 
(24.9 ± 13.7% of control; n = 8; P < 0.05). Interestingly, platelets exposed to the TEIL constructs 
showed a smaller thrombin-evoked rise in [Ca2+]cyt than those incubated with the TEBV, however 
this was not statistically significant (90.4 ± 30.4%; n = 8; P > 0.05). These data therefore demonstrate 
that both the TEBV and TEIL possess the anti-aggregatory effects of the native blood vessel. As the 
TEIL only contains endothelial cells, these data therefore suggest this inhibitory effect is coming 
from the HUVECs monolayer. Interestingly the presence of HCASMCs in both the TEML and TEBV, 
appear to enhance the thrombogenicity of the respective constructs lacking these cells (hydrogel 
for TEML and TEIL for TEBV). These data therefore suggested that the HCASMCs may possess pro-
aggregatory properties.  
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3.2 Platelet aggregometry experiments replicate the findings of the real-time platelet 
activation monitoring experiments 
To validate the results from the calcium signalling studies, experiments were performed to assess 
platelet aggregation using a previously-developed microplate-based absorbance assay 
(Lordkipanidzé et al., 2014). In this assay, aggregation of the platelet sample was tracked as a 
reduction in the absorbance of the washed human platelet sample – since stimulated platelets 
Figure 4.1 – Real-time measurements of [Ca2+]cyt in platelet suspension exposed to tissue-
engineered vessel constructs. Fura-2 loaded human platelets suspension was incubated in contact 
with hydrogel alone, TEML, TEIL and TEBV constructs for 15 minutes at 37˚C off-screen. The 
constructs were then removed and the remaining suspension was stimulated with thrombin (0.2 
U/mL). Results are representative of 4 experiments (n=6). Thr, thrombin. 
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begin to clump and form aggregates within the cell suspension, this allows more light to pass 
through the sample and thus can be observed as a reduced absorbance of the sample. 
A 15-minute pre-incubation of platelets in the presence of collagen hydrogel alone or TEBV 
triggered no change in the basal absorbance readings of the samples– in line with neither of these 
samples being able to trigger platelet activation by themselves (Figure 4.2A, 0 minutes prior to 
thrombin stimulation). However, upon stimulation of samples with thrombin, aggregation could be 
observed in both samples, although this was found to be significantly slower in samples exposed to 
the TEBV at the end of the reading (75.1 ±34.3% of control; P < 0.05; n = 10) – which demonstrates 
that TEBV possesses the anti-aggregatory effects of the native blood vessel. In contrast, after pre-
incubation with the TEML it was possible to observe a significant reduction in the basal absorbance 
reading prior to thrombin stimulation (63.6 ±24.3 % of control; P < 0.05; n = 10). In addition, the 
percentage platelet aggregation was found to be more extensive at the end of the experiment 
(146.5 ±84.1 % of control; P < 0.05; n = 8). This was consistent with our other findings that TEML 
exposure caused platelet activation.   
To further assess whether the TEBV was able to inhibit platelet function, further experiments using 
a conventional aggregometer were performed to assess the effect of preincubation with the blood 
vessel constructs on platelet aggregation. In these experiments aggregation is monitored by light 
transmittance. Upon platelet stimulation, this is typically a biphasic response in which an initial 
decrease in light transmittance caused by the platelet shape from a discoid to spherical form, 
followed by a secondary rapid increase in light transmittance, as the aggregated platelets are lost 
from the normal light path. As can be seen in Figure 4.2B, platelets exposed to the TEML showed a 
slow aggregatory response prior to thrombin stimulation – indicating that these cells were already 
subject to low-level activation prior to the addition of thrombin. After thrombin addition, the TEML-
exposed platelets undergo a rapid aggregation without notable shape change response, which 
provides further evidence of their prior activation. At the end of the experiment, the TEML 
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construct shows a significantly higher average percentage of maximum aggregation compared with 
the collagen hydrogel (154.6 ±15.6 % of control; P < 0.05; n = 4). These data are consistent with the 
Ca2+ signalling studies, and suggest that the TEML is a pro-aggregatory surface. In contrast, platelets 
exposed to the TEBV show no significant aggregatory response prior to stimulation and upon 
thrombin addition there is no notable aggregatory response following the initial shape change 
response of platelets. When compared with the collagen hydrogel, the TEBV significantly inhibits 
platelet aggregation with an average maximum percentage of aggregation of 6.15 ±6.15% of 
control; P < 0.05; n = 4. 
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Figure 4.2 – Shows absorbance aggregation traces of platelets formerly incubated with tissue-
engineered constructs. Platelets were incubated with hydrogel alone, TEML or TEBV constructs for 
15 minutes, with dynamic stirring at 37˚C; A) Absorbance measured using a plate reader.  B) 
Percentage aggregation measured using an aggregometer.  A baseline value was obtained at 0 
minutes, post construct incubation and prior to thrombin stimulation. Results are representative 
of 6 and 3 experiments, respectively.  
 
A 
B 
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3.3 Exposure to the TEML triggers platelet dense granule secretion, whilst pre-
incubation with the TEBV inhibits this parameter 
Another commonly used assay is to assess agonist-evoked secretion of platelet dense granules (a 
key step in thrombus formation) by measuring ATP released into the extracellular medium. This 
experiment uses the firefly luciferin-luciferase reagent to produce a light output proportional to the 
ATP concentration in the extracellular medium from platelet preparations (reaction is shown 
below).  
ATP + D-luciferin + O2 → AMP + PPi + oxyluciferin + CO2 + light 
The luminescence is measured on a plate reader to assay either relative or absolute ATP release. 
Platelets exposed to TEML construct display a significantly higher absolute increase of ATP secretion 
at baseline when compared to platelets exposed to TEBV or collagen hydrogel (140.8 ±23.3 RLU; 
Figure 4.3A; P < 0.05; n = 6).  This indicates a greater amount of ATP being secreted by these 
platelets which in turn binds to the readily available luciferin, yielding a high luminescence. 
Interestingly, this signified that exposure to TEML constructs triggers platelets secretion of ATP-
containing dense granules prior to stimulation with thrombin, suggesting that the TEML constructs 
acting as an agonist. Whereas platelets exposed to TEBV or collagen hydrogel show a significantly 
reduced baseline when compared with those incubated with TEML constructs (60.2 ±6.6 RLU and 
70.7 ± 7.2 RLU, respectively; P < 0.05; n = 6). This result suggests that TEBV constructs inhibits ATP 
secretion from platelets pre-exposed to it.   
To confirm this finding, the thrombin-evoked ATP secretion was assessed from both TEBV- and 
hydrogel-exposed platelets.  For internal standardisation, a known amount of ATP was added at the 
end of the assay to measure a maximal response to ATP to compensate for any variation of firefly 
luciferase activity between samples to ensure these data represented differences in ATP secretion 
and not changes in the maximal luciferase light production potential. This percentage was 
calculated as shown below:   
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𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑜𝑓 𝑚𝑎𝑥𝑖𝑚𝑢𝑚 =
𝑃𝑜𝑠𝑡 𝑡ℎ𝑟𝑜𝑚𝑏𝑖𝑛 𝑠𝑡𝑖𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 − 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝑙𝑢𝑚𝑖𝑛𝑒𝑠𝑐𝑒𝑛𝑐𝑒 − 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 
𝑥 100 
As shown in Figure 4.3B, platelets exposed to the TEBV constructs display a significant reduction in 
thrombin-evoked ATP secretion when compared with those exposed the collagen hydrogel (0.4 % 
and 1.4 % of maximum, respectively; P < 0.05; n = 6). This result suggests that the TEBV construct 
releases anti-aggregatory factors that opposes the stimulatory effect of thrombin. 
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A 
B 
Figure 4.3 – ATP secretion of platelets incubated with tissue-engineered constructs. A) Absolute 
increase in luminescence of platelets incubated with either TEBV, collagen or TEML constructs, 
prior to thrombin stimulation. B) Percentage of maximum of platelets incubated with either TEBV, 
or collagen, post 0.2 U/mL thrombin stimulation. Constructs were incubated with either TEBV, 
collagen or TEML constructs for 15 minutes, with dynamic stirring at 37˚C. The constructs were 
removed and luminescence of the remaining platelets were measured using Luciferin-Luciferase 
assay. The absolute luminescence reading was recorded as baseline prior to thrombin stimulation. 
Followed by calculating the percentage of maximum ATP secretion upon 0.2 U/mL thrombin 
stimulation. Results are representative of 3 experiments (n=6). * P < 0.05. 
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3.4 Fluorescent imaging of the surface of the blood vessel constructs after incubation 
with fluorescently-labelled platelets confirms the pro-aggregatory capacity of the TEML 
and the anti-aggregatory capacity of the TEBV 
To further assess the effect the thrombogenic properties of the acellular type I collagen hydrogel, 
TEML and TEBV, fluorescent imagining experiments were performed to assess thrombus formation 
on their surfaces. Washed DiOC6-labelled platelet suspensions were allowed to interact with the 
acellular type I collagen hydrogel, TEML or TEBV constructs for 15 minutes at 37C.  These samples 
were then washed and subject to fluorescent imaging. These experiments found that type I collagen 
hydrogel alone could only sporadic platelet adhesion on is surface, with no obvious signs of any 
platelet aggregates forming (Figure 4.4 A, B). These data are consistent with our previous findings 
that the type I collagen hydrogel is relatively inert to human platelets. In contrast, the inclusion of 
human coronary artery smooth cells within the TEML construct was found to support platelet 
adhesion as well as supporting the formation of some platelet aggregates (Figure 4.4 C, D). This is 
consistent with our real-time monitoring of platelet activation, and suggests that our TEML had pro-
aggregatory properties that allow it to provide a valid replica of the subendothelial matrix upon 
which to study platelet activation. Lastly, the TEBV construct was found to be very resistant to 
platelet aggregation, however a few individual platelets could occasionally be observed to adhere 
to regions where HUVEC monolayer did not cover the medial layer (Figure 4.4 E, F). These areas 
could be identified by DiOC6 fluorescence leaching from platelet suspension onto HUVECs, allowing 
to their identification for this fluorescent membrane label. Due to DiOC6 being a non-specific 
fluorescent dye for cell membranes, the endothelial cells were also found to be labelled as excess 
dye from the platelet suspension appear to be associated with the nucleated endothelial cells under 
the fluorescence microscope. This labelling of the endothelial cells allowed identification of areas 
in which the HUVEC monolayer was incomplete. The average size of aggregates was quantified and 
TEML constructs generated a significant average number of platelet aggregates per 100 µm2 
compared with the TEBV (20 ±1.4 and 2 ±0.5; P < 0.05, respectively). There were no platelet 
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aggregates present on the collagen hydrogel alone, post platelet incubation period. These data 
therefore confirm the findings of our real-time monitoring system that the TEBV provides an anti-
aggregatory surface, and supports the validity of the TEBV as a potential replica of the intact native 
blood vessel.  However further work will be required to optimise the HUVEC coverage of the luminal 
surface to prevent unwanted artefacts.   
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Figure 4.4 – Optical images of acellular collagen hydrogel, TEML and TEBV constructs after 
exposure to platelets. DiOC6 labelled-human platelets suspension was incubated with type I 
collagen hydrogel (A,B), TEML (C,D) or TEBV (E,F)  for 15 minutes at 37˚C with gentle agitation of 
samples. Platelet aggregation were recorded, after the samples were washed with HBS, in 
brightfield microscope (A,C,E) and fluorescence microscope (B,D,F). Results presented are 
representative of 4 experiments. Scale bar = 50 μm. 
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3.5 The pro-aggregatory properties of HCASMCs do not appear to be due to the release 
of a soluble agonist 
The analysis of the pro-aggregatory properties of the blood vessel constructs indicated that the 
presence of HCASMCs increased their pro-aggregatory properties. The HCASMCs may be able to 
provide a pro-aggregatory property either through release of a soluble agonist or production of an 
adhesive ligand which triggers platelet activation.  To assess whether a soluble agonist was released 
by the HCASMCs, experiments were performed to assess if conditioned media from these cells 
could trigger platelet activation. As platelet activation is dependent on rises in cytosolic Ca2+ 
concentration, changes in this parameter was monitored in Fura-2-loaded platelets exposed to 
conditioned culture media from TEML constructs.  A concentrated suspension of Fura-2-loaded 
platelets (4 x 108 cells/mL) was mixed with an equal volume of either conditioned cultured media, 
basal media supplemented with growth factors which had not been used for cell culture, or HBS. 
HBS addition was used in these studies to assess the impact on the fluorescence of cell dilution. As 
can be seen in Figure 4.5, the dilution of the platelet suspension created a small but consistent 
artefactual drop in the basal fluorescent signals seen in all conditions. Interestingly, when basal 
media was added to the cells, a small, transient Ca2+ signal was observed suggesting that the growth 
factors in the media may have a small stimulatory effect on the cells. However when the 
conditioned culture media collected from the TEML construct was added to the platelet suspension 
it appeared to elicit no discernible increase in the [Ca2+]cyt compared to the HBS control over the 
course of the monitoring period.  These data therefore suggest that a soluble agonist released from 
the HCASMCs was responsible for its pro-aggregatory properties. The growth factors used in the 
basal media may not be accessible after binding to the target cells, thus explaining why there is no 
effect on cytosolic Ca2+ concentration observed in this experimental condition.  
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3.6 Collagen morphology assessment 
As no evidence could be found for a soluble agonist being secreted from the HCASMCs, experiments 
were performed to assess if these cells could affect the thrombogenicity of the constructs by 
altering the structure of the collagen hydrogel. Previous studies have demonstrated that fibrillary 
collagen is more able to support platelet adhesion and aggregation than monomeric forms 
(Farndale, 2009), therefore Reflectance confocal microscopy was utilised to examine whether the 
presence of HCASMC within the TEML  could alter the collagen fibril morphology  compared to that 
observed in the type I collagen hydrogel. As shown in Figure 4.6, distinct architectural differences 
could be observed in the TEML compared to the type I collagen hydrogel. The collagen fibrils 
observed in the type I collagen hydrogel exhibited a larger diameter (244.4 ±56.3 % of control; P < 
0.05; n = 3) and a greater degree of shorter fibrils (40.6 ±16.9% of control; P < 0.05; n = 3) compared 
to hydrogels in which HCASMCs were cultured. Additionally, fibrils of the TEML construct appeared 
Figure 4.5 – Real-time measurements of cytosolic calcium concentration [Ca2+]cyt in 
platelet suspension exposed to various culture media. M231 basal media, M231 
culture media or HBS solutions were added to fura-2-loaded human platelets at 37˚C 
and measured for 6 minutes. Results are representative of 3 experiments. 
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more densely packed compared to those of the hydrogels without HCASMCs. These data therefore 
suggested that the HCASMCs may be altering the structure of the collagen in our constructs. 
 
 
Further examination of the TEML using scanning electron microscopy found that the HCASMCs 
appeared to have created a dense mesh of fibrils could be seen to be extending from the surface 
of the cell in an organised manner (Figure 4.7). This pericellular matrix of highly-arranged collagen 
fibrils emerging from the cells exhibited a different morphology in comparison to the fibrils of the 
type I collagen scaffold observed further away from the cell body. This can clearly be seen around 
the cell, where extensions of organised collagen fibrils merging with the cell membrane. These 
native collagen fibrils emerging from the cells appear to be denser compared with the surrounding 
collagen scaffold. The figure also shows a breakage of the cellular lamellipodia which was an 
Figure 4.6 – Collagen fibrillar morphology in acellular collagen hydrogel and TEML. Confocal 
reflection images of acellular collagen hydrogel (A) and TEML construct (B) cultured for 10 days. Scale 
bar = 10μm. (C) SEM image of the same TEML sample. Scale bar 50 μm. Results are representative of 
5 experiments.  
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artefact created by the cell damage elicited by the standard critical point drying procedure required 
for sample preparation for the electron microscope.  
To further examine this difference in collagen structure, the TEML constructs and collagen hydrogel 
were examined by confocal microscopy after being labelled with a fluorescently-tagged antibody 
to type I or type III human collagens.  Due to the use of rat tail collagen in the type I hydrogel, the 
species specificity of these antibodies should allow the identification of neo-collagen forms 
produced by the HCASMCs. Whilst there was no binding of the antibody to the collagen hydrogel 
alone, there was a strong fluorescence found to occur around the HCASMCs within the hydrogel for 
both type I and type III collagen (Figure 4.8). Highly fluorescent thin fibrils extending from the cells 
are visible appearing for both types of collagen, some of which are away from the nucleus. 
Suggesting that collagen is being released from the cell. These secreted neo-collagens formed into 
a pericellular matrix around HCASMCs within the TEML layer. These data therefore suggest that 
neo-collagen secreted by the HCASMCs is likely to be responsible for the pro-aggregatory effects of 
these cells when included within our tissue-engineered blood vessel constructs (section (1.4.1.1).  
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Figure 4.7 – Immunostaining of types I and III collagen within the TEML samples. Primary-free 
control (A-C); type I collagen in TEML sample cultured for 10 days (D-F); type III collagen in TEML 
sample cultured for 10 days (G-I). The results presented are representative of 4 experiments. Scale 
bar 50 μm. Blue = DAPI; Green = Collagen 
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Figure 4.8 – TM3000 SEM images demonstrating the topography of collagen fibres emerging from 
HCASMCs seeded within rat tail type I collagen. HCASMCs were cultured for 10 days in type I collagen 
(A, B). Collagen hydrogel without HCASMCs (C).Self-assembly of the collagen matrix was conducted 
at collagen concentrations of 3 mg/mL with HCASMCs and then subjected to critical point drying to 
preserve ultrastructure and surface structure of the cells.  
 
A 
B 
C 
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3.7 Coating the PLA nanofibers with native Horm collagen increases the thrombogenic 
potential of the collagen hydrogels 
To assess if an increase of an intact collagen on the surface of the construct was able to enhance 
the thrombogenicity of our collagen hydrogels in a similar manner to the inclusion of HCASMCs, 
experiments were performed to assess the impact of including of native type I collagen from equine 
tendons (Horm collagen) on the surface of our construct.  To do this we compared the effect of 
adding PLA nanofibers with and without Horm collagen coating on top of our collagen hydrogel.  As 
can be seen in Figure 4.9, the exposure of Horm collagen-coated nanofibers does not cause a 
significant increase in [Ca2+]cyt in platelets exposed to these constructs compared with those 
incubated with the uncoated nanofiber sample. However, platelets appeared to be sensitized to 
soluble agonists as thrombin-evoked rises in [Ca2+]cyt could be seen to be potentiated by 135.7 ± 
22.1 % of that observed in platelets exposed to the uncoated nanofibers (P < 0.05; n = 6). These 
data therefore are suggestive of collagen-activated platelets secreting autocrine messengers from 
their dense granules which are then able to potentiate the thrombin-evoked Ca2+ signal as has been 
proposed by others (Fung et al., 2012; Harper et al., 2009; Sage, Pugh, Farndale, & Harper, 2013). 
These data therefore suggest that exogenous inclusion of neo-collagen could evoke some of the 
effects of the HCASMCs.  
The discrepancy observed may be due to the restriction of collagen to the nanofibers, rather than 
all over the construct.  This reduced density of platelet binding sites might reduce the pro-
aggregatory potential of the construct, to assess this further we imaged platelet binding to the 
surface of hydrogels upon which PLA nanofibers with and without Horm collagen coating had been 
affixed. As seen in Figure 4.10, no platelet aggregation could be observed upon the uncoated PLA 
nanofibers, with only the occasional individual platelet observed binding to this structure, with 
average aggregate sizes of 2.0µm ±1.8 and 4.8µm ±2.1, 10 and 30 minutes post-agonist addition, 
respectively. In contrast, Horm collagen-coated nanofibers could be observed to have significant 
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platelet binding along the nanofibers with notable platelet aggregates and average aggregate sizes 
of 4.7µm ±1.9 and 11.0µm ±4.4, 10 minutes and 30 minutes post agonist addition, respectively. 
These data therefore confirm that inclusion of native collagen can replicate the thrombogenic effect 
on the surface of the construct. However, restriction of these aggregates to the surface of the 
nanofibers may prevent the activated platelets triggering as effective an autocrine activation of 
platelets in the underlying suspension. 
 
 
 
 
Figure 4.9 -Real-time measurements of cytosolic calcium concentration [Ca2+]cyt in platelet 
suspension exposed to acellular collagen hydrogel and Horm-collagen coated nanofibers. 
Fura-2-loaded human platelets were exposed to the coated or uncoated nanofibers supported 
with collagen hydrogel for 7 minutes at 37˚C, then the samples were removed and the [Ca2+]cyt 
in the remaining suspension was recorded and stimulated with 0.2 U/mL thrombin, to confirm 
platelet responsiveness. Arrows show Ca2+, construct and thrombin (Thr) additions, 
respectively. Thrombin was added post-construct removal. Horm collagen Results are 
representative of 3 experiments (n = 6).  
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Figure 4.10 - 
Fluorescent images 
of Horm collagen 
coated and uncoated 
PLA nanofibers post 
exposure to human 
platelets.  A) Baseline 
image of DiOC6 
labelled-human 
platelet suspension 
prior to start of the 
experiment. Platelets 
suspension incubated 
with uncoated 
nanofibers for 5 
minutes (B-D), 10 
minutes (H-J) and 20 
minutes (O) at 37˚C 
with gentle agitation 
of samples; Platelets 
suspension incubated 
with immobilised 
collagen uncoated 
nanofibers for 5 
minutes (E-G), 10 
minutes (K-M) and 20 
minutes (N) at 37˚C 
with gentle agitation 
of samples. Results 
presented are 
representative of 4 
experiments (n = 4). 
Scale bar = 50 μm. 
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3.8 Horm collagen nanofibers do not reduce the anti-aggregatory properties of the TEBV 
The earlier experiments demonstrated that the TEIL constructs could inhibit platelet activation 
more than TEBV.  It was possible this might be due to an inhibitory effect of the neo-collagen on 
the HUVECs placed atop this layer. Experiments were therefore performed to examine if inclusion 
of native collagen can affect the inhibitory potential of the TEBV. Figure 4.11 shows Fura-2 ratio of 
platelets exposed of platelets to TEBV constructs incorporating fibronectin-coated or dually 
fibronectin- and Horm collagen-coated PLA nanofibers within TEBVs.  These data show that there 
was no significant difference before or after thrombin stimulation in the fura-2 ratio of platelets 
exposed to TEBVs with the Horm collagen-coated compared to those without it (115.2 ± 42.1% of 
control; n = 3; P > 0.05). Thus, native collagen does not appear to impact on the inhibitory potential 
of the HUVECs.  In addition, there is no additional pro-aggregatory effect of inclusion of this native 
collagen within the construct, as it is likely that platelets do not encounter this due to the 
endothelial cell coverage of the nanofibers.  
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3.9 Assessment of endothelial cell layer of the TEBV construct 
3.9.1 Evaluation of the role of endothelial-derived inhibitors on anti-aggregatory 
properties of TEBV 
Our data demonstrates that the TEBV possesses a significant anti-aggregatory property. In vivo it is 
though that endothelial-derived inhibitors such as NO, PGI2 and adenosine play a key role in keeping 
platelet quiescent inside the intact vasculature (Rumbaut, 2010). Therefore, experiments were 
performed to assess if the anti-aggregatory properties of the TEBV could be reversed by blocking 
the production of these endothelial-derived platelet inhibitors. Initial experiments examined the 
effect of inhibiting endothelial NOS by pre-treating the TEBV with L-NAME. These data showed that 
there was no difference in thrombin-evoked rises in [Ca2+]cyt of platelet samples after incubation 
Figure 4.11 – Real-time measurements of 380/340 Fura-2 ratio in platelet suspension exposed to 
Horm collagen-coated PLA nanofibers within tissue-engineered vessel constructs. Fura-2 loaded 
human platelets suspension was incubated in contact with fibronectin coated or dually Horm collagen 
and fibronectin-coated PLA nanofibers of TEBV constructs for 15 minutes at 37˚C off-screen. The 
constructs were then removed and the remaining suspension was stimulated with thrombin (0.2 
U/mL). Results are representative of 3 experiments (n=3). Thr, thrombin. 
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with TEBVs treated with L-NAME to untreated TEBVs (Figure 4.12; 135.0 ± 52.3 % of untreated 
control; n = 9; P < 0.05). These data therefore indicated that NO from the TEBV may not be solely 
responsible for the inhibitory effect on platelet function.  
3.9.1.1  Combination of L-NAME and indomethacin  
As endothelial cells also produce prostacyclin using a COX-mediated pathway (Caughey et al., 2001), 
inhibition of NOS may not be sufficient to prevent the effect of the TEBV as there may be 
redundancy with either compound able to inhibit platelet function in the absence of the other. 
Therefore, experiments were performed to examine the effect of pre-incubating the TEBV with 
either 1 mM L-NAME, 300 µM indomethacin (a COX inhibitor), or a cocktail of both drugs. Either 
compounds or their vehicles were incubated with fabricated TEBV construct for 30 minutes in 
standard culture conditions. Following the incubation period, the sample was washed and placed 
atop of a 1.2 mL of platelet suspension for 15 minutes at 37°C with continuous magnetic stirring. 
The TEBV construct was then removed and platelets’ [Ca2+]cyt was recorded  from the Fura-2-loaded 
platelet suspensions. Consistent with our previous data, preincubation with the untreated TEBV 
reduced thrombin-evoked signals to 24.0 ± 11.3% of that seen in the collagen hydrogel control 
sample (Figure 4.12A; n = 8; P < 0.05).  Preincubation of the construct with L-NAME alone (18.1 ± 
5.6% of control; n = 8; P < 0.05), indomethacin alone (13.9 ± 1.4% of control; n = 8; P < 0.05), or 
both compounds simultaneously (17.2 ± 3.2% of control; n = 8; P < 0.05). These data demonstrate 
that these interventions did not reverse the effect of exposure to the TEBV. These results were very 
surprising as NO and PGI2 are the classic endothelial-derived inhibitors of platelet function 
(Banerjee et al., 2014; Menitove et al., 1984).  
3.9.1.2 Treatment of the TEBV with L-NAME cannot reverse the inhibitory effect of 
this construct on platelet store-operated calcium entry 
Endothelial cells are known to secrete a variety of proteins that interfere with the blood coagulation 
cascade.  This includes thrombomodulin which is known to bind and restrain the activity of 
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thrombin (Esmon et al., 1982). Although this is an integral membrane protein, it can be released 
from cultured endothelial cells under conditions of inflammation or cell damage (Boehme et al., 
2000; Ishii et al., 1991). Therefore, to ensure the inhibitory effect of TEBV incubation on platelet 
activation was not due to blockade of thrombin activity, experiments were performed to examine 
the effect of TEBV on an artificially-induced platelet Ca2+ signalling pathway. Store-operated Ca2+ 
entry (SOCE) is the major Ca2+ entry mechanism in human platelets (Gresele et al., 2017). This entry 
pathway is activated by depletion of the intracellular dense tubular Ca2+ stores. This can be 
artificially achieved using the sarco/endoplasmic reticulum Ca²⁺-ATPasa (SERCA) inhibitor, 
thapsigargin. This allows passive leak of Ca2+ out of the stores triggering the activation of the store-
operated channel (Tao and Haynes, 1992). Therefore, experiments were performed to assess the 
impact of TEBV preincubation on thapsigargin-evoked Ca2+ release from intracellular stores, as well 
as the effect on store-operated Ca2+ entry both in the presence and absence of antagonists of the 
endothelial-derived inhibitors, NO and PGI2. Thapsigargin-mediated depletion of the intracellular 
stores was unaffected by TEBV compared with the collagen control (Figure 4.12B; 202.8 ± 76.9 % of 
control; n = 9; P > 0.05). This effect was not altered in samples exposed to TEBV treated with 1 mM 
L-NAME and 300 µM indomethacin (122.5 ± 14.2 % of control; n = 9; P > 0.05). These data therefore 
suggest that there is no difference in the filling state of the dense tubular stores for both untreated 
platelets and those that were treated with L-NAME and indomethacin. Upon re-addition of Ca2+ to 
the extracellular medium to trigger store-operated Ca2+ entry, it could be observed that 
preincubation with the TEBV significantly inhibits SOCE compared to that seen in cells incubated 
with the control collagen hydrogel (70.3 ±9.1 of control; n = 7; P < 0.05). This inhibitory effect was 
not reversed by preincubation of the TEBV with L-NAME and indomethacin (60.0 ± 8.0 of control; n 
= 7; P < 0.05).  These data therefore suggest that the effect on thrombin-evoked Ca2+ signalling is 
not solely due to an effect of TEBV on downregulating thrombin activity, but is due to an alteration 
in the intracellular signalling pathways of the platelet.  
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Figure 4.12 – Cytosolic calcium concentration [Ca2+]cyt measurement in platelet suspension 
exposed to tissue-engineered blood vessel constructs with and without L-NAME and 
Indomethacin. Fura-2 loaded human platelets suspension was incubated in contact with hydrogel 
alone and TEBV constructs with and without L-NAME (1 mM) and Indomethacin (300 µM) for 15 
minutes at 37˚C off-screen. The constructs were then removed and the remaining suspension was 
stimulated with 0.2 U/mL thrombin (A) and Ca2+ (B). EGTA (1 mM) was added 60 s after the start of 
recording, followed by 1 µM thapsigargin (TG) prior to 1 mM Ca2+ addition. Results are 
representative of 3 experiments. Thr, thrombin; L-NAME, NG-nitro-L-arginine methyl ester; Indo, 
indomethacin. 
 
A 
B 
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3.9.1.3 The TEBV releases a non-PGI2, non-NO inhibitor of platelet activation 
The previous results suggest that a non-classical inhibitor of platelets is produced by the TEBV.  
However, to confirm this finding it was important to rule out unexpected pharmacological issues.  
In particular, L-NAME is a reversible inhibitor of NOS – therefore transfer of the TEBV into a platelet 
solution without L-NAME may allow the re-establishment of NO production during the incubation. 
In addition, there was a previous publication describing L-NAME as an inactive pro-drug (Pfeiffer et 
al., 1996). Therefore, it is possible that our pharmacological interventions were not successful in 
preventing NO production. Hence, experiments were performed to assess if the use of a cocktail of 
a competitive inhibitor of NOS, L-NMMA, and an irreversible inhibitor, L-NIO, could reverse this 
effect. As shown in Figure 4.13A, platelets exposed to the untreated TEBV sample show a significant 
inhibition of thrombin-evoked rise in [Ca2+]cyt compared to the collagen hydrogel (24.0 ± 11.3% of 
control; n = 8; P < 0.05). Pretreatment of the TEBV with high concentrations of both L-NIO and L-
NMMA still maintained a significant platelet inhibition (33.8 ±4.5% of control; n=6; P < 0.05). 
However, this showed a significant difference compared with the untreated TEBV construct (172.5 
±39.5% of control; n=6; P < 0.05). This suggests that a partial reversal of the TEBV mediated 
inhibition can be achieved by the NOS inhibitors L-NMMA and L-NIO. 
Indomethacin is considered to be a relatively non-selective inhibitor of COX-1 and COX-2, however 
there is a greater potency for COX-1 (Mitchell et al., 1993).  Although controversial, there is some 
evidence that COX-2 may be an important mediator of PGI2 production in humans (McAdam et al., 
1999). Therefore, we considered whether remnant COX-2 activity might be responsible for this 
inhibitory effect. To confirm the presence of a non-PGI2, non-NO inhibitor of platelet activation we 
therefore pre-treated our construct with a cocktail of inhibitors of PGI2 and NO production including 
NS398, a selective COX-2 inhibitor. The TEBV constructs were preincubated with (L-NMMA, L-NIO, 
NS398 and Indomethacin for 1 hour at 37°C. The sample was then washed and incubated with 
washed platelets for 15 minutes. The construct was removed and the [Ca2+]cyt was measured from 
the remaining platelet suspension. As shown in Figure 4.15B, platelets exposed to the untreated 
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TEBV sample show a significant inhibition of thrombin-evoked rise in [Ca2+]cyt compared to the 
collagen hydrogel (20.6 ±6.2% of control; n=6; P < 0.05). When all four inhibitors collectively, L-
NMMA, L-NIO hydrochloride, NS398 and Indomethacin, thrombin-evoked rises in [Ca2+]cyt were still 
inhibited to 25.6 ±3.6% of control ( n = 6; P < 0.05). These data indicated that the inhibitory effects 
of TEBV are mediated at least in part by a non-NO, non-PGI2 inhibitor of platelet function.  
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Figure 4.13 – Cytosolic calcium concentration [Ca2+]cyt in platelet suspension exposed to tissue-
engineered blood vessel constructs with and without a combination of NO synthase and PGI2 
inhibitors. Fura-2 loaded human platelets suspension was incubated in contact with hydrogel alone 
and TEBV constructs with and without (L-NMMA, L-NIO hydrochloride , ndomethacin  and NS398) for 
15 minutes at 37˚C off-screen. A) TEBV samples incubated with L-NMMA and L-NIO hydrochloride; B) 
TEBV samples incubated with L-NMMA, L-NIO hydrochloride, Indomethacin and NS398. The constructs 
were then removed and the remaining suspension was stimulated with thrombin (0.2 U/mL). Results 
are representative of 4 experiments. L-NMMA, NG-Monomethyl-L-arginine, monoacetate salt; L-NIO, 
L-N5-(1-Iminoethyl)ornithine; NS-398, N-[2-(Cyclohexyloxy)-4-nitrophenyl]methanesulfonamide. 
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3.9.2  Assessing the effect of inflammatory endothelial cell phenotype using induced by 
TNF-α 
3.9.2.1 Platelet adhesion 
In addition to haemostatic responses to the damaged endothelium, platelets are also known to 
modulate their function in response to inflammatory stimuli (Gawaz et al., 2005). To assess if 
triggering an inflammatory response alters platelet function in response to the TEBV, experiments 
were performed to examine the effect of inducing an inflammatory phenotype of our TEBV by 
treating it with TNF-α. Previous studies have shown that TNF-α induces changes in endothelial cell 
functions to change into a procoagulant phenotype, which in turn stimulates platelets adhesion and 
activation (Kirchhofer et al., 1994; Pircher et al., 2012; Wagner and Frenette, 2008). In addition, 
activated endothelial cells contract, increasing the distance between endothelial cells which 
increases the blood vessel permeability (Morgan BL, 2013). Activated endothelial cells also express 
proteins onto their surface that are adhesive such as ICAM-1.  Therefore it would be expected that 
exogenous application of TNF-α might increase platelet adhesion to the TEBV, as well as sensitize 
platelets in the underlying suspensions (van Buul et al., 2010).   
TNFα-treated TEBV was generated to study how platelets would react to an inflamed HUVECs. In 
this experiment, DiOC6-labelled platelets were incubated with TEBV for 15 minutes at 37°C with 
continuous magnetic stirring. Figure 4.14 shows HUVECs monolayer, TEIL and TEBV constructs 
treated with two different concentrations of TNF-α, 100 and 1000 U/mL. The baseline image shows 
individually scattered discoid shaped platelets around the sample. Alternatively, the HUVECs 
monolayer shows ubiquitous platelet aggregation regardless of TNF-α treatment and 
concentration. Untreated TEIL sample shows no platelet aggregates on its surface after incubation, 
however a large number of aggregates are observed on TEIL samples treated with high and low 
concentrations of TNF-α. A similar observation can be made on the TEBV sample except that there 
are less platelets aggregates on the low TNF-α treated TEBV construct. These findings confirm that 
TNF-α increases platelet aggregation on the surface of TEIL and TEBV constructs.   
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3.9.2.2 Measurement of [Ca2+]cyt of platelets exposed to TNFα treated TEBVs 
To further assess whether the induction of an inflammatory phenotype in our HUVECs alters 
platelet activation, experiments were performed to assess if this treatment altered the ability of 
our TEBVs to modulate platelet Ca2+ signals. Fura-2-loaded platelet samples were pre-incubated 
with TEBV constructs treated either with or without 1000 U/mL TNF-α (Figure 4.15). No difference 
could be observed in the [Ca2+]cyt in the treated and untreated TEBV constructs when they were 
incubated with Fura-2-loaded human platelet suspension for 15 minutes on-screen. Following this 
incubation period, the TEBV constructs were removed and the remaining platelet suspension was 
stimulated with 0.2 U/mL thrombin. Although there was a tendency to slightly increased thrombin-
evoked rises in [Ca2+]cyt in platelets exposed to the TNF-α-treated samples, the difference was found 
to be not statistically significant (98.3 ±19.5 % of control; n = 6;  P > 0.05). These data highlight that 
although TNF-α influences platelet adhesion to the endothelial lining of our TEBV, it does not 
significantly affect either its ability to directly or indirectly influence platelet function in the 
underlying platelet suspension. Further studies will need to examine if other inflammatory stimuli 
can independently alter the effect of our TEBV on platelets either alone or in synergy with TNF-α.  
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Figure 4.14 – Fluorescence images of TNF-α treated TEIL and TEBV constructs after exposure to 
platelets. DiOC6 labelled-human platelets suspension was incubated with HUVECs monolayer (B, 
E, H) or TEIL (C, F, I) or TEBV (D, G, J) for 15 minutes at 37˚C with gentle agitation of samples. TNF-
α was used at two different concentration 100 U/mL (E-G) and 1000 U/mL (H-J). A brightfield 
baseline (A) and untreated samples (B-D) were imaged for comparison. Platelet aggregation was 
recorded, after the samples were washed with HBS. Results presented are representative of 4 
experiments. Scale bar = 100 μm.   
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Figure 4.15 – Cytosolic calcium concentration of platelet suspension exposed to tissue-
engineered blood vessel constructs treated and untreated with TNF-α. Fura-2 loaded human 
platelets suspension was incubated in contact with TEBV constructs with and without TNFα 
(1000 U/mL) for 15 minutes at 37˚C. The constructs were then removed and the remaining 
suspension was stimulated with thrombin (0.2 U/mL). Thr, thrombin. 
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4. Discussion 
Physiologically, the endothelial cell layer acts as an inhibitor of blood clotting through preventing 
platelet interaction with the pro-thrombotic subendothelial matrix as well as producing and 
secreting a variety of anti-thrombotic molecules (e.g. NO, PGI2 and Protein C). Therefore, to create 
a functional replica of the human blood vessel, the intimal layer of the construct should possess an 
appropriate anti-aggregatory property by both acting as a physical barrier to platelet interaction 
with the subendothelium, as well as via its secretion of paracrine inhibitors of platelet function. In 
contrast, the medial layer of our construct in the absence of the endothelial lining should be able 
to replicate the pro-aggregatory properties found in vivo.  
In this chapter, experiments were performed to assess the pro- and anti-aggregatory factors arising 
from the fabricated tissue engineered constructs. By assessing platelet reactivity to the fabricated 
tissue-engineered constructs it was possible to validate the functionality of each layer. The pro- and 
anti-thrombotic properties of each of the blood vessel constructs have been assessed using the 
novel protocol established in chapter 3. These studies have demonstrated the similarity of these 
constructs to the equivalent structures found in native blood vessel, with the endothelial lining of 
the TEIL and TEBV found to strongly inhibit platelet activation, whilst the TEML was able to trigger 
platelet activation independent of further stimulation as well as potentiate thrombin-evoked Ca2+ 
signals.  As far as we know, this is the first time that the strong pro-thrombotic effect from 
underlying neo-collagen can be demonstrated to be completely suppressed by the presence of an 
endothelial layer in a 3D human blood vessel model. 
Platelet aggregometry is the most widely-used assay utilised for assessing platelet function in both 
research and clinical laboratories. Here we have used this technique to validate the results of our 
Ca2+ signalling studies. One of the notable results in this experiment is the basal absorbance of 
platelets exposed to TEML constructs is lower than that seen in collagen hydrogels prior to 
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thrombin stimulation. This indicates that some of the platelets has already aggregated in response 
to TEML exposure. Platelets exposed to the TEBV sample showed an initial higher absorbance with 
less light passing through the sample during the experiment. These opposing effects caused by 
TEML and TEBV, respectively reveals the expected ability of the TEML and TEBV to both activate or 
inhibit platelet function, consistent with the known physiological functions of the medial layer and 
intact blood vessel. Similar results were also observed using LTA, thus confirming this result through 
this well-established technique. As well as providing data on platelet aggregation, LTA is also able 
to monitor the initial discoid-to-sphere shape change as an initial rise in absorbance after agonist 
stimulation. Platelets exposed to the TEML constructs prior to observation in LTA do not show 
shape change after thrombin stimulation. This likely due to the pre-activation of these cells, by the 
neo-collagen in the TEML construct during the incubation period. In contrast, platelets exposed to 
the TEBV construct shows a prolonged shape change phase which only slowly turns into fully-
fledged platelet activation indicative of the significant inhibitory effect of the TEBV on platelet 
activation. These findings are further confirmed by the data from our luciferin-luciferase-based 
assay of platelet dense granule which demonstrate that the TEML is able to trigger ATP secretion 
without further thrombin stimulation, whilst the TEBV is able to significantly inhibit thrombin-
evoked ATP secretion.   
The above data therefore all demonstrate the TEML and TEBV fulfil their physiological function as 
pro- and anti-thrombotic layers of the blood vessel. Further assessment of the pro-aggregatory 
potential of the TEML demonstrated that this was not due to the secretion of a soluble ligand but 
was instead associated with the laying down of a pericellular matrix of type I and III collagen to 
increase the thrombogenicity of the collagen hydrogel. It is well-established that cultured smooth 
muscle cells are able to produce and secrete both type I and III collagens (Hospers et al., 1996; 
Rocnik et al., 1998), which are  key mediators of thrombus formation in vivo (Jung et al., 2012). 
Therefore, this was shown using SEM and confocal reflective images of TEML constructs verifying 
the generation of a solid form neo-collagen agonist that are possibly responsible for platelet 
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aggregation (Figures 4.6 and 4.8). These collagens represent the major collagen isoforms found 
physiologically within the native blood vessel (Lodish et al., 2000). Further analysis will be required 
to assess if other extracellular matrix components, such as elastin, can also be discovered to be 
synthesised by these cells. This work therefore suggests that alteration of the culture conditions of 
the TEML may further enhance the thrombogenicity of this layer – further research will be required 
to assess if the optimal culture conditions are being used. 
 
The anti-aggregatory properties of our TEBV are likely related to the ability of the HUVECs to secrete 
paracrine inhibitors of human platelet function. The vascular endothelium secretes NO, which 
protects the vessel wall by inhibiting platelet aggregation, secretion and adhesion (Bredt and 
Snyder, 1994). Endothelial cells also produce PGI2 which acts synergistically with NO in inhibiting 
platelet activation and opposing the pro-aggregatory properties of thromboxane A2. Therefore, 
experiments were performed to assess if blocking the production of these paracrine regulators of 
platelet function could mitigate the significant inhibitory effects of our constructs on platelet 
function.  
Although two different concentrations of L-NAME were used in an attempt to reverse the HUVECs 
inhibitory activity, both experiments were not able to demonstrate a reproducible ability to reduce 
the inhibitory effect of the TEBV on the platelet suspensions. This might be caused by two factors 
which relate to the actual drug itself or due to preparation or handling of the drug. It has been 
reported that L-NAME is an inactive prodrug which only inhibits the NOS enzyme following its 
hydrolysis to the free acid NG-nitro-L-arginine (L-NOARG) (Pfeiffer et al., 1996).  If dissolved in 
buffer at physiological pH, L-NAME was non-enzymatically hydrolysed to LNOARG with a half-life of 
6 hours at room temperature (Pfeiffer et al., 1996).The enzyme kinetic characterization of the 
inhibition of eNOS by L-NOARG revealed a reversible inactivation of the enzyme (Mayer et al., 
1993). Therefore, it is possible that L-NAME was in an inactive form during the experiment. L-NAME 
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has also been shown to have a direct effect on platelets that will interfere with platelets ability to 
aggregate due to blocking platelet NOS enzyme (Banerjee et al., 2014). As L-NAME treated TEBV 
samples were washed prior to incubation with platelets to ensure cell culture media or L-NAME 
was not transferred into the platelet suspension, this may have caused the reversal of NOS 
inhibition by L-NAME. This could significantly confound our analysis, so alternative methods to 
inhibit NOS were investigated. The use of irreversible inhibitors of NOS, L-NMMA and the potent 
NOS inhibitor, L-NIO, did partially reverse the inhibitory effect of the TEBV on platelets exposed to 
it. However, when these NOS inhibitors were combined with PGI2 synthesis inhibitors 
(Indomethacin and NS398), the inhibitory effect mediated by TEBV construct on platelets was 
apparently lost.  
Although a minor reversal of HUVECs inhibition of platelet was achieved, there is a still a 
signification inhibition of platelet function mediated by TEBVs treated with the cocktail of inhibitors. 
This suggests that there are other mechanisms that may also be working to block platelet function 
in a non-NO-, non-PGI2-dependent manner. One possible mechanism is EC-mediated production of 
14,15-epoxyeicodatrienoic acid which has previously been shown to inhibit platelet aggregation 
(Heizer et al., 1991). Other possible methods may also involve adenosine production by the ecto-
adenosine diphosphatase (ADPase) found in the plasma membrane of ECs. Its anti-platelet effect 
occurs via metabolising ADP, which is a potent stimulator of platelet aggregation, into the potent 
platelet inhibitor, adenosine (Marcus et al., 2005). This molecule is known to indirectly inhibit 
platelets aggregation in a manner distinct from NO and PGI2. However further experiments will 
need to be conducted to understand and rule out the remaining platelet inhibition elicited by our 
NOS- and COX-inhibited TEBVs. 
4.1. Conclusion 
In summary, we have shown that the endothelial lining of the previously fabricated TEBV construct 
possess an anti-aggregatory characteristic. Investigation of these anti-aggregatory mediators using 
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NO and PGI2 inhibitors revealed that additional mechanisms may also be responsible for mediating 
the inhibitory effect of our constructs on platelet function. In contrast, the previously fabricated 
TEML construct was shown to provoke a pro-aggregatory appearance on the surface of the 
construct caused by the neo-collagen generated by HCASMCs within the constructs. These results 
therefore suggest that our constructs possess anti- and pro-aggregatory properties of native blood 
vessels, however the molecular mechanisms by which the anti-aggregatory properties of our TEBV 
are produced may still be distinct. Therefore, further experiments will be required to investigate 
how this is elicited, and to characterise the efficacy of this mediator in the ability of native blood 
vessels to inhibit platelet function. 
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Chapter 5 
Using tissue-engineered 
blood vessel constructs to 
recreate a ferric chloride 
arterial thrombosis model 
in vitro 
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1. Introduction 
Ferric chloride (FeCl3) induced vascular injury is the most commonly used in vivo model of arterial 
thrombosis (Bonnard and Hagemeyer, 2015). In this model, FeCl3 is applied to the outer surface of 
an intact vessel, triggering vascular wall injury and denudation of the endothelium (W. Li et al., 
2010).  FeCl3 causes vascular damage through triggering the generation of free radicals, which leads 
to lipid peroxidation and destruction of endothelial cells. This in turn triggers activation of 
circulating platelets and components of the coagulation cascade, which can then be monitored by 
intravital microscopy (Chen et al., 2011). This model has most commonly been performed on 
carotid and femoral arteries and venules in mice and rats, although other species such as guinea 
pigs and rabbits have also been used (Bonnard and Hagemeyer, 2015; Kurz et al., 1990; W. Li et al., 
2013). However, FeCl3 is not the only injury model with other methods of inducing vascular injuries 
have also been used to trigger arterial thrombosis, such as those triggered by laser, photochemical 
damage or mechanical abrasion (Rosen et al., 2001). 
Although the application of these models in mice has significantly furthered our understanding of 
how thrombus and thrombosis formation may occur in vivo, there are potential limitations that 
could affect the interpretation of the data obtained. The first of which is the difference in clotting 
response seen between different injury models. For example, thrombosis in FeCl3 model being 
primarily dependent upon collagen signalling, whereas the laser injury model relies mostly on 
thrombin signalling (Furie and Furie, 2007). In addition, the FeCl3 model leads to variable clotting 
responses between labs, such that better standardisation of this technique is required to help 
ensure reproducibility (Owens et al., 2011). For example, the time from injury to complete vessel 
occlusion can range from 5 and 30 minutes after the FeCl3 application in different studies in mice. 
Analysis of these data have suggested that there are number of variables that may account for the 
difference in the thrombotic response observed in this model such as FeCl3 concentration applied, 
method of anaesthesia, surgical technique, mouse age and genomic background, method of 
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measuring blood flow, as well as other environmental variables (W. Li et al., 2013). In addition, the 
effects of FeCl3 vary based on the vessel to which it is applied. For example, in a study in mice lacking 
the extracellular domain of glycoprotein Ibα (GPIbα), the FeCl3 injury model results in occlusion of 
mesenteric venules but not in the carotid artery (Ciciliano et al., 2015). This wide variability makes 
it very difficult to compare studies from different groups and may make detection of subtle 
differences difficult. 
Furthermore, given there is significant variation in these arterial thrombosis models observed 
between different mice strains (Westrick et al., 2007), there must be a question raised over whether 
results obtained from these animal models are indicative of the response seen in humans. Whilst 
there are similarities in the basis haemostatic processes between mice and human, there are also 
a number of differences including variations in blood haemodynamics (Weinberg & Ross Ethier, 
2007),  as well as differences in the mRNA and protein expression between human and mice 
platelets (Janssen et al., 2004). These factors should be considered before attempting to apply 
results obtained from in vivo mouse models to human clotting pathways. Therefore, an ex vivo 
human arterial thrombosis model is required to complement the work performed in vivo models to 
better understand mechanisms of in vivo in thrombus formation in humans.  
Lastly, these in vivo experiments require the use of general anaesthesia which could interfere with 
the normal clotting responses observed. A previous survey of investigators performing intravital 
microscopy found that ketamine, xylazine and pentobarbital are the most common anaesthetics 
used to undertake the surgery (Janssen et al., 2004). However other studies have demonstrated 
that each of these anaesthetics can have an inhibitory effect on platelet function (Chang et al., 
2004; Janssen et al., 2004; Nakagawa et al., 2002; Undar et al., 2004). Previous studies have 
reported that ketamine inhibited platelet aggregation through suppression of IP3 formation 
(Nakagawa et al., 2002) as well as by inhibiting thromboxane synthase activity (Atkinson et al., 
1985). Further research has also shown that ketamine can also interfere with endothelial NO 
 156 
 
production (Ogawa et al., 2001), as well as smooth muscle Ca2+ signalling (Akata et al., 2001), thus 
suggesting this drug could have multifactorial effects on the normal biology of blood vessels. 
Therefore, the potential ability to conduct an ex vivo assessment of whether inclusion of general 
anaesthetics with ketamine might artificially alter the types of thrombotic response in vivo. If this 
is found, it may question the potential physiological relevance of studies on the effectiveness of 
drugs and platelet-specific gene knockouts on normal haemostatic responses. Hence, this chapter 
aims to establish an alternative to intravital microscopy using ferric chloride and assess the effect 
of ketamine anaesthetic on the TEBV responses to platelets.   
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2. Methods 
2.1. TEML and TEBV constructs fabrication for spectrophotometer-based experiments  
To prepare TEML constructs, HCASMCs were mixed at a density of 5 x 105/mL into a neutralised 
solution of 3 mg/mL type I collagen obtained from BD biosciences, according to the manufacturer’s 
protocol. 0.2 mL of the mixture was then loaded onto a 1 cm2 square shaped filter paper frame, and 
the collagen-cell mixture was left to set for 40 minutes at 37˚C, 5% CO2. The formed gel was then 
covered with supplemented medium and with changing the media every 2 days. HCASMCs were 
subsequently allowed to grow in the TEML until they were observed to possess an elongated 
spindle-shaped morphology for up to 10 days.  
TEBV construct was fabricated by placing a PLA nanofiber mesh coated with a 10 ng/mL fibronectin 
solution on the 3D TEML, to create the initial layer of the luminal surface. After successful 
attachment of the nanofibers to the TEML hydrogel, 4 x 104/cm2 of HUVECs were then seeded on 
top of the nanofibers to create a full TEBV construct. The TEBV constructed was covered with 
supplemented medium 200 and medium 231 (7:3) and with changing the media every 2 days. The 
TEBV construct was cultured for further 4 days after HUVECs attachment.  
2.2 Platelet preparation 
Human platelets obtained using the standard method of extraction described in chapter 3, however 
platelets were labelled with DiOC6 to allow us to examine platelet adhesion and aggregation on the 
surface of the construct aggregation when exposed to the tissue-engineered blood vessel construct 
both under static or flow conditions. Blood was obtained by venepuncture from healthy volunteers 
who had given informed written consent. 5 mL of blood was mixed with 1 mL ACD anticoagulant 
(85 mM sodium citrate, 78 mM citric acid and 111 mM d-glucose). The ACD contained DiOC6 to 
provide a final concentration of 1 µM. The blood was mixed with anticoagulant and dye, and left to 
incubate for 10 minutes at room. PRP was then obtained by centrifuging at 1500 g for 8 minutes. 
The collected PRP was then treated with 100 μM aspirin and 0.1 U/mL apyrase.  In some 
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experiments, the samples were labelled with Fura-2 by preincubating the PRP with 2.5 µM Fura-
2/AM for 45 minutes at 37°C.  The PRP was then washed by centrifugation at 350 g for 20 minutes. 
The collected platelet pellet was then re-suspended into supplemented HEPES –Buffered Saline 
(HBS) to a final cell density of 2x108 cells/mL.  To make supplemented HBS, HBS (pH 7.4, 145 mM 
NaCl, 10 mM HEPES, 10 mM d-glucose, 5 mM KCl, 1 mM MgSO4), was supplemented on the day of 
the experiments with 1 mg/mL Bsa, 10 mM glucose, 0.1 U/mL apyrase and 200 µM CaCl2 
(supplemented HBS). CaCl2 concentration of the supplemented HBS was adjusted to 1 mM prior to 
individual sample analysis. 
2.3 Ferric chloride model 
2.3.1 Measurement of platelets’ cytosolic Ca2+ concentration ([Ca2+]cyt) exposed to FeCl3 
induced TEBV and TEML constructs 
TEBV and TEML constructs were pre-incubated with a piece of filter paper (0.25 cm2) saturated with 
10% ferric chloride solution and placed directly on the basal side of the constructs for 5 minutes, 
and following the removal of the medium (Figure 5.1). The filter paper was removed and the 
construct was washed three times with HEPES-buffered saline to remove excess ferric chloride 
solution. The FeCl3-damaged or undamaged (exposed to HBS treated filter paper) constructs were 
placed in the sample holder developed in chapter 3, and then exposed to 1.2 mL of Fura-2 and 
DiOC6-labelled human washed platelets under continuous magnetic stirring for 15 minutes at 37˚C. 
Each construct was treated just prior to incubation with platelets. The constructs were then 
removed and the fluorescence of platelets were continuously monitored using Cairn Research 
Spectrophotometer (Cairn Research, UK), using excitation wavelengths of 340 and 380 nm, and 
emission of 515 nm. Platelets were monitored for 1 minute followed by stimulation with 0.2 U/mL 
thrombin and observed for a further 4 minutes. Changes in [Ca2+]cyt were calculated using the 
340/380 nm fluorescence ratio and calibrated as previously described in chapter 3. Thrombin-
evoked changes in [Ca2+]cyt were quantified by integration of the change in fluorescence records 
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from the point of thrombin stimulation with a total recording of 5 minutes, including baseline 
measurement. 
 
2.4 Perfusion system 
A Watson-Marlow 505 series peristatic pump (Fluid technology, UK) was used for the perfusion 
assay to pump the labelled human platelet suspension through a PFC-1Proflow Chamber (Warner 
instruments, USA). A reservoir containing DiOC6-labelled platelets was connected with the inlet of 
the parallel plate flow chamber via a polyethene (PE-90) tubing while the outlet was connected to 
the peristatic pump (Figure 5.2B). The chamber was assembled per manufacturer’s instructions. 
Specifically, a 15-mm round cover glass and gasket were mounted onto the top plate of the 
chamber using a vacuum grease. This was followed by mounting a previously casted PDMS gasket 
with the desired area, in this case a rectangular cavity fitting the construct, to adjust the height of 
the flow channel. The preparation was left to set overnight and once solidified, the round shaped 
PDMS was cut into smaller circles of 2.8 cm in diameter, bearing a rectangular cavity shown in Figure 
5.2A. In addition, spacers were generated from acetate cellulose with a window in the middle. 
These were placed inside the gasket cavity, to create a flow channel path of 300 µM depth through 
Figure 5.1 Optical images showing ferric chloride incubation with TEBV construct. A) The cell 
culture plate was taken out of the incubator and the media was removed. The construct was 
overturned and a filter paper saturated with 10% FeCl3 was applied onto the basal side of the TEBV 
construct for 5 minutes. B) TEBV construct after applying FeCl3 and washing three-times with HBS.  
 
A B 
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which platelets can flow above the construct. TEML constructs were placed atop of the three 
spacers and the top and bottom plates were eventually assembled together, sealed with nylon 
screws. The chamber was put on a fluorescence dissection microscope stage for visualisation.  
To prevent platelets adhesion to the perfusion system, prior to the start of experiment, the 
assembled perfusion system was perfused with 1% BSA solution for 1 hour with exclusion of the 
construct. In addition, the gasket and the spacers were coated overnight with 1% BSA solution.  
 
2.4.1 Shear stress calculation  
For a laminar flow within the perfusion chamber, wall shear stress ƮƜ was calculated using the 
following equation:  
 
Ʈ𝑤 =
6𝑄𝜇
𝑤ℎ2
 
 
Where Q, refers to the volumetric flow rate; µ, indicates the solution viscosity (1.5Cp) and w and h 
refers to the width and height of the chamber, respectively. Flow rate was used at 0.077 cm3/s. The 
width and height were measured to 5 mm and 30 µm, respectively to yield a shear stress of 15.4 
dynes/cm2. 
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Figure 5.2 Schematic diagram showing perfusion chamber set-up. A) Parallel plate flow chamber 
assembly using a top and bottom plates with central gap fitting a PDMS gasket, 3x cellulose acetate 
frame spacers and a TEML construct. B) Perfusion chamber set-up enclosing a parallel plate flow 
chamber, peristatic pump and platelet suspension reservoir.  
 
A 
B 
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2.4.2 Real-time monitoring of DiOC6-labelled platelet adhesion and aggregation on 
TEML constructs under physiological flow conditions 
To avoid unwanted platelet activation, within the perfusion system, a 1% BSA solution was perfused 
into the system for 1 hour prior to construct inclusion. In addition, the gasket and 3x spacers were 
all coated with a 1% BSA solution overnight. Prior to the start of the experiment, 1.2 cm2 TEML 
constructs were made to fit the perfusion chamber with proportionally adjusting the cell number 
and collagen volume which was inserted in the sample site in the parallel plate flow chamber. 
Washed DiOC6-labelled human platelets were treated with either 100 µM ketamine hydrochloride 
(Pfizer, USA) or HBS for 1 hour at 37°C, and then loaded into the perfusion system reservoir. 
Platelets were then perfused over the TEML constructs at a shear stress of 15.4 dynes/cm2 for 15 
minutes. Fluorescence images of platelet adhesion and aggregation were captured using CCD 
microscope camera (Leica Microsystems) using an excitation wavelength of 485 nm and emission 
of 501 nm for 0, 7 and 15 minutes.  
2.4.3 Development of FeCl3 arterial injury model using the TEBV construct. 
To recreate the FeCl3 arterial injury model, TEBV constructs were made to fit the perfusion chamber 
(1.2 cm2) with proportionally adjusting the cell number and collagen volume which was inserted in 
the sample site in the parallel plate flow chamber. TEBV constructs was pre-incubated with a piece 
of filter paper saturated with 10% [v/v] ferric chloride solution and placed directly on the apical side 
of the construct for 5 minutes, following the removal of the medium (Similar to the image shown 
in Figure 5.1, but rectangular in shape). The filter paper was removed and the construct was washed 
with HEPES-buffered saline to remove the excess ferric chloride. The TEBV construct was assembled 
into the sample site of the parallel plate flow chamber. DiOC6-labelled platelets were perfused over 
the damaged TEBV construct. Undamaged TEBV constructs were also perfused for comparison. At 
the end of perfusion, the TEBV constructs were removed for imaging under the fluorescence 
microscope. Overall, FeCl3 damaged and undamaged TEBV constructs were imaged using an 
excitation wavelength of 485 nm and emission of 501 nm at 0, 7 and 15 minutes of perfusion.  
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2.5 Measurement of platelets’ cytosolic Ca2+ concentration ([Ca2+]cyt) exposed to 
ketamine treated tissue engineered constructs 
2.5.1 TEML constructs 
1.7 mL of washed unlabelled human platelet suspension was pipetted into spectrophotometer 
cuvette and incubated with either 1 mM ketamine hydrochloride or HBS for 15 minutes at 37˚C, 
during the incubation with the constructs. Ketamine-treated TEML constructs were placed atop of 
washed platelets treated with ketamine whilst untreated TEML constructs were placed atop 
untreated platelet samples, using the sample holders previously described in chapter 3. 
Fluorescence was recorded from stirred aliquots of Fura-2-loaded washed human platelet 
suspensions in contact with the blood vessel constructs at 37°C using Cairn Research 
Spectrophotometer (Cairn Research, UK) with excitation of 340 and 380 nm and emission of 515 
nm. Changes in [Ca2+]cyt were monitored using the 340/380 nm fluorescence ratio. Data were 
calibrated using the method of Grykiewicz et al., (1986). Agonist-evoked changes in [Ca2+]cyt were  
quantified by integration of the change in fluorescence records from basal with respect to 15 
minutes after agonist addition. 
2.5.2 TEBV constructs 
TEBV constructs were incubated with ketamine (1 mM) or HBS for 1 hour at 37°C prior to the start 
of experiment. Solutions were discarded and constructs were washed with HBS. These TEBV 
samples were matched with corresponding 1 mM ketamine or HBS treated 1.2 mL platelets which 
were incubated together off-screen for 15 at 37°C. Following the incubation period, the constructs 
were removed and the remaining platelet suspension was monitored as described above using a 
spectrophotometer for 5 minutes post 0.2 U/mL thrombin stimulation. 
2.6 Platelet aggregometry  
Following the incubation period, the constructs were removed and 200 µl of the platelet suspension 
was transferred into a 96-well plate and then placed into a plate reader prewarmed to 37°C (BioTek 
Synergy 2 microplate, USA). Baseline absorbance readings were taken once at a wavelength of 600 
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nm, obtaining an absolute absorbance reading post construct incubation. In the present assay, the 
plate reader was set-up to use a fast shaking mode between absorbance readings to aid in sample 
mixing. 
2.7 Dense granule secretion assay 
Platelets from both ketamine treated and untreated samples, were collected following 15 minutes 
incubation period as described above. Subsequent to the incubation period, 200 μl of each platelet 
suspensions were transferred into a 96-well plate and then placed into a plate reader prewarmed 
to 37°C (BioTek Synergy 2 microplate, USA). ATP secretion from platelet dense granules was 
assessed by adding 10% [v/v] luciferin-luciferase reagent to the platelet sample. Baseline readings 
were obtained both prior to and following stimulation with 0.2 U/mL thrombin. 
2.8 Statistics 
Values stated are mean ± SEM of the number of observations (n) indicated. Analysis of statistical 
significance was performed using a two-tailed Student's t-test. P < 0.05 was considered statistically 
significant. 
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3 Results 
Ferric chloride has been previously used to create artificial in vivo damage to the endothelial lining 
to induce arterial thrombosis. This effect is caused principally by the generation of free radicals, 
which triggers damage to the endothelial cells facilitating the exposure of the subendothelial 
matrix. The results presented in the previous chapters have demonstrated that the TEBV construct 
can prevent platelet aggregation on the surface of the construct, whilst a TEML construct lacking 
the endothelial lining can provide a substrate to support thrombus formation. In this chapter, 
experiments were performed to assess if experimental damage to the TEBV could also support the 
triggering of platelet activation, and as such provide initial evidence that the blood vessel construct 
could be used to provide an ex vivo human arterial thrombosis model in which to perform similar 
studies to those currently performed in vivo. 
To initially examine this, experiments were performed to assess the effect of FeCl3 damage on the 
anti-aggregatory properties of the TEBV.  To do this, we assessed the effect of preincubating Fura-
2-loaded platelets with either an untreated, intact TEBV or one damaged by application of FeCl3. 
Following a 15 minutes incubation, the FeCl3 damage elicited no significant change in the baseline 
[Ca2+]cyt observed in these samples (89.4 ± 30.4 % of control; P > 0.05; n = 6). These data suggest 
that the presence of undamaged endothelial cells is still able to prevent significant activation of the 
platelets in suspension.   
Following this, platelets were stimulated with thrombin to assess if the anti-aggregatory properties 
of the FeCl3-damaged TEBV had been diminished. As can be seen in Figure 5.3, treatment of the 
TEBV with FeCl3elicited a significant increase in thrombin-evoked rise of [Ca2+]cyt in platelets 
compared with platelets pre-exposed to the undamaged TEBV construct (239.2 ±50.8% of control;  
n = 6; P < 0.05). These data therefore suggested that the anti-aggregatory properties of the TEBV 
had been diminished by the FeCl3-induced endothelial damage.  
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To ensure this effect was due to endothelial cell damage and not due to a sensitising effect of the 
remaining FeCl3 solution leaking into the platelet suspension, the FeCl3 solution was applied using 
the same method onto a TEML construct.  As the TEML lacks an endothelial lining, if the effect of 
FeCl3 is through its leaching into the platelet suspension, a similar effect should be seen here. As 
seen in Figure 5.4, there is no significant increase in the baseline [Ca2+]cyt (159.2 ±55.1 % of control; 
P > 0.05; n = 3) or thrombin-evoked rises in [Ca2+]cyt in platelets exposed to FeCl3-treated TEML 
constructs compared to their untreated controls (74.1 ± 17.6% of control; n = 3; P > 0.05). However, 
as this experiment was only performed 3 times, this may have prevented a significant finding from 
being observed due to a lack of statistical power. This experiment suggests that the effect of FeCl3 
on the TEBV model was due to FeCl3 mediated injury of the endothelial lining. These data therefore 
indicate that the TEBV may be used to develop an alternative methodology to the in vivo FeCl3 
arterial thrombosis model. 
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Figure 5.3 – Thrombin-evoked rise of [Ca2+]cyt in platelets pre-exposed to FeCl3 damaged TEBV 
construct. The tissue-engineered blood vessel construct (TEBV) was pre-incubated with a piece of 
filter paper saturated with 10% ferric chloride solution and placed directly on the basal side of the 
construct for 5 minutes. The filter paper was removed and the construct was washed 3x with 
HEPES-buffered saline to remove the excess ferric chloride. The FeCl3 damaged or undamaged 
constructs were incubated with 1.2 mL of washed human platelets for 15 minutes at 37˚C. The 
constructs were then removed and the remaining platelets were exposed to thrombin (Thr) to 
measure the increase in cytosolic Ca2+ concentrations. Results are representative of 3 experiments 
(n=6).  
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3.1 Assessment of Ferric chloride arterial injury model using platelets perfused over TEBV 
construct at arterial shear stresses 
To allow assessment of thrombus formation under dynamic shear stress conditions found in vivo, 
the TEBV constructs were created in an elongated rectangular shape to allow their introduction into 
a commercially-available parallel plate flow chamber. This allowed labelled platelet suspensions to 
be perfused over the construct under physiological arterial shear rates – thus allowing us to 
Figure 5.4 – Thrombin-evoked rise of [Ca2+]cyt in platelets pre-exposed to ferric chloride damaged 
TEML construct. The TEML construct was pre-incubated with a section of filter paper saturated 
with 10% ferric chloride solution and placed directly on the basal side of the construct for 5 
minutes. The filter paper was removed and the construct was washed 3-times with HEPES-
buffered saline to remove the excess ferric chloride. The FeCl3 damaged or undamaged TEML 
constructs were incubated with 1.2 mL of washed human platelets for 15 minutes at 37˚ off-
screen. The constructs were then removed and the remaining platelets were exposed to thrombin 
to measure the increase in cytosolic Ca2+ concentrations. Results are representative of 3 
experiments (n=3).  
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recreate the physical environment found in vivo. Experiments were performed to examine if 
application of FeCl3 to the construct could elicit significant thrombus formation when perfused with 
DiOC6-labelled human platelets under conditions of arterial shear stress for 15 minutes. In an 
untreated, intact TEBV construct, no platelet adhesion or aggregation on the surface of the 
construct could be observed (Figure 5.5A). This is consistent with the findings in chapter 4, that 
demonstrated that anti-aggregatory properties of the TEBV. In contrast, the FeCl3-treateded TEBV 
construct showed significant platelet aggregation on the surface of the construct after 7 minutes of 
perfusion, which progressed further over 15 minutes (Figure 5.5B). These data suggest that our 
construct is able to support platelet aggregation after endothelial cell damage, and as such this 
provides a suitable system in which to recreate the FeCl3 arterial injury model.  
 
 
 
 
 
 
Figure 5.5 – Fluorescent images of perfused platelets aggregation on the surface of intact and 
FeCl3- treated TEBV constructs under arterial flow conditions. DiOC6-labelled human platelets 
were perfused over FeCl3 damaged and undamaged endothelial lining of TEBV construct for 15 
minutes using a parallel flow chamber at a shear stress (15.4 dynes/cm2). Fluorescent images were 
recorded in real-time over the course of 15 minutes of perfusion using fluorescence microscopy. 
(A) Undamaged TEBV construct exposed to perfused platelets; (B) Lower magnification image of 
FeCl3 damaged TEBV construct exposed to perfused platelets; (C) A higher magnification image 
showing surface platelets aggregation. (T0) Beginning of perfusion; (T7) 7 minutes post-perfusion; 
(T15) 15 minutes post-perfusion. Arrows indicate auto-fluorescent filter paper. 
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3.2 Ketamine has no significant effect on the anti-aggregatory properties of non-
damaged TEBV constructs  
Ketamine is commonly used to induce anaesthesia in mice undergoing the FeCl3 arterial thrombosis 
assay (Denis et al., 2011). However previous studies have demonstrated that ketamine treatment 
can inhibit endothelial production of NO, contraction of smooth muscle cells and platelet activation 
(Akata et al., 2001; Chen et al., 2005; Nakagawa et al., 2002; Undar et al., 2004). To assess if the 
platelet responses in currently used in vivo models might be affected by ketamine treatment, 
experiments were performed to assess if either treatment of platelets or the TEBV could alter the 
responsiveness of platelets to this construct. Figure 5.6 shows thrombin-evoked changes in [Ca2+]cyt 
of platelets pre-exposed to TEBV constructs with and without ketamine. Ketamine-treatment of 
both the TEBV construct and platelets does not provoke a significant effect on the thrombin-evoked 
rise in [Ca2+]cyt in platelets elicited post-construct incubation compared with the untreated sample 
(89.3 ± 18.5% of control; n = 6; p > 0.05). Treatment of only the TEBV construct with ketamine 
causes no significant change to the thrombin-evoked rise in [Ca2+]cyt of platelets elicited after 
incubation with the TEBV construct (124.1 ± 30.9% of control; n = 6; P > 0.05). Similarly, ketamine-
treated platelets pre-exposed to untreated TEBV construct does not elicit a significant rise in 
thrombin-evoked changes in [Ca2+]cyt when compared with the untreated sample (104.8 ±25.5% of 
control; n = 6; P > 0.05). All together these results suggest that ketamine does not influence the 
anti-aggregatory properties of the TEBV construct. It is possible that ketamine has an opposing 
effect on the EC and SMCs layers. Ketamine may reduce the anti-aggregatory capacity of ECs, but 
also reduce the pro-aggregatory capacity of SMCs. Although applying ketamine causes platelets 
inactivation, this makes the two effects cancelling each other with an overall [Ca2+]cyt level similar 
to the untreated samples. 
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3.3 Ketamine inhibits the pro-aggregatory properties of the TEML constructs  
To investigate if ketamine pre-treatment of platelets or TEML constructs, could interfere with the 
pro-aggregatory properties of this construct, real-time monitoring of construct- and thrombin-
evoked changes in [Ca2+]cyt of platelets pre-incubated with TEML constructs with and without 
ketamine are shown in Figure 5.7. Prior to TEML construct removal, platelets exposure to TEML 
constructs did not cause a significant increase in the construct-evoked rise in cytosolic Ca2+ 
concentration compared to ketamine-treated sample. However, following TEML construct removal, 
Figure 5.6 – A real-time measurement of the effect of ketamine on cytosolic Ca2+ concentration in human 
platelets pre-incubated with TEBV constructs. Tissue-engineered blood vessel constructs were incubated with 
and without 1 mM ketamine for 1 hour at 37˚C prior to start of experiment. Platelets were also treated with or 
without 1 mM ketamine for 15 minutes. Both corresponding TEBV construct and platelet suspensions were 
incubated together for 15 minutes at 37˚C off-screen, the constructs were removed and the remaining platelets 
were stimulated with thrombin (0.2 U/mL). Results are representative of 6 experiments. 
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samples in which platelets and the TEML had been preincubated with ketamine were found not to 
elicit the same rise in [Ca2+]cyt seen in control samples in which neither the platelets or TEML had 
been exposed to this general anaesthetic (40.2 ± 11.6% of control; P < 0.05; n = 6). The control 
sample did not show a Ca2+ rise post-TEML construct addition due to the higher volume of 1.7 mL 
used in the experiment when compared to the previous chapter where, lower volumes has been 
used. This may make the propagation of the activation signal insufficient due to the availability of 
more platelets that need to be stimulated. However, thrombin-evoked rises in [Ca2+]cyt examined 
following construct removal were not significantly difference between the treated samples 
compared with the untreated control samples (90.9 ±16.7% of control; n=6; P > 0.05).   
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The failure of ketamine-treated samples to demonstrate a rise in platelet [Ca2+]cyt after TEML 
construct removal suggests that ketamine may inhibit local signalling events between the platelets 
in the suspension and the platelets or vascular cells on the surface of the construct. This may be 
due to ketamine influencing the dense granule secretion of the platelets activated on the surface 
of the construct. The autocrine signalling molecules released from these platelets upon construct 
removal could be mixed in the bulk platelet solution upon construct removal – triggering this small 
Ca2+ signal.  
0
100
200
300
400
0 240 480 720 960 1200 1440 1680 1920 2160 2400
[C
a
2
+
] c
y
t
(n
M
)
Time (s)
TEML
addition
TEML
removal
Thr
Figure 5.7– A real-time measurement of ketamine effect on the cytosolic Ca2+ concentration in 
human platelets incubated with TEML. Tissue-engineered medial layers were incubated with and 
without ketamine (1 mM) for 1 hour at 37˚C prior to start of experiment. TEML constructs were 
incubated with corresponding platelets suspensions with and without ketamine on-screen. After 
15 minutes, the TEML constructs were removed and 2 minutes later the remaining platelets were 
stimulated with thrombin (0.2 U/mL). Results are representative of 3 experiments (n=6). 
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To investigate whether ketamine affects platelet’s dense granule secretion, ATP release was 
measured as described previously in chapter 4. The TEML and washed platelets were both either 
treated with or without ketamine were pre-incubated together for 15 mins at 37°C. Following this, 
ATP release into the extracellular was measured using the luciferin-luciferase luminescence assay. 
As shown in Figure 5.8, the ketamine treated samples reduced ATP secretion from platelets 
granules compared with untreated samples (P < 0.05). These data suggest that ketamine can 
interfere with TEML-induced dense granules secretion. 
 
Figure 5.8 – Platelets dense granule secretion post TEML construct incubation with and without 
ketamine. Platelets treated or untreated with 1 mM ketamine were incubated with corresponding 
1 mM ketamine treated or untreated TEML constructs for 15 minutes at 37˚C, with dynamic 
stirring. Luminescence of platelet suspension was measured using 10% Luciferin-Luciferase 
reagent. Results are representative of 6 experiments (n=13).  
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3.3.1 Inhibition of conventional PKC isoforms does not prevent the Ca2+ signal induced 
by TEML removal 
To investigate if this ketamine-induced interference with dense granule secretion could be the 
cause of the construct removal-induced Ca2+ signals, experiments were performed to investigate 
the effect of the convention PKC isoform inhibitor, GÖ6976, on this parameter. This compound has 
previously been shown to completely inhibit collagen-evoked dense granule secretion when used 
at concentrations of 3 μM and above (Gilio et al., 2010). As shown in Figure 5.9, pre-treatment of 
platelets with 3 μM GÖ6976 did not affect Ca2+ signals evoked by TEML removal (90.4 ±16.8% of 
control; P > 0.05; n = 4). Neither did it significantly alter Ca2+ signals evoked by the addition of the 
construct (105.3 ± 21.9 % of control; P > 0.05; n = 4). However, as the experiment was only repeated 
4 times, which is considered further replication will need to be conducted to confirm these 
preliminary findings. These results indicate that the construct removal-induced Ca2+ signals was not 
caused by dense granule secretion from platelets. 
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3.3.2 Ketamine inhibits TEML-induced platelet aggregation 
Following the establishment of ketamine presence influencing the pro-aggregatory capacity of the 
TEML constructs, we assessed whether this could be seen to inhibit the aggregation of the platelet 
solution. Ketamine treated and untreated TEML constructs were incubated with corresponding 
platelet samples for 15 minutes at 37°C. Following the incubation period, the TEML constructs were 
removed and the remaining platelet suspension was analysed for changes in TEML-evoked platelet 
aggregation using a previously characterised plate reader assay (Lordkipanidzé et al., 2014). 
Ketamine significantly suppressed aggregation of platelet after 15 mins of incubation in the treated 
sample compared with untreated sample as the absorbance of the sample was significantly higher 
Figure 5.9 – Cytosolic Ca2+ concentration measurement of human platelets treated 
with GÖ6976. Fura-2-loaded human platelets were treated with or without GÖ967 (3 
µM) for 10 minutes at 37˚C prior to start of experiment. Tissue-engineered medial layers 
were incubated with treated or untreated platelets for 15 minutes at 37˚ on-screen. 
Following the incubation period, the constructs were removed and the [Ca2+]cyt was 
measured for a further 5 minutes. Results are representative of 3 experiments (n=4). 
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(169.4 ±29.5; P < 0.05, n = 11; Figure 5.10). These results suggest that ketamine Interferes with the 
pro-aggregatory capacity of the TEML construct. 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.3 Ketamine inhibits platelet aggregation on the surface of the TEML construct 
To assess if the inhibitory effect of washed DiOC6-labelled platelet suspensions treated or untreated 
with ketamine, these platelets were allowed to interact with corresponding TEML construct pre-
treated with or without ketamine (Figure 5.11) in cuvette holders under continuous magnetic 
stirring. Fluorescence imaging of the DiOC6-labelled platelet-exposed surface of the TEML 
Figure 5.10 – Bar chart absorbance of platelets formerly incubated with ketamine treated tissue-
engineered medial layer constructs. TEML constructs were incubated with or without ketamine 
(1 mM) for 1 hour prior to the start of experiment. The TEML samples were incubated with 
corresponding ketamine treated or untreated platelet samples for 15 minutes with dynamic 
stirring at 37˚C. Absorbance was measured post TEML construct incubation using a plate reader. 
Results are representative of 5 experiments (n=11).   
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constructs revealed that ketamine-treated sample exhibits very few platelet aggregates forming on 
the surface of the TEML construct (Figure 5.11D-F). In contrast, the untreated sample show to 
provide a greater platelet adhesion as well as the formation of multiple platelet aggregates, 
consistent with our previous findings in chapter 4 (Figure 5.11A-C). These data therefore showed 
that ketamine could significantly inhibit the normal aggregatory potential of platelets 
3.3.4 Ketamine inhibits thrombus formation in platelets perfused over the TEML at 
arterial shear stresses  
Finally, to assess if the use of ketamine has the potential to interfere with the structure of thrombi 
induced in arterial thrombosis assays in mice, experiments were performed to see if ketamine 
treatment of platelets could prevent thrombus formation when perfused across the TEML.  As 
shown in Figure 5.12, perfusion of untreated platelets at arterial shear stresses stress (15.4 
dynes/cm2) over an untreated TEML construct elicited significant platelet aggregation upon the 
surface of the construct, consistent with our previous findings in this and the previous chapter. 
However, when the platelets were treated with ketamine, no platelet aggregation could be 
observed on the surface of the TEML construct with only occasional, isolated adherent platelets 
being observed. These data highlights that ketamine treatment can significantly impair platelets 
adhesion and aggregation upon the subendothelial matrix. Therefore, it raises questions about the 
potential for the anaesthetic regime used to create artefactual findings in in vivo studies of arterial 
thrombosis. However, to confirm this conclusion, similar experiments will also need to be 
performed on the FeCl3-injured TEBV.  
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Figure 5.11 – Fluorescent and brightfield images of platelets aggregation to the surface of tissue-
engineered medial layer incubated with and without ketamine. Tissue-engineered medial layer 
was incubated with ketamine (1mM) for 1 hour at 37˚C followed by incubation with 1 mL of 
washed platelets treated with ketamine (1mM) for 15 minutes at 37˚C.  The constructs were then 
washed and the adhered platelet aggregates on the surface of the construct were imaged using 
fluorescence microscopy. (A-C) untreated sample; (D-F) Ketamine treated sample. Left panel: 
brightfield image, middle panel: DiOC6, left panel: overlay. Results are representative of 4 
experiments (n=6). 
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Figure 5.12 – Fluorescent images of perfused platelets aggregation to the surface of tissue-
engineered medial layer incubated with and without ketamine using high shear stress. Ketamine 
treated (300 µM) and untreated platelets were perfused over tissue-engineered medial layer for 
15 minutes using a parallel flow chamber at a shear stress (15.4 dynes/cm2). Fluorescent images 
were recorded in real-time over the course of 15 minutes of perfusion using fluorescence 
microscopy. (A) Untreated sample; (B) Ketamine treated sample. (T0) Beginning of perfusion; (T7) 
7 minutes post-perfusion; (T15) 15 minutes post-perfusion. Circles, indicate individual platelets 
adherence. 
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4 Discussion 
In this chapter, we have developed a human ex vivo ferric chloride arterial injury model using our 
TEBV constructs. Through monitoring the [Ca2+]cyt of platelets exposed to the FeCl3 damaged TEBV 
constructs, we were able to show that this treatment reduces the inhibitory effect of the 
endothelium on the platelet sample. In addition, platelets aggregation could be observed upon the 
FeCl3-injured construct under flow, where it was prevented in the untreated construct. This result 
was found regardless of where on the construct the solution was applied. The data also 
demonstrates that effect is due to the damage caused by the action of FeCl3 on the endothelial 
cells, as the ability of FeCl3 to enhance platelet activation was not replicated in TEML constructs 
treated with this solution. The data in chapter 4 demonstrate the pro-aggregatory effect of the 
TEML construct is mediated by native collagen synthesised and secreted by the human coronary 
arterial smooth muscle cells. Therefore, a traditional explanation of this model would suggest that 
FeCl3-mediated oxidation induces endothelial cell denudation and subsequent exposure to neo-
collagen which activates the platelets. Dubois et al. 2006., have examined the influence of the 
extent of collagen exposure in thrombus formation in FeCl3 damaged vessel. The study found 
differences in the rapidity of collagen exposure in mild FeCl3 injury compared with severe FeCl3 
injury (Dubois et al., 2006). After mild FeCl3 vascular injury, the appearance of collagen was 
considerably reduced in comparison with severe FeCl3 injury. However, the mechanism of FeCl3 
induced thrombus formation remains incompletely understood.  In particular, the relative 
importance of collagen-dependent platelet adhesion via GPVI and integrin α2β1 in this model 
remains controversial (Cheli et al., 2008; Dubois et al., 2006a; Konstantinides et al., 2006; Kuijpers 
et al., 2007; Massberg et al., 2003). Whereas some groups reported severe inhibition of FeCl3-
induced thrombus formation in GPVI-immunodepleted mice (Bender et al., 2011), others concluded 
that GPVI deficiency did not impair thrombosis in this model (Eckly et al., 2011). These different 
results are difficult to interpret as the vascular lesions were not examined in these studies and the 
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differences could arise from differences in experimental conditions, such as the FeCl3 concentration 
(7–20%), the method (filter paper or drop) and time (2–5 min) of FeCl3 application, or the vessel 
bed targeted (carotid or mesenteric artery). Such differences in experimental conditions can cause 
variations in the depth and extent of the vascular lesions, which consequently may modify the 
exposure of specific proteins to blood flow.  Therefore, these discrepancies might be reconciled via 
using our model system to provide a standardised testing system in which to identify if these key 
variables could alter the relative importance of GPVI in these experiments. 
Although previous studies have identified collagen-mediated activation as important in mediating 
platelet activation in the FeCl3 injury model, more recently this interpretation has been challenged 
by the work of Eckly et al. (2011). This group identified spherical bodies filled with iron originating 
from endothelial cells exposed to FeCl3 (Eckly et al., 2011). These spheres were surrounded by a 
bilayer characteristic of a plasma membrane budding off from the endothelium. Platelets appeared 
to adhere to the rough material present on the endothelial-derived spheres, suggesting that FeCl3 
might activate platelets through presentation of endothelial cell microparticles. Therefore, 
investigations into whether similar endothelial-derived microparticles can be observed to trigger 
platelet activation in our system may provide a basis for better understanding the FeCl3 vascular 
injury model.  
In this chapter, data is also presented showing that the effect of ketamine alters platelets ability to 
activate in response to TEML or TEBV constructs. However, ketamine does not have a significant 
effect on untreated TEBVs. These results therefore suggest that ketamine inhibits platelet ability to 
activate upon the subendothelial matrix as thrombus formation upon the TEML construct is 
inhibited by ketamine both under static conditions as well as under physiological flow. This failure 
to aggregate upon the surface is also linked with a reduced aggregation of platelets exposed to 
these constructs – suggesting that the absorbance difference is due to a failure to form thrombi 
upon the subendothelial matrix. However individual platelets are able to adhere to the surface as 
can be seen in both static and flow conditions. These data therefore suggest that ketamine does 
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not prevent collagen-mediated platelet adhesion but interferes with a process that helps recruit 
platelets to the subendothelial matrix. This effect is therefore is likely mediated by the ability of 
ketamine to inhibit dense granule secretion, as the ability of autocrine signalling molecules released 
from here are known to be critical to recruit circulating platelets to the surface of the forming 
thrombi (Stalker et al., 2012). Previous studies have demonstrated that ketamine can block platelet 
aggregation both by inhibiting thromboxane synthesis (Atkinson et al., 1985) or by suppressing 
agonist-evoked rises in [Ca2+]cyt (Chang et al., 2004; Nakagawa et al., 2002).  As all studies were 
treated in aspirin-treated platelets, it is unlikely that the effect on thromboxane synthesis is 
responsible for the inhibitory effects observed and thus the effect on Ca2+ signalling appears to be 
the most likely explanation. Previous studies have suggested that ketamine can inhibit platelet Ca2+ 
signalling by inhibiting inositol triphosphate formation  (Chang et al., 2004; Nakagawa et al., 2002). 
This would explain the ability to prevent platelet granule secretion and aggregation.  However, Ca2+ 
signalling is not significantly inhibited in response to exposure to the construct alone or stimulation 
with thrombin post-construct removal. The only effect observed is after construct removal - this 
may be due to improved signal propagation within the platelet sample from activated platelets 
which mixed freely in response to TEML construct removal. Previous studies have shown that 
ketamine reduces NO biosynthesis in endothelial cells by down-regulating endothelial NO synthase 
expression and intracellular calcium levels (Chen et al., 2005). A reduction in the production of NO 
would be expected to reduce the inhibitory effect of the TEBV on human platelets. However, this 
effect was not observed, with inhibition of thrombin-evoked Ca2+ rises in human platelet incubated 
with the construct found not to be significantly inhibited by ketamine treatment. These results 
therefore suggest that in this 3D system that ketamine is not able to significantly inhibit NO 
production, or that NO is not a significant inhibitor of platelet activation in our system. This latter 
effect may be due to the inhibitory effect of NO being redundant with another endothelial-derived 
platelet inhibitor such as prostacyclin. Further work will be required to assess these possibilities. 
 
 184 
 
4.1 Conclusion 
In summary, we have successfully generated a ferric chloride injury model using our TEBV construct 
which mimics the results previously reported in in vivo mice models. This model offers a number of 
advantages including the replacement of animal models, removal of the requirement for expensive 
intravital microscopy equipment, and are likely to be cheaper to produce than the costs of housing 
a colony of mice. In addition, data is presented which demonstrates that the lack of need to 
introduce anaesthetics such as ketamine into the blood sample could improve the physiological 
relevance of the clotting responses seen. The ability of ketamine to inhibit thrombus formation on 
the surface of the construct could play an important role in artefactually altering the size and 
structure of thrombi seen, and may lead to overestimation of the effective of putative anti-platelet 
therapies observed in these systems. However, as experiments were performed using high 
concentrations of ketamine further studies will be required to more adequately assess the extent 
to which this anaesthetic may interfere with the aggregatory response observed.  
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1. Discussion 
The layers of the native human blood vessel create a complex tissue with intricate and unique 
biochemical and mechanical properties (Boland et al., 2004). These structural and functional 
properties represent incredible challenge for those scientists aiming to tissue engineer an arterial 
replica for use as an alternative to autologous vascular grafting. Such an artificial blood vessel would 
have to be mechanically strong to withstand the high pressures and fast, pulsatile flow rates of 
arterial blood similar to the native artery, as well as provide a non-immunogenic and non-
thrombogenic surface that will not activate the immune, primary or secondary haemostasis 
systems (Isenberg et al., 2006; Lopez and Zheng, 2013; Sankaran et al., 2014). In this thesis, we have 
adapted some of these previously developed techniques to produce a viable 3D human tissue 
engineered blood vessel model which can be used to replicate the in vivo physical, chemical and 
cellular environment within human blood vessels as a tool to study haemostasis.  
This study aimed to develop a tri-layered 3D tissue engineered blood vessel model generated from 
commercially-available human primary cells fabricated using a layer-by-layer methodology. 
Utilising this method, it has been possible to use tissue engineering techniques to manipulate the 
individual layers of our blood vessels alone and in co-culture. This has led to four major collections 
of work in this thesis; (i) establishing and optimising culture conditions for each layer of the 
construct individually as well as together in co-culture, (ii) developing a real monitoring system to 
test the physiological relevance of the fabricated tissue-engineered vessel constructs, (iii) 
investigating the pro- and anti-aggregatory capacities of medial and intimal layers of the construct 
and (iv) using the TEBV to recreate the FeCl3 arterial thrombosis model.  
1.1  Establishing and optimising culture conditions for each layer of the construct 
individually and when assembled together 
Endothelial cells play a key role in haemostasis through maintaining platelets and the coagulation 
cascade in a quiescent state. Therefore, it is important that in the developed blood vessel model 
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the endothelial cells possess and maintain these anti-haemostatic characteristics. In culture, 
HUVECs grew as a homogenous monolayer of cells with distinct cell boundaries. These cells also 
display a cobblestone appearance during culture. These results were in agreement with those 
reported by other articles on the morphology of these cells in culture (Unger et al., 2002). HUVECs 
show a well spread morphology on fibronectin coated nanofibers indicating excellent compatibility 
of cells with the fibronectin coated PLA scaffold. Further, the images show that the cells were 
specifically orientated in the direction of the nanofibers, thus demonstrating that the nanofibers 
are able to direct HUVECs growth in the construct. Further, experiments demonstrated that the 
generated HUVECs monolayer of the completed TEBV was found to maintain itself separately from 
other layers of construct as well as stably maintain its endothelial phenotype as shown by the 
continually high CD31 expression of these cells in the fabricated TEBV. The cobblestone morphology 
displayed by the cultured HUVECs and their high CD31 expression were consistent with previous 
findings (Sankaran et al., 2014; Unger et al., 2002). In addition, endothelial cell alignment using 
underlying PLA nanofibers did not influence CD31 expression on these cells as a high fluorescence 
expression was observed in both aligned and randomly orientated HUVECs, as was also reported 
by Sankaran et al., (2014). These data therefore demonstrate that HUVECs within the 3D culture 
system does not adversely affect the cellular phenotype of these cells.  
HCASMCs cultured within TEML were found to express F-actin which is associated with a contractile 
phenotype of these cells  (Gutierrez-Pajares et al., 2015). Typically, vascular SMCs can play two 
distinct physiological roles changing between synthetic or contractile phenotypes (Rensen et al., 
2007). Following an injury to the smooth muscle layer, SMCs switch their phenotype to become 
more proliferative and migratory and producing more ECM proteins. Therefore, vascular SMCs are 
plastic cells that may undergo reversible phenotypic changes in response to local growth factors, 
reactive oxygen species, mechanical forces, and alterations in ECM (Crosas-Molist et al., 2015). The 
use of phalloidin to visualise F-actin expression can give crucial information such as fibre orientation 
and distribution (Na et al., 2007). This was reported in a study using cultured HCASMCs in 
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poly(ethylene glycol)-conjugated fibrinogen (Peyton et al., 2008). However, as F-actin is 
ubiquitously present in all cells, phalloidin staining is not a specific marker of a contractile smooth 
muscle phenotype, and so further experiments will be required to more fully assess other 
phenotypic markers such as smooth muscle α-actin (Beamish et al., 2010; Yuan, 2015). 
Live-dead staining was performed for both HUVECs and HCASMCs to ensure their viability within 
individual layers as well as within the assembled TEBV construct. HUVECs seeded on PLA scaffolds 
and HCASMCs within the medial layer were both shown to be viable throughout the culture period 
(up to 14 days). Sankaran et al., (2014) have previously shown that HUVECs cultured on electrospun 
PLA nanofibers maintain high cellular viability, as we have similarly observed here (Sankaran et al., 
2014).  Previous studies of HCASMCs cultured within a fibrin gel have found them to be fully viable 
with no dead cells reported for up to 3 weeks in culture (Gundy et al., 2008). Experiments 
performed in this thesis have similarly demonstrated a high viability of HCASMCs when cultured in 
type I collagen hydrogel.  These data demonstrate that there is no impact on the viability of either 
cell type of culture within the TEBV. 
Fluorescence imaging studies using cell tracker dyes has shown that the layer-by-layer fabrication 
technique yielded a TEBV construct that displayed a layered tissue with anatomic similarities to its 
native counterpart. The construct was observed to maintain distinct intimal and medial layers 
separated by the PLA nanofibers (mimicking the internal elastic lamina). These cells were also 
observed to remain in the layer of which they were initially seeded and do not migrate through the 
different layers – thus demonstrating that our TEBV construct can create a stable structure which 
mimics the anatomy of the native blood vessel. In this project, we have also shown that dextran 
permeation was reduced in TEBV constructs by almost 20% at the end of the run compared to the 
collagen hydrogel sample. In general, dextran permeation through the TEBV construct showed no 
change in fluorescence compared to the collagen hydrogel – thus suggesting that the TEBV was 
largely impermeable to the dextran. However, there are some limitations associated with the 
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design of the methodology that needs to be altered to make it more reliable.  This includes 
modifying the design of the gasket and better sealing of the sides of the construct to prevent 
artefactual results caused by leak of dextran down the sides of the construct rather than its 
permeation through the TEBV. Overall, the initial characterisation has demonstrated that the 
human cells were able to maintain their viability and cellular phenotype when cultured within the 
TEBV, to produce a construct with anatomical similarity to its native arterial counterpart. 
1.2 Developing a real-time monitoring system to test the physiological relevance of the 
fabricated tissue-engineered vessel constructs  
The second aim of this thesis was to assess the functional properties of the fabricated blood vessel 
construct through assessing their ability to trigger or inhibit the activation of the primary 
haemostatic system. To do this, a novel real-time monitoring system to assess human platelet 
activation in response to exposure to our constructs was developed to test the haemostatic 
functionality of the fabricated tissue engineered vessel models. This method utilised the universal 
role of rises in [Ca2+]cyt to trigger all aspects of platelet activation including platelet shape change, 
α- and dense- granule release, TXA2 formation, integrin αIIbβ3 activation and platelet aggregation. 
Due to the ability of all platelet agonists to signal via a rise in [Ca2+]cyt this system provides a sensitive 
system to monitoring pro-thrombotic functions of the construct. In contrast, endothelial-derived 
platelet inhibitors such as NO and PGI2 also significantly inhibit agonist-evoked rises in [Ca2+]cyt, 
therefore post-exposure measurements of thrombin-evoked rises in [Ca2+]cyt can be used to monitor 
the anti-thrombotic nature of the construct. This method therefore has a number advantages over 
currently-used methods including sensitive and dynamic measurements of both platelet activation 
and inhibition by the endothelial layer as well as allowing for analysis of platelet activation in the 
underlying platelet suspension. By utilising this method, it has been possible to perform a number 
of experiments investigating pro- and anti-aggregatory phenotypes of the fabricated medial and 
intimal layers of the construct individually as well as when assembled together as a full TEBV.  
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1.3  Investigating the pro- and anti-aggregatory capacities of medial and intimal layers of 
the construct 
1.3.1 The TEML possesses a pro-aggregatory phenotype due to the production of a neo-
subendothelial matrix 
Using the real-time monitoring system it was possible to observe that the TEML was able to activate 
human platelets in the absence of any exogenous stimuli – with a small rise in [Ca2+]cyt being 
observed in the underlying platelet suspension exposed to the TEML compared to that seen in those 
cells exposed to the collagen hydrogel. However, this Ca2+ signal is small in amplitude and therefore 
took much of the 10-minute incubation to become apparent from that seen when platelets were 
incubated with the hydrogel. This correlated with the results from analysis of DiOC6-labelled 
platelets that had adhered to the surface of the construct that demonstrated significantly enhanced 
platelet aggregation on the TEML over that observed for the collagen hydrogel. The slow activation 
could represent the small proportion of the platelets in the suspension actually in contact with the 
surface of the construct at any one time. The volume of the platelet suspension used in the 
experiment was restricted to a minimal volume required to ensure the blood vessel construct was 
not positioned in the path of the excitation light which would interfere with the ability to make 
fluorescence readings from the platelet suspensions. Thus, having a large volume of platelet 
suspension not in continuous contact with the subendothelial matrix could dilute the pro-
aggregatory signals being released from this surface. Further refinement of the spectrophotometer 
set-up to reduce this volume may help demonstrate a stronger activation signal. Alternatively, the 
accessibility of collagen at the surface of the construct may be limited – a mechanical injury may 
help us better expose more of the collagen within the medial layers to the platelets, which would 
provide a more realistic replica of blood vessel injury found in vivo.  
The activation potential of our TEML was more clearly observed after exogenous thrombin addition, 
where those platelets exposed to the TEML had a significantly enhanced thrombin-evoked rise in 
[Ca2+]cyt. Activated platelets release a variety of autocrine signals which trigger the activation of 
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other circulating platelets to help recruit them to the growing thrombus. The ability of thrombin to 
potentiate the Ca2+ signal elicited by platelets co-stimulated with collagen is well known, and has 
been shown to be a critical factor in helping platelets expressing procoagulant phenotype in which 
phosphatidylserine is expressed on the extracellular face of the platelet plasma membrane 
(Kulkarni and Jackson, 2004). In this study, we have used washed platelet suspensions and therefore 
not examined the ability of the construct to trigger the activation of the coagulation system and 
natural thrombin production from plasma.  Future experiments will be needed to examine whether 
the medial layer-evoked Ca2+ signals can be further enhanced by the activation of the extrinsic 
coagulation cascade when they are exposed to clotting factors present in platelet-rich plasma or 
whole blood.  
This thesis has also demonstrated that platelet aggregation upon the surface of our construct is 
dependent on the presence of neo-collagen created within the TEML. The data shown in this thesis 
demonstrate that platelets failed to aggregate on the surface of the type I collagen hydrogel used 
for construct fabrication, whereas the use of other forms of collagen such as Horm collagen or type 
I and III collagen produced by the HCASMCs, supported platelet aggregation. Examination of type I 
collagen hydrogel used in construct fabrication only elicits minimal platelet adhesion to the surface 
of the construct and presents no ability to trigger Ca2+ signalling in the underlying platelet 
suspension – suggesting that platelets are inert to this form of collagen. This is supported by 
previous studies that have shown that type I collagen films made from rat tail’s possess low 
thrombogenicity and can only support cell spreading but not aggregation (Boccafoschi et al., 2005).  
A potential reason for this is the difference in the structure of the soluble collagen used within the 
hydrogel and the mature neo-collagen forms produced by the HCASMCs. Previous studies have 
highlighted the importance of collagen structure in eliciting platelets aggregation, with different 
collagen preparations varying in their ability to aggregate platelets and support their adhesion, due 
to the structure of the collagen contained within them (Farndale, 2009; Farndale et al., 2008). For 
example, a previous study by Jaffe & Deykin (1974) showed that microfibrillar collagen purified from 
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rat skin is a potent initiator of platelet aggregation, whereas soluble, monomeric collagen from the 
same source was not (Jaffe and Deykin, 1974). This has been supported by further studies that have 
shown that fibrillar collagen is much more potent in inducing platelet activation than the same 
collagen type presented in its acid-soluble form (Farndale, 2009; Savage et al., 1999). Type I collagen 
used in creating the hydrogels for the TEML is a monomeric collagen solution dissolved in acetic 
acid – which according to these previous studies would have limited thrombogenic potential. The 
collagen was reconstructed in the laboratory to form the desired hydrogel constructs. Although the 
gelation process creates microfibrils of collagen, which are more effective initiators of platelet 
aggregation – this format was still found to be ineffective at eliciting platelet activation in these 
studies. The formed collagen microfibrils may be inefficient at triggering platelet aggregation due 
to the lack of critical tertiary and quaternary structures of collagens found in native collagen 
samples. For example, most native collagens are mixtures of different collagen isoforms, which can 
elicit alterations in the final collagen structure. For example, previous studies have shown that the 
presence of type III collagen alongside type I collagen has been shown to alter fibrillogenesis, as 
type III collagen has been shown to regulate the diameter of type I collagen fibrils (Liu et al., 1997; 
Stuart and Panitch, 2009). This difference in fibril diameter might explain the heightened pro-
aggregatory capacity of the HCASMC-produced neo-collagen. In addition, the produced neo-
collagen may also be cross-linked which is also known to increase platelet reactivity to collagen 
(Kawamoto and Kaibara, 1990).  Further work will be required to assess which of these factors are 
important for mediating the enhanced pro-aggregatory capacity of the TEML. 
1.3.2 The TEBV replicates the anti-aggregatory phenotype of the native artery  
In contrast to the data obtained from the TEML, analysis of the haemostatic function of the TEIL 
and TEBV constructs have found them to be anti-aggregatory, consistent with the role of the tunica 
intima in the native artery. Both the TEBV and TEIL had no effect on platelet [Ca2+]cyt during the 
incubation period, but significantly inhibited thrombin-evoked Ca2+ signals in a manner dependent 
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on HUVECs seeding density upon the construct.  In addition, there was minimal platelet adhesion 
observed to the surface of the TEBV, and platelets exposed to the TEBV displayed significant 
inhibition of both thrombin-evoked dense granule secretion and aggregation, demonstrating that 
platelets preincubated with the TEBV has a reduced capacity to activate than those exposed to the 
collagen hydrogels.  These anti-platelets effects of the TEBV were likely to be mediated by the ability 
of HUVECs to create endothelial-derived platelet inhibitors.  NO and PGI2 are widely considered to 
be the main endothelial-derived platelet inhibitors – however despite many attempts to block the 
effects of both of these paracrine regulators, we were only able to elicit a small partial reversal of 
this inhibition.  These data will therefore need to be further investigated to examine whether this 
was due either to an inability of our drug cocktails to completely inhibit the action of either or both 
of these platelet inhibitors, or due to the TEBV producing a non-NO, non-PGI2 platelet inhibitor 
which was able to mediate the same anti-platelet effects of these compounds. The next stage of 
work would be to characterise the effect of the inhibitor cocktails on construct NO and PGI2 
formation to address this question. Whilst there may be differences in the mediator of these anti-
platelet effects, it is clear that the TEBV does possess appropriate anti-aggregatory properties of 
the native blood vessels. 
1.4 Using the TEBV to recreate the FeCl3 arterial thrombosis model   
Whilst the real-time monitoring system provided a useful system for characterising the haemostatic 
properties of tissue-engineered blood vessel constructs, the stirring conditions used in the 
spectrophotometer did not recreate the physical environment found in vivo. In this thesis, 
experiments were performed to assess the ability of our TEBV to provide normal haemostatic 
function under physiological flow conditions when incorporated within a commercially-available 
parallel flow chamber. As shown in chapter 5, these data demonstrated that under arterial flow 
conditions the TEBV could resist platelet aggregation for to the entire 15 minutes perfusion period.  
In contrast, when the TEML was used, this could support significant platelet aggregation upon the 
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surface of the construct. These results therefore suggest that our construct may provide a more 
physiologically-relevant substrate to use in place of 2D monolayers of either endothelial cells or 
components of the subendothelial matrix currently used as part of flow chamber assessments of 
human platelet activation.   
Further experiments also demonstrated that our construct could be used to replicate the in vivo 
FeCl3 arterial thrombosis model, which is commonly used to assess haemostatic function in rodents. 
This work therefore provides a proof-of-concept that our TEBV could be developed further to create 
an ex vivo system in which to recreate and study the cellular events of human haemostasis. This 
new methodology provides advantages over the mouse and rat models currently used.  For 
instance, these TEBVs could also be used in place of animal models providing a viable route to 
replace and reduce the number of rodents currently used in platelet research. In addition, the use 
of human cells over rodent cells provides a humanised system to perform preclinical testing of new 
anti-platelet drugs. Due to differences in the signalling pathways of mouse and human platelets- 
this might provide a platform for better predicting the potential benefit of any developed anti-
platelet agent.  Further, the design of microfluidic flow chambers that incorporate our TEBV could 
be used to support high-throughput testing of anti-platelet agents. 
 However, for other researchers to adopt such a system it is important to demonstrate the potential 
advantages of this model over the currently used in vivo system. One potential issue in current 
intravital microscopy studies is the need to anaesthetise the mice with general anaesthetics during 
the experiments to minimise their suffering. Commonly used anaesthetics for in vivo arterial 
thrombosis experiments include ketamine, xylazine and pentobarbital (Denis et al., 2011)– all of 
which are known to have anti-platelet effects (Bergqvist et al., 1974; Chang et al., 2004; Dwyer and 
Meyers, 1986; Sato et al., 2003). In this thesis, experiments were performed to assess whether 
ketamine could impact upon the ability of our TEML to support platelet aggregation under both 
static and physiological flow conditions. Both when the platelet suspensions were treated with the 
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anaesthetic alone or together with the constructs, ketamine inhibited platelet surface aggregation. 
The main motive for treating both samples was to replicate in vivo models where ketamine is 
injected and exposed to both platelets and the vessel wall simultaneously through the bloodstream 
(Akata et al., 2001). Treating the tissue engineered constructs alone becomes irrelevant since 
ketamine is not only exposed to the vessel wall but also exposed to platelets. From the results 
obtained here it appears that this effect of collagen-platelet interaction was inhibited due to the 
presence of ketamine and this suppression was stronger than the pro-aggregatory effect caused by 
the TEML. Thus, these results therefore question the potential whether the results of intravital 
microscopy experiments may be altered by the use of differing anaesthetic regimens.  However, 
the dose of ketamine used is high and so full pharmacological characterisation of this drug alone 
and in combination with xylazine to properly assess its potential to alter the results of intravital 
microscopy experiments are required (Akata et al., 2001; Dubois et al., 2006b; Falati et al., 2002; 
Furie and Furie, 2008). 
1.5 Future work 
Numerous novel techniques have been developed throughout this project which have allowed us 
to develop and characterise a functional tissue engineered blood vessel construct for use in the 
study of haemostasis. However, whilst the work provides an experimental basis for developing and 
characterising tissue-engineered blood vessels, further work will be required to complete the 
development of the construct. 
The most imminent question that remains to be answered is the mechanism by which the TEBV can 
elicit its anti-platelet effects even when treated with inhibitor cocktails to attempt to prevent 
production of NO and PGI2. The most likely explanation is the inability of the inhibitor cocktails to 
fully inhibit both NO and PGI2 production.  Therefore, it would be interesting to investigate NO 
production of the TEBV in which HUVECs have been loaded with the fluorescent NO sensor, DAF-
FM, both in the presence and absence of the NOS inhibitor-containing cocktails used in chapter 4.  
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This compound is essentially non-fluorescent until it reacts with NO to form a fluorescent 
benzotriazole (Figure 6.1; Mainz et al., 2012). Therefore, monitoring increases in DAF fluorescence 
will allow us to identify any residual NO production that may account for the remaining anti-platelet 
effects of our construct. Additionally, another useful experiment would be to examine total VASP 
and phosphorylated- vasodilator-stimulated phosphoprotein (P-VASP) proteins using western blot 
platelet samples exposed to TEBV, TEIL and TEML constructs. When platelets are exposed to 
endothelial derived inhibitors which elevate cAMP and cGMP respectively, such as PGI2 and NO, 
VASP protein becomes phosphorylated (Wentworth et al., 2006). Thus, assessing the degree of P-
VASP in platelet cell lysates exposed to the TEBV constructs in both the presence and absence of 
our cocktails could also indicate the likely presence of any residual NO, PGI2 and/ or non-NO, non-
PGI2 mechanisms working through inhibitory cyclic nucleotide signalling pathways. If no residual 
activity is found this would necessitate a search for a non-NO, non-PGI2 signalling pathway which 
may require a chemical analysis of substances released into conditioned culture medium used to 
co-culture the TEBV. This system will hopefully help us identify the signalling pathways preventing 
platelet activation in our construct, and allow us to adapt this to become similar to the effects 
observed in the native artery. 
 
Figure 6.1 – Shows reaction scheme for DAF-FM diacetate (Mainz et al., 2012). 
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In addition to refining the biochemical characteristics of the construct, there are also structural 
aspects of the construct which can also be refined. For instance, the TEML constructs can be further 
modified by aligning HCASMCs to resemble the architecture of native SMCs where cells are seen 
aligned in the medial layer to provide a robust vasoconstrictive response when stimulated 
appropriately, as seen in native arteries. In addition, an adventitial layer can be introduced to form 
a blood vessel which fully replicates the native arterial structure. The inclusion of an adventitial 
layer would increase the mechanical properties of the construct and could potentially alter the 
ability of the construct to activate the extrinsic coagulation system, as adventitial fibroblasts are 
known to be a significant source of tissue factor in the subendothelial matrix (Butenas et al., 2009).   
Furthermore, the biocompatibility of the PLA nanofiber could be improved by incorporating other 
native proteins beyond fibronectin onto them. This could improve cell retention whilst maintaining 
the mechanical strength of vascular constructs. Collagen and elastin are major extracellular matrix 
proteins found in the subendothelial matrix, and the use of these natural vessel wall components 
for fabricating electrospun nanofibers has been described previously in literature (Boland et al., 
2004; Buttafoco et al., 2006). These electrospun nanofibers could therefore also be used to mimic 
the native extracellular matrix whilst further improving the mechanical strength and elasticity of 
the construct. 
Lastly, another way to increase the mechanical properties of the constructs is via plastic 
compression of collagen hydrogel scaffold for media layer in the presence of HCASMCs, which will 
increase collagen density and strengthen the mechanical properties of the TEML (Braziulis et al., 
2012; Hu et al., 2010). This process has also been demonstrated to improve collagen fibres 
alignment in cultured limbal epithelial cells grown in collagen hydrogel where the fibres within the 
compressed gel were densely packed and more evenly arranged (Levis, 2010). This may assist in 
better aligning HCASMCs within the medial layer. An attempt of compressed type I collagen 
hydrogel is shown in Figure 6.2. It is evident that the acellular collagen hydrogel incorporated with 
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PLA nanofiber sheath showed a mechanical stability compared with the hydrogel of which the inner 
lining is incorporated with high density PLA nanofiber. These nanofiber sheaths were primarily 
produced by electrospinning 5-times of 0.2 mL of PLA solution to produce a thick nanofiber scaffold 
on the collector. This was then sealed atop of a compressed acellular collagen hydrogel using a 
collagen solution. Once this was set, the construct was rolled using a metal rod. This improved 
mechanical strength also makes it possible to create a tubular vessel model – therefore better 
replicating the normal arterial geometry than the basic sheet model used throughout this thesis. 
Therefore, structure improvements to the TEBV may not also improve the stability and biological 
functionality of the construct, but could also be used to better replicate its native structure. The 
creation of a tubular TEBV with realistic lumen diameter could have significant impact in replicating 
the normal blood flow conditions that occur through the TEBV – thus further improving the 
biological validity of our constructs.  
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1.6 Conclusions 
In this thesis, a successful fabrication and characterisation of a tri-layered TEBV was generated using 
a layer-by-layer fabrication approach. In addition, it was demonstrated the ability to create a novel 
testing platform to enable analysis of the effect of tissue-engineered blood vessel constructs on 
platelets activation. Through exposing the constructs to washed human platelet suspension 
labelled with Fura-2, we are able to assess in real-time the activation status of the platelet 
suspension, or modulation of platelet responsiveness to soluble agonists. Through this method, we 
were able to optimise suitable HUVECs seeding densities and duration of incubation with tissue 
engineered constructs. We have also shown that the endothelial lining of the fabricated TEBV 
construct possess an anti-aggregatory characteristic. Investigation of these anti-aggregatory 
Figure 6.2 Compressed acellular type I 
collagen hydrogels. 1) Rolled type I 
collagen hydrogel with inner PLA 
nanofiber sheath. 2) Rolled type I collagen 
hydrogel with inner high density PLA 
nanofiber. C) Unravelling the rolled 
scaffold from 1, showing the inner PLA 
sheath. Two forms of PLA nanofibers were 
fabricated using electrospinning 
technique. PLA nanofiber sheath was 
fabricated by increasing the volume of 2% 
PLA solution pumped onto the collector (1 
mL) whereas the high-density PLA 
nanofiber was generated using a lower 2% 
PLA solution volume (0.2 mL).  
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mediators using NO and PGI2 inhibitors revealed that additional mechanisms may also be 
responsible for mediating the inhibitory effect of our constructs on platelet function. In contrast, 
the fabricated TEML construct was shown to provoke a pro-aggregatory appearance on the surface 
of the construct caused by the neo-collagen generated by HCASMCs within the constructs. These 
results therefore suggest that our constructs possess anti- and pro-aggregatory properties of native 
blood vessels.  
In addition, we have successfully created an ex vivo ferric chloride arterial injury model that uses 
the fabricated TEBV construct by recreating physiological blood flow conditions inside a 
commercially-available parallel flow chamber. Using this model, we have demonstrated the ability 
of ketamine to inhibit platelet aggregate formation on the surface of the construct which could play 
an important role in artefactually altering the size and structure of thrombi seen in vivo mice 
models. In summary, although this project has reached a milestone in fabricating a new TEBV model 
and investigating its functionality using a newly designed testing platform, these findings require 
further investigations to more adequately assess how the anti-aggregatory properties of the TEBV 
model functions to inhibit platelet activation. 
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